var title_f24_5_24656="Mid-borderline leprosy";
var content_f24_5_24656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mid-borderline leprosy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tuberculoid- like lesion of mid-borderline leprosy with hypopigmentation and anesthesia. The raised border is prominent in this case.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from McDougall AC, Yuasa Y. A New Atlas of leprosy, Sasakawa Memorial Health Foundation, Tokyo, 2000, and Guinto RS, Abalos RM, Cellopna RV, Fajardo TT. An Atlas of Leprosy, Sasakawa Memorial Health Foundation, Tokyo, 1983.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24656=[""].join("\n");
var outline_f24_5_24656=null;
var title_f24_5_24657="Limits of the dissection for mastectomy";
var content_f24_5_24657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Limits of the dissection for mastectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Inset) Limits of the modied radical mastectomy are delineated laterally by the anterior margin of the latissimus dorsi muscle, medially by the sternal border, superiorly by the subclavius muscle, and inferiorly by the caudal extension of the breast approximately 3 to 4 cm inferior to the inframammary fold. Skin aps for the modied radical technique are planned with relation to the quadrant in which the primary neoplasm is located. Adequate margins are ensured by developing skin edges 3 to 5 cm from the tumor margin. Skin incisions are made perpendicular to the subcutaneous plane. Flap thickness should vary with patient body habitus but ideally should be 7 to 8 mm thick. Flap tension should be perpendicular to the chest wall with ap elevation deep to the cutaneous vasculature, which is accentuated by ap retraction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24657=[""].join("\n");
var outline_f24_5_24657=null;
var title_f24_5_24658="FDG-PET scan diffuse metastatic paraganglioma";
var content_f24_5_24658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F59671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F59671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    FDG-PET scan showing diffuse metastatic paraganglioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scan from a 28-year-old woman shows a diffuse metastatic paraganglioma (coronal image on right and sagittal image on left).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William F Young, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24658=[""].join("\n");
var outline_f24_5_24658=null;
var title_f24_5_24659="Junctional EB Herlitz 2";
var content_f24_5_24659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Generalized blistering, crusted erosions, and extensive areas of denudation in JEB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24659=[""].join("\n");
var outline_f24_5_24659=null;
var title_f24_5_24660="Echocardiogram PLAX view of calcific AS";
var content_f24_5_24660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/59344/aoslngec_conv.mp4?title=Echocardiogram+PLAX+view+of+calcific+AS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echocardiogram parasternal long-axis view of calcific aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 480px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHgAT8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDz6irmi2X9p6xY2PmeV9qnjg37d23cwGcd8ZrtNO+Hsd94quNDGoXtvLBFJM0tzp+xXCuqAoPMO5Tlju46d88cOLzLDYNtV5Wsr7N6d9EVGDlsef0V6Bd/DyPTYJ5dY1Z7Vbe2tZ5wtr5pjM0jIV4fkKV5IzkdB68pqOhXWm+I20a/kt4LhZViaV5MRKGxhy3ZcEHOMgdRnipw2a4TFNqjO9tdn2T0utbJq9r2uu43CUdzKortNQ8G2Wn6va2d/q9xZRy3Mls015p7xLhRxIh3FWQtgZ3AjIJGOaIvAzLfwafeagkWqfZprm5so4xLLGE5RE2tiR3HzBcggc+mY/tjB8qlz6NX2lsr3e2ytr2uv5o3PZyOLorsdL8IWl94qj0M6ndQzzRq8fmaeUZDsLskqM4KkAcbd4OQc0zR/ClnqVrHeLqdxHZXGoR6bbsbQGRpGXcS6+ZhVGRyGYn0FOWbYWHxSeyfwy2le3TrZ/cw9nI5Giuh8TeGJNA0/T557lJZbma5hdETCoYZNhwx+8D16CpvG/hePwvd/ZTcXs8u4BZJLIRQyLtBJR953EblBGPXn10p5jhqsoRhK7nzW0evK7S6dH/wNBODRzFFFFdxIUUUUAFFFFABRRRQAUUUUAFFJuHTNLQAUUV6bp/gfTdV8E6HqAmexm+wajf3k6RmZplgmRVUIXVQdrHoR7+tAHmVFem3XgjTdF0Tx5Dqsz3Gp6O1qLeeKMhVWUgqcbwCWBAYEHZjILdKe/woSPxBp2jSeIrL7dPIYbiFFVpIT5BmDqgfcycFcsEOcHBBFAHl9FdnoHg/T/Euu3ek6BrvmXKR77Z7y18iO5KthwMOzD5cMPlJIDZC4yb+n/DyzvrbU7uPxLZQ6fb3rafb3VwEjjmlWMuWJMmAhOApXexBztABoA89orvtS+H0Vj4Zi1htVd0S0sr66iFqMxxXLMo2Hf8AOylTwdoI7jpW14t8BaDDr/iyS31GbStL0SO1Z4ham4JeVeFQmTJyQvJxy5HAXJAPJ6K9F8M+BbbxLoNg2mXaLJc6w9kZ7i2ZJERYWlz8srKRsUHbtB3HG/AyWab8Oo9RWaW31WZbYf2e0TTWDxO63Uvl5KswHynJypZW7N1wAee0V6bL4JtpfDf2Szs3n1iDxK+jm6t1YyTRKjMWMbPsBHXqoAXkjk1HdfDS2sLXU77Ude8rT7Sytb6OSK1EzyrOXVVwsm0NuTAIZlOQdwFAHm1FPuBEs8gt3d4QxCO6BGZc8EqCQDjtk/U0ygAooooAKKKKALOmXkmnalaXsCo0ttKkyBxlSVYEZx24rbbxbOLzUrqDTtPgn1GCeC5aPzTvEpBZsM5AII4xxyeDxjm6K5quEo1pc1SN3t8hqTWx2k/xE1S7Mx1Cy028E0MEUqzRPtk8l2dSQrAZLMSR0PTGM55e81O8vdVfUbyX7RePIJGeVQ4YjoCpGMcAbcYxxjHFU6KjD5fhsM26MEr/APAX6L7l2G5t7s29X8RTahpv9nx2dlY2RuWvGhtUYK0pG3PzM2ABwAuBz06YffeJ7jUPEV3q97ZafPJdR+XLBJEWiI2BeOdyngHcGBB744rBopxwNCKso91562b131svuQczOki8Y6hD4i0/V44bUSWEAtraDaxijjCFQv3tx+8TksTk+nFQ6F4outHs0tVtrW6giu0volnD/u5lGAwKMpPGODkcdOtYNFJ5fhnHlcFayX3Xa/N/ew52dDqPiu51TTIrPU7Kyumiad47hhIsivK5d2+Vwudx4BXHHSofE/iF/EV3Jd3en2UN7Iyl54PNDMAu0DDOVxgDoM8fWsSinTwNClJShGzV7Wb6u702s2rtbXByb3CiiiuskKKKKACiiigAoopO/wAxAX1NADWdVBJOAOSa7v4X6FHdajLe36T740IS0t5JIZmjPBYyR4K56Y3D3FcxZWKl4ku5I7a4kfhJ9yBE4O8tjv2/n2r0zSdIt7WzkhivJy0gVBLakNuLdCGwc4xzkqT60AcD4r8N2+keJrQRXUraJPfeVPGyBZ7RCfusBksAOd/U859+x+J2j+FLLwTJd6Z9jg1CPb/Zz28+5rxMnOVyQ49XIJGMZFaPizSdQikjmtLy2WY23lS3kEe6a5BwuxmyQg56Ac84z1rzzx14Mn8IR6e809teLLGDKlvy1sx5+Yc/Lz97uaAOeicPGCAa0otY1OK1W2i1G8S2WOSERLOwQRuQXQDONrEAkdDjmsyGRZUyuR7Ef5/Onk4pNpasqEJTfLFXZffWNTkurm5fUb1rm6jMM8pnYvNGQAUc5yy4AGDxwKeuv6ur2bLq2oB7JSlswuXzApG0hDn5RgAYGOBWZgnr09KdSTb9DWUadNWbvLy2Xz6/LTrd7E9jeXOn3SXNhczW1ymdksMhR1yMHBHI4JH41JZ6lfWMFzBZXtzbw3K7J44pWRZVwRhgDhhgng+prrPA3iu00DRdRtbubUFNwxcLYr5Eu4RsEP2lZFYDc2drJIoxkDJNdDpHj3T5rPwjpEdtDaR21zYpcmeL93EYpizTpJ5gVGbJ3fuwSGbLHAqjA4TSG8Q+IrqLRNPu727kuIlhW2a6IR44gzqnzMF2r8xAPA7VRl1jU5bVraXUbx7Zo44TE07FDGhJRCM42qSSB0GeK9U1j4kWNh8QdNvLQXN7Dp095DdXSuoa6illYqikEh44wQUyQDjonWsyw+IGmReFp9Pu/wC057xLLUrKKdo1b7R9pdXEshL5VgVIIG/rncelAHnVvqV9bwRwW97cxQxTi5SNJWVUlAwJAAcBgP4utTx6/rEWoy6hFquoJfyrskuVuXErrxwWzkj5V4z2HpXr9x8X9HuNRkNxDq0unS35me3dEZWtjZ+UYipfBBl+fb079eK8OoAvf2xqf/QRvf8Aj5+2f69v9f8A89ev3/8Aa6+9SXuv6xfJMl7quoXCTKqSrNcu4kVSWUNk8gEkgHoSTWbRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVrf2Ddf8Ip/wkHmQ/Yvtv2DZk+Z5nl784xjbj3zntQBk0VeTR9Tktba5TTr1ra6kEMEogYpLISQEQ4wzZBGBzwa6x/hd4gW6ubQCF721sjezQIkzFRgFYw3l7XdvmACswJRxnigDhaKKKACiiigAoopUVnYKoyx4AFAAql2CqCSeKof2raxXbRZS4I/dmMHq3seh/M/Ss/xLri2yvYae4Mx+WaZT0/2F/qaqaXo0JVJYrtGmO0mIr8wz6KTliM9s0AdRBr0Uk7LcMFBjBVcbS3+yOg/lWnHrspCLAzxwNhLeJTlIkGASB/GR+PXp0rnLy4mhs2iv4Y5VlfY8rJglRjGO6t19qLm1TU5En0QXMfkQ7UjLtIye24DgdeMUAdZfeJ74azNP9puPKDARNI22aVVA+6SOcDkA4qJ/FM+JLwXkv26cOkuxcM6HszBvmJA5JxXL20BREaUKZgME9cfjWNe6gLKYLasrAvv3bs549R/L2rlhio1JunDp1PexWQ1cFhaeLxLspfZ6rt/we2nV2OmsI2vG2WcBd0jMhWFS+1ByTwOg7np709CpAKkEEZyD1rgL6+mnOBIQgfeoH9716DNdd4Zv5tYhmVYHM1um+XyoyVCDA3kgcDJ710KPV7njzrNrkgrR/P1fX8uyRp0UgIPQ5FLVGIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVu+CdN0/WfEdtpmqzzW0d5mCGeLny5m4jLLg7lLYUjK9c7higDCrqNN8SWMfg1vD2p6bc3EP2/7eJre8WFg3lhNpDRuMYyf889ZpPgPw5eeJNd08ahqE8WjrDFIsIJmuJC+2aREWNmCocjaFbJIJcA5qOP4f6LceEDqFpf3s1y1lqF9FcfKsUiWsyoP3RXcN6sDy3ynselAGFrXj271Pwla6KIPs/l20FpO6GMpcRQkmPIMe8MCR0k2/ewo3Gp7r4gfafGeua2+mYttYsmsJ7YT/ADrG0aoSkm3AbKA8qR1GO9dZd+GPDOsSaVcm0vbTSoPC51CSWweImaSJgHQnywrSrkhycEkrkLjnm/CujaNrfhrxHLE02mxw3NjGJrp4ZxFHLKELFjErLt+diVZAQQD0yQDz2ivZtA8J6bo3xU0bTTYTSWl39silt9VSCfzEj8zZKgxuVW2KQSi9DhmBNcvr/hDRtM8A2GsJqNzJf3UEMyFYmaCR3Zg8O4JtRkA7yEkq3yrxQBwNFFCKXcIoJY9AKABFZ5Aiglj0ArC8Sa8lpHLY6e4a4IKzTD+Ef3V9/U0eJtfWzjey02XNwflmmX+H/ZU+vqa5n7EJ7Bbu3eNmUkSxbsOvuAeo57ZoAqRgEoGPGcnjp+NbVzDGGW80eeZhHGpbzDhom9Af4vbgfSsUhguWUgN0PrVrTr+602QyWMzRM4w+D99fQ0AdhpuviFH+2ATrGnzOUDEv755H1xxUFlqIZ23QiMysTI6SMhwe2M/MMHrVWDUtEnuVaexCySQhXZnKRxN3ZQvJPpnPJqK5sli1FfsoaRLiLILsrnB6N3x0+v0oGm07os3drJcSsLMpdSOMrGrsWC/THGPXNZWp6O8UAuLd/OQ9cEEg4+vPepLYeXMHJeMxP91RyCO+R1Ht+tbmk6zbyvJLqduJCcgR7WzyDhvlwBg84pJW0Q5Sc3zSd2cMenJPPagFkYMpw6nKkdQa6fX9PsIYgbK4FxLKxKopA8oerEqM59Ki0zwhq2oRmSC2kZWOECrzJ7jtgeuaZJseGr6bV4pAsEz3ECeZMUQsAmQN5I6DkZzWr+dcNrWnPoepG0l2i6jIYsDny/oQcH6V02hXz6lazSCKRzbKGnkVCVCk4DHH3QTQBp0Udz7UUAek/CjwTp/iKx1O8124htraT/iX2Dyybc3bjIKgOpZlGMIeG3exqpH8NbweHbi+u71IL+KC8uBaeXuXZayLHKGkDcNljgAMDj7wzxxcGp31tBHBb3tzFDHOLlI0lZVSUDAkAB4YDjd1qR9Y1OS1ubZ9RvWtrqQzTxGdikshIJdxnDNkA5PPApXuU4uNrrc7e98GaHonxC0nw9eavc6jK93BHdRpZeWgV8EJu83OTlMkDgMSCSNtWG8FWGoXXjG30Z0WWx1SCyt1uoXHlCW48sbXWU8A7gSyMSqgjBJA85vry51C6e5v7ma5uXxvlmkLu2BgZJ5PAA/Cta4bxDc6Fd6xc3d7Npt5cpaXM0l0W8+VF3orqWy21eQSMDtTJJ/GvhqPw5cxJb3k13E8k8BeWzeDDxSFG2k5V14BBViecMFPXm6t6nqV9qk6z6ne3N5Mq7BJcStIwXJOMsScZJ496qUAFFFFABRRRQAUUUUAFFT2Nnc6hdJbWFtNc3L52RQxl3bAycAcngE/hUmp6bfaXOsGp2VzZzMu8R3ETRsVyRnDAHGQefagCpRRU81ncw2tvczW00dtcbvJleMhJdpw209Dg8HHSgCCiip/sd19h+2/ZpvsXmeT9o2Hy/MxnZu6bsc464oAgooooAKKKKACiiljRpW2xjLUDTs7oRYy7BV3EnoAaz7nUYEuWhEhkC53MmCMexzz+FVNc1qFCtjaNudm2yzr/DjshB/M1RMkVu8E8oQ+UcYVjsYHqw9D6jvio9nHodH1us/ifN62f53sVdYgjhPnrBb3ELtzIC4wff5qpRG2e5RBGUJGA0UhUfTBBOe1dpHqLw6c8tjFHPFOgLxHhXHoRg89etcnfaSyGCaJV23ALeU0igx+2Qfyzg8dKORf02L61Psv/AY/5Gnoz2cdm8cpiTc/3JZVYkcew/KsfURpvmf6HJNnGcBcrn05II6e/Wn6dZvK11C1vI86oWQMGyo+g/rxVY27YiBicll3YHGPwxxWMMNyTc1J6np4jOniMLDCzow93rbX5WtbzXUqggHOMj0rQ0y+gtLlZHhlHy4LQy7Dj8QR+lUzbSYDKpfgk7QePY014ZUSN5I2VHzgkdfpXSeIb1jrVhb37XU2mmZwQwLyZJPqcjGffFQXHiC5luzMkcKJk7YtoKID7dz7msQc556UvBxigDRj1S5Kywny5A5B+cDt2BNfTPwy8apL4Wt7PT7G2ufECpkZQRLCgAydxJyeM9utfKg5wMZOcYHeuo0R77TZgbR3OoSAKlvEctjsD/higDr/AImeGLx7/UvEF+sMMU5LiJQ285JyRvwx5zyfwrzrQNauvD+t2Gp2Hlm4spRLCsyCRQc5HBr0Xxi+sSadENdLwvLApSDdsaQHvk8gD06f7NeXSxBQWG3aDgEH730oA71PEFx4ku73Vb2GKK8uJS03krsRj1yFz6Hvz7mrKMXHpXCjWbtYUjt/Kt0QYARP55zXT+G7/wDtC0kaR4Umh2q6NKitJn+JFJBb3ABxXLGFZ1HKTtHse/XxGWU8HGjQg5VVq5NaeatfbtdefU1QMV6jqvxNS/8AiXZ6zMt7c+HbSRHh0+baNhEZXzAgJUurMzAk56DI4x5dnNLXSklojwpSc3zSd2et6d8StHttae4e21AP9ksYG1JI0+1XDQSBpC439JQNh+duEXO7oOb1HxpFf+C9V0NY7mySbVDf2sMLBoViYkm3Iyu1VJDjAILdl61xFFMkKKKKACiiigAooooAKKKKAOs+Fer2OhePdL1HVZ/IsofN8yTYzYzE6jhQT1I7VpaD4r0+8nhtNctNPs7CxsLqLS08h5oLe5kO4SyK5kZwTxghgDjCjk1Bo3wx8R63ZadfaTHbXVheKG+0CYIsJ3FWVw2GypBztDD0JrM03wdf6po+q6np0sNxbad5jSEJKokRNpZkdkCdG3bSwfAPy0AdgdY8Gf2n4jks00+ysZpzJaObLz5xtiPCRSxPF5byHIXdEwHUgAAR6P4q8PXOjeB7TxAsMltpNzOl7bG0GWDZMUgKrgoDjeM5YjJV+tE3gfQj5/knU0z4XGvw77iNtknzfu2/djcv3eRtPB9RjkPCXhO+8Tm5NnLbW8Nu0MbzXDMF3yuEjUBVZssx64wMckUAdfceJvDFva+JJrPS9G/tJra0hsi9r9ojlkBYSyqGhjWNtrLkbFUsmcHPMHhLXfCv9kaYPFNrZyXUetNNMIrBVb7MYmwWKKAyCVgSmTwMBSABWa/hG003wPqWsaxO7ajDftpi2cUmzyZlBzubYwc9DgFV2g/Pk7RX8KeF7fxB4T1y5gS5bWLOe1itkWVBFKZ5RGFIK5BBzzuA5HTHIB0t34i8J2ena1Jp9ppNzrDWFlFE8mm7oZbkbhPLEjIFQbWU4KqCy/dPfy64maaeWaQIrSMXYIgRQSc8KoAA9gAB2r0bT/hXeR+MdJ0jXbyGC2vvOZJYA5aTyifMjUMgIbAyGYbSDkFuAc3VvDWjL4CuPEOm3r711T7FHC8rSBkCZ6+ShLE5cEgDYQD83FA42vrscNuHY5+lG4e/5GnU62CS39nbuZALiZYsxpuIyeuMjOBk9ai0+6+7/gnRzYf+V/8AgS/+RImcKpZgQo6mt9PDeo/8I5d39zby2ttJGAtwW2+UjHAlZQrNs6g8L25POJrDSk03xxJa3KR6lb6feLCxjJ8sk4ILZHB9RzivpG306S9EkS+aLeWLEdwADtY8FGU9uuVIIIPUUcr7/l/kL20P+fa/8m/+SPi280ewdS7KYedxZGx+GDxVDT9PhvEeNJGlUPsJI2EHoO/Q16z8QPh9e6NcQ2EwjhmMz3FnMi4SUnjYjjO3t8jdhwK8kure50ue6t54pIZ1fy5UHfnPHtkduKxoUZUvim2ejm2Z0MdJOjh40/Nb/hZfg/U09Os3huJIWkdbmNCqRlcFh0+hHuT9DVrVrYzWQSZpRLapgxuMNsPoQMlfak0Mw6jA1rPdRRySfLCZMhRIPujIHB+uPrVvX7DxHC9st9amaP7PuUKVcgLwSuMnj14rpPGOHF4YZW8oFgwwueCB25BrR0rxC0WqWs+pxm4t0dN4XG7aD2zkH8QayL2VnnmLA7i38S4NQnaduMhsc55oA77xJ4h8Oan4ki1LTbCW0wMNAQqxnA4bCkDPqBjrVPxLrGp+K1jitVjktLZOESXGcd9rHP8AMVyCQl03KQTnoOoB71uaf4cvr7RpL6zijMMOfMmWYAhR1LKece44oAwRBILgQSDy3bGN3yj9a67SvBiXF7YLdarapa3GPMaP5mU/3R6nr0zV/wAN+G4o4LnUNZvdtja4wYhuJJGQwIP+c1m+JPEssuq2ssLzT/ZlCobzLMDnOBnoKAt1On8UfDqz0pLBbWaeS4nfH2WYCN0T++XbAI/Cuv8AhHpt3Za602g+H7a6vYjsNzJL5ixYx8xPTrzlfwryPXfEt1fXKTtcuSFztPG1u+McDr1xVzwx451DRPK+zSCJULbgI1bfu65yD+dAHrvxV8LTz2tzqut63Bc3sjmWGI4KyKMg4XHI56ceo5ryUQ2BVi0Fuu0AtuQDAP4dKXxX4tu9Z866urp55JiFUAkbAO5z1Hp+XFcbNM803mSt8xIyxGePpXPXw6rW1sz2MpzieWuXuKcX0ffo/wDNdV962tR0sPKI9Pi3+Z842lQXJ9Bn7o6dazY9Pu0Xzo2CtEeGVujD0PStO68Qv9iS0sYvsyKAGdGJeY+rnr+HQelXNP1BGktk3hmiAflsJGf4nOep75Petfej5nDJ0qrvflb+a/zXlo/U2dN+0SaeLi7RI2GFwXClye6qTuYepAIHrVgHIyKrRXsVxMUSTHQebJk7ie/T9KS1vraUyx/aEFykpj8ght7AD7+cbcfjn2pqSexlUozp6yWnfdfetC3RSAg9KWqMgooooAKKKKACiiigAooooA3dJ8W63pOhXmjafe+Tpt5v8+HykbfvUI3zFSRlQBwaNP8AFut6fo8mlWt7tsXjlhMbxI5WOXHmIrMpZVbAJCkDIz15rFt5WgnjmQIXjYOA6B1JBzyrAgj2Iwe9eo3fiHwLJ4m8NtBo1tDo7Mb3VFSIuVndSBH8ygmONgCVT5GBPynGCAcR/wAJbrf/AD+/8w3+yP8AVJ/x6/8APP7v/j33vejw/q2veH7WXUNJM0NlLIkLytAJIGlQiRAd6ld643D+IdR1rvtO8ReDI9Q1KSew0mIltOjR/sn2iOZVl/0iRVMCCMmM4ICLkrlcnFQWPibw7HpEmiiS2TTLfxKl5Gk1mXE1jv6A7CxYDk78MU+XJ+7QBwkGoa5rFmdEga5v0uLtr4wJH5sss+whnyAXJ25zzjqfemaJq+r2cM+naNPMn2+SHdHAgMkkkb7otpA3Bgx42kHNdnpvijQpfif5+o2ejReFkknjRI9Kj2GLafLYqELliVQ5PIywGASKoa7qPhqbwRZ2+mLZR3q21ujwmxb7SLkNJ50hnyBsYFcKTJ1ACpjIAMm88QeItM8WjVLofYdegyWY2UcLguDlnTYAWIc8sCTkc9KyYdXvotGuNKSfOnzyLM8LorASLwHUkZRscErgkcHI4r1zXPFvgi81XxJfy2ttqdxPPG0ZuUeMXEAtQmxG8p2jYSBjnEZJ2nfgYrxZFZ2CoMsegoAQAswVQWY9hWRrer/ZXiSx+Zkf95LwF/3Qeuf8Kg8T6wlvFJY2LBpjxNKMED/ZX39TWJpTRPENrbZNw3pk4YenuPrQB6F4G1iC11FLqeERRMuy5iK7g6E/eUjnI/H1r6Z8PeJ7uCzEARbq2eIm0uUbO7soPqM8ZPPqK+RdGf8AfyxRRfvf4Iycgj0Ddvx/OvWfh9PqGl2C6il0yafFMPNUMMRnJ4cEZjPv0680Ae9WOoWniXSZdN160hLyKy3FrLz8v94ZAyPcdDXjPjP4MPbRyxoovrIgpa3T8PbJ1WOUjJ2j++Bx3wDXT+JfF+nXV1a6taNGt1AnkT25kHzqTn7wIXr+HvXQaF4+hnR2e5s5YlGTEJWyc8kAsuMjn5c9sCgD5Nbwre6TqV1bajbzx4GCTFuKN256Mh9R14rqfCWpaQ0UGnalPPDcRzZSdfmCED7jIR8699uPxr2fxN8LrDxLP/aPh28e3s5P3k2nGLIWQ/xIGICHB+709MV4u/ht9MW9+0l5DHI0KhI2Rg4J4wyjBxzjGOlAG1oVppc+qahJeiSZbtTtVYUVnf0YElQhPYAY/CuM8QeCPtkOo3WjJGJbP55oFkGBzg7c8n8CRXRRXA8tPtqfZ18kKtxDMuUIGMPgh1HOcfd/nTra1ilfb9pNzMI9rOxbcGHPBAA59896APLNV0LUNE8gaxYXFnFcqJInZdxceq8gGun+HV5P9png07Urm1uZozAFt7RpRIp6rgdCeO3416G0kS6bbpBLG4DBZYblsHPOMORgYwBgn6elXvAOq+G9G1h7jWLCE3Ejb95Rdi89QFH3uOmO/WgDyR7e6i1aaykaZbSBt5idz9/PB25yvryK5jW41j1a4Vf727n3AJ/nXf8AxW1iC48f3U+k7UspA1xtVQhbAJO4BRjOMdM9+teaXd1PeSLJcvvcAKDgDj8PrXMoT9u5N6WPcqYjC/2TChGLVTnbb0s9Nt7rRrvs+43uTigDr60wfzpxzjjFdJ4Y7c33Sx2gYxmkAxwe9SwRPPLsiQuxBOB9KakZYYGAcZ544pX6FcrS5raf1/mgRN7AcdenrVuIPbyFSFO4845B9OajtIybldpJwp3bWwfpmn3U5kkV1jRFA2kKMK2P89aZJcN8bdopIG3Ogzzx5Z9R7+9RRXc5kTJaV4zv3SZO3njB6jn3GaqCQeaS+RgjaM8Dmum0ew/0optVVQGQk5zK3r7KOT/nhOKe5pTqzpv3Hb9fXuaOlX8V7aI3nRi55D2+G3qB/ETtCnPsSfYVdBB6GuK1JrQ6ifsM8xjhBJnKjLSDuBngdK6fRLkahp8c7XEJuASJYlRwydMMTt28+gJ+lTaS2NPaUqn8RWfdf5bfc0X69fx4V/4VX/wjf9oQ/wBqfYv7e+0+Yvl/aenkY8z/AFuz93tx0+bGeK8fAI75ra0PwvrOuwedo9i94gnW3YRMpZGYZBZc5VeD85AXg88VSd9zKcVF2i7npqaF8OjrGjR/arI2Ulyybmv2Hn232QN5k53fun87gL+7zyNp7YXgHX9HGseIkXS9M0yK+0m4trWGW5l2O55EbyPIANw4LZX7g27STnjLfw9qNza6hcWsUNxHYbjcCG5ikdVUgM4RWLMg3D51BXvng1u614BvYJLX+wTNq8c+mwakVWJUnWOVioAiDszYwMlcgZ5x1LIOh0yLwxqHhnw0moXFt9sisNQZbKXUJFhNyrKIlkDSYhDgM5wYwzd8YFcD4rhsbfxHfxaV5P2JZCIxBcNPGOOQsjKpZQcgHHQdW+8b0XgfxFLNexQ6f5slnIYJRHPG2ZQhcxphv3jhVJKJlhjkCuboAKKKKACiiigAooooAKKKVEZyFQEk+goAEUuwVRknoKw/EmupaA2WmzBpWAEtwn8Of4FPr6mjxBryWZezsiJZT8ssgPA9VBHOfeuTYC4lLRAZ/u+9ADY9rO3nghB/F39qfEYfKeKWNi+cpKh5X6juKfBI23BXJBwCPvL/AIj2NaltbW1xcWzuVUMQNwOFbHfI6H+VAG74ejF99nmu9qO2I47lDgMwxhWx91vrxXoerajc6Vp8dvdXPkXqjdb3agIzAHlHA++pAHB/OuMt7CWwia6sZI45QpMhZQwZBg4lTGCD/wA9AB71zmp60+oW0Udy22WA/KhcsMc42Engc+uMUAdPd3tv5fmmANbyMzr5TBNrkn7vt3wM9an0a/t7aWRFikhuZC0cwb5CVI68ZGO/PX+fHxXph8p5IEeJW3HHRSfoRg8V1B1JJGt54GAgl/dK6YMkbY6E8HHfBXHvQB638O/G2o6Q/wBlWOS405V2xgOCucDucn8gP5V7As2g+J9Alk1e3szE4CzpIc45yASQD15HAr5f8NfZLO8hEs0gxJvKoxEUgGCdwH3e/AwvWvR44NdudQzpcA1C1njyhQK4hJ+9nDAdPYH60AXtW+De9b2XRb9bjTXy0cAVHn3d9spwB6Afr2rzrTPA3in7Xci10O9+yu5CGe3Mcm0H72W/i9169s163dWemeFbBb3XIrm0EJVQ7XRYse5TB39z8uCffrXI+Nfi3dG+SPw489nCMqkrbXMwHfay55GPvc8UAVz8NPFLTODp5+zLF5pnlmTO7GduN24n3I61i3fgHxTK8Esej3HnAZK7tsRUHlsZKjj3NQv8RfFt3ZbE1CWIGNlfod2PfBwfpV7SfizqWjSWsWsyyGVkGzzXkJY5wDgHBHHpz+lAHAfEzQb7TbyK5vlTb5JiCh0LAn5SDsJAxu788dK86+xjGQ4HUqvU17p8QtauvF9vBFC73MUe6Y+UFWRfu5LMByMnuP8AGvKNQjjtrw27QBI8fKQ4G49jnGDUR3bOitpTppdm/ndr8kjDFkxRHAcIy7iSMce2adJajyyVGG6YLcmrsgQ20hTAydjOvzY+vpn2x0qCIP5pQlpIUGB8xUD24/wqznHWLtbXVufPCIvzNwOnce/H/wBatXX7W2SI3I/dzgE/KPvfX8SOf/rVgu5VyzOAX6qnzcfypxugJjJsDyNnLFuSCMEGuarQcqiqRdrfiezgc0hRwlTB1qakptNN/ZfV277bNba6ESyN91dyhhzt/i+vrU0SqAzzhvKYbd55ZvQCkkhzJuhGYWG6Nc5Zhkjp68HP0qNQPl4K84G7nH+P0xXQndXR5M4OnJxYo+WSJkCjHzYAzz2zmtG41WZrE2yjE8xw5jHzPyOCe9UjbyzXccFuHaYkBF6MT647Vqw2TWQ8yQqrJ8ryBs4Y+h7n6fnTIM20sTNKbc5Eo4ZR1z6Z6Ae5r2LwtoVroOjLDOVea6w8sZ5Qxjk9+TwMNwBXAaEpsiLmaFSwXEcRI6cZY/4np71a1PVrnWAFaQC0ZxuYDAYDoPUjgen0oA2tU+wmVJtNmVoJQSsJV/MiAPG8kYOfYmtLwp4r1PwyNROlS+X9utmtpMsw2Z6SLtIw687W5xk+tcHe3puSfs7EN5gVWXgyN/Cq46D3710SWlzFpiXM8VyNrBJ3MIWKNz0UMGJPHchfpQB1WieO9T0jwxdaFbQWTWlxFPEzsjB9sqgMflYKzDaMMwYjoDjin2PxB1ix1vSNUt0tlm02wTTUjw4jliUEDzAGyxyc9QMqDjiuQ74PWigDqNI8c63pek39hDcu6Xk5uWmM0qTJMVKlw6OpYngkPuXKg4655eiigAooooAKKKKACiiigBVUuwVepOBWB4l19LVHstPfMpyss47eqqf610Or6Rrr+C5da0iwln08O0VxdKnCDHOAeq9PmGR9K8qyCeSPSgB6rvbng9QfWpYgWkATaHHTtn/69QK2Oh56/SpCQwHY5/yaALluucuCVPPzNzz6HFbuipCwm3IJAq5mtnPLf7SkEevXqKwYJhjEvDDoccH6/wCNXZZU+zl4SGUHkdwf6UAX9W1N7e2+yW107xo26MSffjz/AA//AFxg+1c2rFJlfHv161KZizDzwXU8Z6sB6j/69MLYDJGx8onJzzxQBZTUJhMzq5TK4IBxkYrX0PUYIpVTUbf93ggCIiMrkcHB4P1IrntoVm3jcDzlWGR71atGVsI8avjIDeYEb9eo/wA5oA9U0GWwfThAl9bSyqpZOPJmifPC4ztaMHuDuOehrt/DGrahY6yJJkhd0BZZGzsXnO4EZB59s14RZXKQWufOImH3YmQAf/WH5mvVfgpqu3WLe2P2RZQ4LJOGBfp/FgjGPpQB7Nc/ELS73TJLDxFpqSwSxEbWcOsoAOcqf5HmvnXx1b6RJrXk6TstNNjXzdsZ2nPZRGWYsMd+/avrDxb4U03xVoJGo6TZXNwFJieSQwmMEcESR5OM44zg18U+L9EudE1q8sJhLA1tO0Tyeb5kb8nG0kDt6k+tAFRp/skciWlxJvlbIjQsC2f4uRj8OtVrdWK7/KEZjbCkH5gfU9Tmqbm4Rljb94vTJ2k49Mg5/Wt7R5ZnCBookCEBf3mB7ls5yMds0Aet/C+Zb4xxWvmf2ibaRGO4tHNJIVIB+UnA8sZ9c9tp3R+Mvh1rd0G83SZmkt0Zy1sjGGHJJPJ2gnH8IzXYfBnTjcpqN7pkFiAFjgV2nkUvIAWZgBwM+Yv028dSa9ckv9YjslitbdZbvIQFo5PLj/3mbBYe4FRDZvzOnE6SjFbJL8Vd/i2fDtx4Rv4ZpYvIkjjXpJONhlyTyo7VBf6UtjMolk811TJKHIT+RJ9ua+uPE/hHSLmymutXvEgvFma6uHtRKpkcjopLjYxzwM+leOap8KVNnc6kI/sEMe6QG+mjZpe4HykKhPT5mJzVnMeMReS8jyTzFVBJWP8A56Htxjj9ajd9tk6sNrh9wXjGP7p9frXTav4TuLeGKaVJNr4byhEQQhGd2e/4DHvVO70KS3nhgEDytMN6DaVLL0yWIwMe2aAKNnHcTWo81OW5hJXpnHp2PqfaoYoHuLuOIoMZAUAYGfX3reGmXYkAaBnSNCEUPgKBn6HH4GtbS/DxkeKTWRJCkil444+sv09D6kjP9I+F+TOj+ND+9H8V/wAD8uyRS0uCC2lMOmK0t7JmNphH5hH+yo6fkfz6Vb0CCAO0l+hlkSTCp5nyA55du5I7KMDNd/Hd6ZoWjfZdM0uJJpE2SEYLsSByznuc9OR7CvJdUnuTKV+YLD0RWyWBPdgcD6LmrOc6DXpbP7VLiMtaoBstlYbjnnfK/RQeyjJ6fWqej6Jq3jDXbfRdDtQqf8tFA4Vc8lj/AAj9aPBWg3viVxDaxRwQgjzrzBKQj0Ax8zewr6L8PxaL8PvDDafpLKNSlw13fTHDKD/G2M47EJ/OgDC0j4YWen3tva6fANQ1SIB3u5FMcNu3T92MHdgg84x6YNa+rz6f4ds5dD05rSaGRGbWL11yWzwyZIOSeeeSPrUEfie9v5Li30O4LmdN0+oT/Jsi/ifA+6PQcHj8K5zX7mziso7W3iYxrlkV8K10ccyvg5WPPRTycZoA841W0t7eVptLWdrZjnEigLHk8Kr53MP95VP1quDkc9a7G4t0sbCS61MxeayF1t5GIXb3kbHI9B3Nc/r+jz6PDp120d0tjqEQlgmuY9gYnoqnnPHrg+1AGfRRRQAUUUUAFFFFABRRRQBJHM8YAQgDOelc3rvh1DHPfWPzLy8kBOWXnJZe5H+c10FOjcxuGUkEd6APLWAU8cg9/WlA5GRwK7rVNAjv3U2Xlw3EhwyMAsbk9wf4T+n0rk7rT5bV3WRGSSNtro/Vf/re9AEUbmNdsiZU+nGPeoQSpYEj8O9JIHT5XBB7UnfnrjmgB2ehz+NBGB3zTS3Bx0oH3hnHNAEmN3zpk4PQ9R+VShVlCoiEHG5stnn1Ht/nNQxPtDcDB45FSwKJT8xCFfmz1z9R6UAWLaCaCb96o2MNvz/dOe2QePzr2H4O6nHo+px+bZQyfP5isZih6jgtjkcdADmvKbWZkjWG4BMWdyZztXPpkdK6Xw3dTaXq8FyjnzShKIGBXOOp3YH4DmgD6S8SfEy1gntRaoySjmYkOFXPHIU84I71y3j/AMD6F42S01XQIZp7t8rctDGTFnksxkcA5HJ+93/GvK7lri9VbidWDvIZfMYsokYdTxnp716P8M/FV1a6tHb3F6J4VwscAXKDkc5yDnGeMUAchb/Ca+eXbYW8Mxl+WNkmXIA7/ewPrmuu8A/CCwi1CSfxDcJHHGdw8m8U7+Oh2sT/ACr3jT9Q0253taQmU7N0gjjzz/PrxiuT+K1zf/2RctJCyWCFAiwM/nu3JycFdqjnuf0oAq+ENS8LeH7XUlaWC0F1fTLA0oLFRGPJHzMMkkxl8dt+Oep0J/ijptreR2mTLGy8XisGTPuF5Uf72PpXzjfrPJ5c3kyTwsPOUSlzh3JbAP49e/Ws+6v7uEwGGLbjPCKZNv55xj14qKfwpnRi/wCPNdnb5LRfgj6/j1KHVJYJZLeKWADdHIk0mSf93YB+tQ6roNuzWcmmK4lgm8wRBjhmwRh5NrEAf3RxXy3beK9UsU3efMxYeWwLZAUjn5VPT9K9E+HXj+3lklhvrm6lmCELCkkkMSLgDIUE9MdePwqznPXrfwis0Kw6ncqBjIt7dFRAMgkEdG57lc1Fc/DTwzdKPtVk0sgGPMMhVjz0ypHHt0rE1fxNFHpEy6Pc7LUxGWV43ZHDYycStu7d8DHrmsz4f+N7y4cpKlx9gJzG08nIJ7MzAs3HPyigDo5vBHhXSdSN0+nJKxTCw8LHCg6vjIyenq3oK8d8e+JrfVJGsvDkKJEr4tvs1kI5ZSMjh2bdjnBb5SQfu4Neu+MJlure7OYdkkZj3ou4kkHA8sHLkc/eI+leBalZbYjHrchVASscS7PMYDp5mzAUEH7vP04pNXVmVCbhJSjujM04RSibDSytArNMsPOADjAfoO/OCK5jW1+13EfnxQ2dnz+6jYlnyc5LZLN069PYVsXN4JoHUW0tvYQsHS3RtocgffCgcE9/XA9BWPLp1zqM6MkDRu4ykajkdwf/AK5NKL6Pc0rQWk4fC/w7r5flY2NI8ZSaZbx2WmMYYIW42sVyTwcE9OP4v511VtZl7SDU/E87JCVMlpaxqdjD1VCVz1OZGOPSuI0v+yPDUgkP/Ew1hfnKKcrFkAg5PG7ryAR7iln8TSXt+Jboma5mbd5MYzk5zyT1xjqTiqMTr7zWp57fEUMcVsCGEAYsZCOjuSB8n1454B61eGrpYzC81FxNfNhoIyM5wOGYHqB2FcDca5Nd37rAqSyoMhVYbEPqx6E89sipFE0shnu5PNuW+83YewHYUAaGrahNqVzNNPJ5kkjl5HbBZj7n27DgCqeOme1LRQAUUUUAFFFFABRRRQAUUUUAFFFFABk1Hd2tveweXcx7h0Drw6D2P+RUlFAHF61oVzZL5kR+0WuSQVGSg9WHb69Kw8885Ar1FWIYEEgjuDyKzNV0Szv33xqLebHVR8re7D19xigDg9vykjpntSjr6Vo6jot1p6u8i7oweHTLKfx7fjis/aNy7iVOOp5FADVyAfc/Sp0kKkF139sg4P5iomRlxnGCMgg0JgON33e/f9KANjR447u8BjAHHzBiFJPoOv8AKvUfCHhm7v4XWytEuLhxzGkilu4Knccr26Ka8n0y4aGRfKiSV8dicj8D1+gr0TwJq407Vorlv3UpjMewkhXycj5uo7dwKADxDYatpV+8N3pl7ZzH5UjKDBI/iBwCR3q7pMUnm27XIVoQAJMKdxHfscH8K7zxVrt5f6VCA32Z8gbGIkTbg52YHf3Y1wepanq8O4xXzCEg5KTeX5Y45ORgfmelAH0R4Q1rQ4dEsQL+7jaHny5pgCTjpt4yOBjiuZ+Kniq7ghPmGK5hbLwCM+UMA4O5TJluvUenSvHY9bt7SBHvzNdOcMJpbkHdzyQfTPp05rP1jW1umkeG6mSMg/uztIxzxnaO3rk1M3aLaNsNBTrQjLZtfmQQeIUjbZfrDGI8RqGBLDaMYOOtNm14xPs8iG4RweDZgZGOSAQcjml07VtJk2RX0hds/wAMakk+vBrq0n8HuqtDDrLLjJO0DH4YIppWVkZzm5yc5bs8/wBZ1O4uZ1aKOSNPLwERmQY/AYxUGkXVxp8qpHCy7/mJQb/z6D+VR+IpEN5L5KTQ2yklPNlw4HPt146A1z8948g5mkOT0YHAH4f4UyT1W48TXK6X5R3CVcKvJd2XrgZBAHqGH40zS/EUqsihLje/dVwh9j/kCuE0bUbeJZFu2kkUkHESYz9Twf5/StJbyO4mWcRCIpICAg3EfQAAfXNAH0HZ+KF1LQxYxjynZQksvlqAc9QMcDuclh9K53TLHSNMu5rrU7j7NCA5aRRufbnGAegJ55JHXqa5XwzrUl0zQqX3D5ASxYoOucDp178VmeIruGe5jDNJLJu4QndtbuQB8qfXigDZ1vXrFbieSw0dYrErm0gB3SMSAN5Occ+uDj1Nc893cyWVtFOkVvF97y4dvzZOcFjksQBjODjH56lvbWg01pbl0Z9+1huGw+gJ6sc9sY96wtYhFzckxscHAJA2KFz0GOf5VMl1XQ3oyWtOWz/B9H+j8mznNfYpdzLEyx+acnHLkHsSck/XP4U/S9JnmiWSQ+RC4wVAw7j1J7CvT/grpFjefEjR4L+1t7uB/ODRzxh1OIXPIOQeRmtjwL4Cj1C41KPxPHqdhLaxwypZpA63EsbybWkVfLdmVcHgIQSRllGTTTvqjKUXBuMt0ecQW8VvHshQIg6KKmr0mK30LS/hje31ta/b5ZNaOnNessYaWAIW3RiSNvKyh7fMGwSxAC1m/GS0sbTx1cjSLNLawlghlhMIUQzK0Y+eIKANp6cZywY55wGScRRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKGI6Gs680eyusnyhC5G0mLCg/UdK0KKAOSvfDNzGR9kkFwuPuk7GH58Y/H8Kx3imtrgpLC8cm3iOReo/H+dei/SkcCRCkgV0PVWAIP1FAHD2YEckVwg8pgevIXPswzz+VdJZapK8qwSBAScDLIxz+B5/WpZNIs3LsItjM24lCR+Q6CpLKwS1kZkctn+8BQB2unXWofZ1kmmeZFOQrTuzJx9OP6ZqBrAavBNctCEfzDGRdyISR1yCT6npmqFpqTp5SqlkqoMmSVGDhv8AZ2gj8Tirdk9vJnzTYzqpyVnJXcfTPFAHBazY3uh6gsImVPNBkGZFddueDheB9KhZnlWWSVvnCEBsYHIxnge+a0/FLLeybbW1SFC+PKgt2AGP9osSfwP4VgbvKt5U2jqIijjoTzk5yf4f1qJ7WOjC6VL9k380m1+KH2s0aQDbOZccDczL+vWtVrv/AEUCZ9wx8oxvUfgWOf0rF03T2ubkCCaCKTOSVfgD1rqrPwkHRZbnW4AwJ4Dsc+3A/rVnOYEtobiLzoZolHJJysZH0GSawblGWQgtu9+f8K7m+hieGZLUyNn5BtDopI7YJHHvXNDQL64yxjjiP91pCT/WgDLtVR2AlZguew7fWti1sraOcAi4dX5+Rd2R6EelWrXwyI2zNck5HIVBwfxz/Kti00+C1bMQbgY+Zifx5oAZa310kEljGrQ24bd5IkGGx2Kpwe3DEfUVMTeXEi+e0cVsowIkRQzD1YgZI6cEt9asjjpRQAxYwvck9MkknHpz2p/p7UU+3dYp45HiSZEYMY3JCuAfunaQcH2IPuKAOi0PwVrureI4NF+wzWV7LG03+mxSRhIxn52+UkKSNoOMZIFUD4a10WstydF1MW0W/wAyU2smxNhIfJxgbSCDnpg5rs7n4nouseHL3TNChtItGkuWW3Eq7HSb7ygJGgXAyAcHsTuOc81rvif+0fC2jaDa281tZabJPIA9x5nm+Y5ZdwCqNygkZ77jgDOKAINQ8J6zZyRxnT72WRo4pHVLOZTE0jFURg6L8xYFRjIJ4BNRw+FPEM6F4NB1aRAzIWSzkIDKSrDgdQQQR2IIrsNP+KH2ZbOKXSPMtoLKwtmVbna7SWkpkRw2wgKSSCuCfRhRd/FD7RZ3UH9kbfPttSt932nO37ZMJM/c/gxjHfrx0oA85uIZbeeSC4jeKaJijxupVkYHBBB5BB7Uyt3xx4g/4SnxTe6x9m+y/adn7nzN+3aip97Az93PTvWFQAUUUUAFFFFABRRRQAUUUUAFGKKVeuR1+tACUU455zSc9DnHWgBKMUoHGf60D73PpQAnvRS9jnjtSccemKACilzhT2/Gk9Mc0AFevp4U8FLfeDYr6a9tru+srKWayjVnW9aY7ch937vDAl+mVxtwc15Aeeo4q2+pXz3FpO97dNNaIkdvI0rFoVU5UIc5UA9MdKAPTV8G6Ib6JmXFkfFjaQ8QicyKgLbYw/nYKEBAW2hwSTk4AbN13wXodpB4g1dtWurLT7TWJdMgtksvOdiAG2gmUcDLcseQmep21wc+p31xDLBcXtzLBLMbl45JWZWlPBkIzyxH8XWpb3V9V1CN47/Uby6jeUTus87OGcKFDEE8naAM9cDFAHSR+C54PBh8TTEYt/JnksbpAglhkkZFZSkm/aSB1VMgkqxxkx/EzRdM0T4i3+m2Ub2umxND8qZlZFaNGYjc2WOSTgsPTIrnjrGpnTDpp1K9Gm/8+nnN5X3t33M7fvc9OvNQX95dahdNc311Nc3MmC8szmR2wMDLHk8AD8KATa2O3174dNpWpaRYW+qJqd3qk5NtFp8YkJteMTHLjBIyQPu4VjvwK07PwPZaZda7a6iIdRjPhx9ZsrkOyPGwGBkI5Q8k93B2qQeSK85l1G+ea1mkv7pprREW3cysWhVDlQhzlQD0AxirEuu6xdzyzzapqE0zQG3kke4dmaEnJRjnJQnPynigDq734exR6bpN5a67bXCa1PBBpkewB3Z+H80BjsEZO07fM5IBxWT478LQeF7yKG21e21Es0scqIUEsLxvtIdVd9oIwRk56ggEYrn5ru5uLSC2nuJntrbd5MTyFki3HLbR0XJ5OOtO1LU77VZ1m1O8ub2ZV2CS4laRgoJO3JJ4ySce9AFWirumIjrllU5fHIqvdbVnYKNqhsYFAEVFJ0y2OKOoFABn3paAME59OlIDlkQfeY4A9T6UALRRIpQsHUgg4IPrSdcD8aAFoo5x9KQnIGelAC0UmO/eloAKKKKACiiigAooooAKKKKACg5x8uPqaKKALiNY7F329yWHUidQM/TZS79P5/0e7/8AAhf/AIiqQ4J9MUH6jrnpQBox3dlbKXt7FpZyQv8ApMgkQL3IQKMn3OfpTL2KxgmkNvPJdLu/doqeUADz98kkkf7oqj1JzQAPpQBcMthk/wCjXX/gQv8A8RSiXTgylrW7PqDcqMj6+XVPPUdOOtNA4PNAF5m05F3Kt1LuOSuVj8v/AGc4bf8AXC/Sm+Zp+M/ZrvP/AF8L/wDEVUHTnGaQ8gDtmgDQgGlyTRrcx30Vux/ePHMrMF9htHP41JdS2uo2cV2xhsmhkNstvAhLugHyuwJAz6tnk1me2ePegcDGe9AFvNjGDn7VOOpOVh2n0/jz9ePpRLPZMqxxWJWMEN5nnkzE9wWxsx9EB96qNyfwpMnGPegC4DY4WRkuiGGDFuUFP+B4O7/vkfU05G03LboLtSBlAJ1bcfQ/IMfXn6VSwMgk0jcg0AXBLYc/6NdY/wCvhf8A43VuzvrcK+n2sRtre9XbPPPLvbdkbckABVHHGMnHWsjHA9BQenY80AWUSzQbmlupmA2mMxrF+O7LfltqRZ7KNG8uzlZ2BXE0+5RkdQFVTuHbJI9QapADijnnmgDXsXgxi1jeMbsESSByfyA4qK6mtYZVCWfmSbi0hnkJU/7oTbgfUk1ShnkixsOBnPTvUcjM7lmOSeaALSyWAHzW11uxyRcKBn/vinCTTyMm2uuv/Pwv/wAbqljpj0o7UAXTJp4yTbXf/gQvP/jlSQ3llaOtzBZTSXkWHt/OuA0aODkMVCgnHpnFZ3egjrQBp3b2M11PeTzSyy3BErQxJgK5HzZdunPYKR71Bv084zb3eOn/AB8r/wDG6p4zgnqKXqDmgC2ZLF5Bm2njRRtBSYEn0LZXk/TaD7VFcJbrCn2eaWaQt8wkiEYUe2GbP6VBig0AGcn3paQZxzS0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAG7/wAJj4m/6GPWf/A6X/4qj/hMfE3/AEMes/8AgdL/APFVhUUAbv8AwmPib/oY9Z/8Dpf/AIqj/hMfE3/Qx6z/AOB0v/xVYVFAG7/wmPib/oY9Z/8AA6X/AOKo/wCEx8Tf9DHrP/gdL/8AFVhUUAbv/CY+Jv8AoY9Z/wDA6X/4qj/hMfE3/Qx6z/4HS/8AxVYVFAG7/wAJj4m/6GPWf/A6X/4qj/hMfE3/AEMes/8AgdL/APFVhUUAbv8AwmPib/oY9Z/8Dpf/AIqj/hMfE3/Qx6z/AOB0v/xVYVFAG7/wmPib/oY9Z/8AA6X/AOKo/wCEx8Tf9DHrP/gdL/8AFVhUUAbv/CY+Jv8AoY9Z/wDA6X/4qj/hMfE3/Qx6z/4HS/8AxVYVFAG7/wAJj4m/6GPWf/A6X/4qj/hMfE3/AEMes/8AgdL/APFVhUUAbv8AwmPib/oY9Z/8Dpf/AIqj/hMfE3/Qx6z/AOB0v/xVYVFAG7/wmPib/oY9Z/8AA6X/AOKo/wCEx8Tf9DHrP/gdL/8AFVhUUAbv/CY+Jv8AoY9Z/wDA6X/4qj/hMfE3/Qx6z/4HS/8AxVYVdCPB+sS6RpOoWVs98mpLM8UNpG8sqLE4Ri6heBlhggnr2oAj/wCEx8Tf9DHrP/gdL/8AFUf8Jj4m/wChj1n/AMDpf/iqksPB+sXuh61qiWzpDpLBLiOSNxJuzhgBtxlBywJG0c1QXQdYZ7NF0nUC96pe2UWz5nUDcSnHzDBByM8c0AW/+Ex8Tf8AQx6z/wCB0v8A8VR/wmPib/oY9Z/8Dpf/AIqql7oGsWKTPe6VqFukKq8rTWzoI1YlVLZHAJBAJ6kEUNoOsK94jaTqAeyUPcqbZ8wKRuBfj5RgE5OOOaALf/CY+Jv+hj1n/wADpf8A4qj/AITHxN/0Mes/+B0v/wAVVR9B1iOC1nfStQWG7ZEt5DbOFmZxlQhxhiR0A61ra34D8RaXrdzpa6bc301uqO0llBJLGVcZBB2g4yGGcdVYdqAKn/CY+Jv+hj1n/wADpf8A4qj/AITHxN/0Mes/+B0v/wAVUcnhrVItOiupbS5R5bv7FHA1rMHeTkYB2bCdysu3duyD8vGagOgawJ54DpOoedA0aTR/Zn3RtIQIwwxkFiRgHrnigC3/AMJj4m/6GPWf/A6X/wCKo/4THxN/0Mes/wDgdL/8VUknhLUU8Pxaouxy9/8A2Y1mqSfaI7jBOwoVAzgDoT1A65AqQ+Gtdmuri2h0XU5Lm32+dElrIXi3DK7hjIyORnrQBP8A8Jj4m/6GPWf/AAOl/wDiqP8AhMfE3/Qx6z/4HS//ABVYtxDLbzyQXEbxTRMUeN1KsjA4IIPIIPamUAbv/CY+Jv8AoY9Z/wDA6X/4qj/hMfE3/Qx6z/4HS/8AxVYVFAG7/wAJj4m/6GPWf/A6X/4qj/hMfE3/AEMes/8AgdL/APFVhUUAFegXPw9jh8W2mgHUL1Zbhm23MmnhYWVYi5KN5nzEfKpGBjJ5458/rrpPHV23iSPXl0zTU1RWyZVE2HHlmPBUyYxgjoAcge+fLzGONk19Udvdn2+Ky5N+i1vb7u1w5ftGxffDJtPLm/1N41S2u7ttlsHby4HUDA34y6uGxkY6GuO8SaLJol/HE0qXFvPCtzbTqComhb7rbTyp4OQehHfgnZt/HuqR2NrZzQWVzDb2UungSowLQybMglWHIEagEY465PNYGt6tdazfG6vCgIURxxRrtjhjH3URf4VHYfzJJrny6nmkan+2TTjrtbvpayvt3f3vUqbhb3TovFXgr+xo9Sazv/tp0ySNL1Wh8oxiRQY3X5iGBJIPQgjpjmpoPAE0/j+48NRXu5LeMSy3XlAbVKK2dm7n5mVeD3zWZ4j8Y6hrsdwksNrai6kWS5+yqym4KqFQOWYkhQOFGBkk4zzU1z471iW51m4iMVrPqvk+bLbl0aPyhhdh3ZGRwc569qxhTzj2CTkudxau7aN8ivorO37xpLRrlTuwvTv/AF/XYfongyS9hu2vJ7iOW1vRZS29na/a5YmwdzuqsMIMEZG7JBwOOYdL8PabeaHquoyatcKumsgmENmHVw7lVMZaRSRxk7gpGakm8bXVxrMuqXWmaVPdtPFcozRODE8ahRtZXDEfKCVYlcjOKzF8RX32LW7aTypf7YkSW5kZcNuVy+VwQBkk54+mK2UMzndylytuG3LZarnSum3pfV21tYPcNn/hCv8AiXb/AO0P9P8A7J/tnyfJ/deTn7vmbs78c424zxnvR/whX/FxP+EW+3/9vPk/9MfM+5u/Dr7+1Uv+Ex1D+zvs3k2vnfYP7M+1bW837NnOzG7Z04ztzjvnmrUnjq7bxJHry6ZpqaorZMqibDjyzHgqZMYwR0AOQPfOPLmy59b3jNL4dJacr22Wu933Qfu9DA1uyj0++NtH9tDKo3reW32eRWPONm5uMYOc9+nrQqzf3MV1MHgsrezULgxwGQqTk8/OzHP444qtXu0eb2a59+t7fpoZvcKKKK1EFFFFABRRSMQFJPQUABOBmuu+HXh2PVb2a91a4Ntp8aYjWNY5JZSeNwWRWUjnup571h6fo93eeUywuEkAaI8HzMnHHb88V6XoGmT6CfJup7S31KKZZFLRs4OVyFwqkk5AyQdoAP1oA898ReHW0TxJp1ncXiNpF/dFIb1GG9Yy+PnVsbXH/fPp7dn8SPBOk6J4Jm1bTZZo7izkWHErBhdAknPs5GORxx92tTxjpE0t3GYobe91SS2dp5oyjxGM8jcrkqrZ6NnJOcDABrzfxn4f1jwzBpMevTvNBJCqW484yCM4yU25+QjPPGOepoAw4XWSMMucHseorvdL+IH2HwtBo/8AZnmeVpt9p/nfaMZ+0ur79u3+HbjGec9RXAwOjxBo/un2xUlAHda58QP7XuvFbS6Z5dtr0duDGtx88MkIXYwbbhlyDlcAnPBGMnWf4u3cniDTtTk0/wDdwSG4uLRJI1jlm8gwh1YRb14J4Zn4wMjAry4nt39KAO561PNrZGvsmo889O3n/wADzOp8C+Mbzwt4qOtMr3ryrIlyjyYacNzy5DEHcFbPU49zWloPxI1HS9M1CEpvvri9fUY72MRB453QoxKvG6lTnooQ/eGcGmeBvClprmi6heXMOoSTW7EoFb7Nb7FjZ3zcGORA3C8PsAyDuOcDZg8A6CdF8NXEup3jXOqyWa7ooy0TmWUrJEGCFEdBzy7ElGyg4qjIydU+IH27wtPo/wDZnl+bptjp/nfaM4+zOz79u3+LdjGeMdTUmr/EaXUIPEpSxe2u9egtY7iWO5IVGiGG2rtztdeNpY4yeSDius0zwd4e8PfEbw9b3ivLDeteQmz1J422tG7xxSMCgDLKB8i4HzYIZsYrFsPh/pl74Wn1Uf2nDLBZalNcQtIrfZp4HURQyfIMMUJJBwTjIwOKAMbwb4+l8MaXY2kGnpO9tqh1Eu8pAdWgMLR4A4OGJDZODjg1b0j4ix6bcSImlTSab5dkkcUmoO8qm1kEiHzGUjaW3ZRUUYIxtwSevuPhR4ebUZNPt7jVkmN+dOSZ543VW+x/aRIVEYJGfl27h65HSvDqAO6Pj2CSOWK70OG6gl199beGaYlGDKV8ogKM4znceDjlSMg29d+JjahpGo2Fppr2Yu7C108SJcgFEhd2PCRquHWQqVAUAZ7HFedUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFa3h/QrrXf7S+yPCn2Cylv5fNJGY48ZC4B+bkYzge9AGTRVuz02+voLmeysrm4htl3zyRRM6xLgnLEDCjAPJ9DXSad8PdbvdO0q8KpbjVJxDZxyxylpAcfOdqFVXbubLEEqjEAgcgHIUVe13SrrQ9ZvNMv123NrIY3wCA2OjDIBKkYIOOQQao0AFFFFABRRQASQACSewoAACTxVK81C3t5mhLq8qYJUHP8uv0qHxDraaVE1takPfuvzMCD5IP/s3t2rmdGhttQ1FIpJPKd+hds7zkfxY6/gKAPQbHxDJPcQTMX822Crbt1KqOdnPQe1dNYeLWsYrmS1kkimlm+0gE4kL4wVJ7KQO3/164gMYnS3mjyiThTJLiRieANhPQD/9VRa3PIk32i0kyqyMHiZWCx46H7x3A89SaAPQZPHNyqqyqZXuXMkiNKTIrAjB5BB6cHPGBxVHXfFN5fSXclyoMc4UhbrZIC2042pjZv54YKD/ADrzyfUVKBw26ZVLqMgcn1xwV9qr2DTX0cjrNiQdsnaPYj/P0qZzjCPNJ6G+Gw1XFVVRoxvJ7I6BWjSZo+VmUZZGb5wPVhk/nUmc/dOfeuQk1W90yeURTSRXUibJNkhHyddrEHke33fUHtvaPqsWpK5RfLlX78Wc49x7Uk+fbYtwWHdqi99dOz8/Py6deqNIcUtFFUlbRHPKTk+aW4VPYXc+n31teWj+Xc28izRPgHa6kEHB4PIHWoKKZJPf3c+oX1zeXb+Zc3EjTSvgDc7EknA4HJPSoKK3dI8K6nqvhzVtbtIt1lpu3zflYs+euzAIO0YZskYBBoAwqKvJo+pyWttcpp161tdSCGCUQMUlkJICIcYZsgjA54NbWieA/EWqa3baW2m3NjNcK7rJewSRRhUGSSdpOMlRnHVlHegDl6K2ZPDWqRadFdS2lyjy3f2KOBrWYO8nIwDs2E7lZdu7dkH5eM1m31nc6fdPbX9tNbXKY3xTRlHXIyMg8jgg/jQBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFPtzEs8ZuEd4QwLojhGZc8gMQQDjvg/Q0AMrofBniGLw9PqhuLN7uHULCWwdEmETKshXLBirDIC+neuzu/APhqLxN4b0mDW7qVNZY3azuojEdqykxJhh80jkFQ2Rg4+TkCp9O+H3hy41DUo2udWdLZtOiaHBgkhkuZfLdWMkILgfK4Oxcg496AOe0Dx+fD2kXenaNZzQRm5+2Wc7zRSywSmLy23FoSrKf8AZVGxkbuazf8AhL5Y9M8JW9vaIs3h+eWdJHcsszPKsgBUAEAFcdefauzsfC2jy+GpNGa3ee/tvFSaddXsJQSpEzeWJD8pKRnkBSSN/OT92qnh/QfDsnxaTw9Yxan5UMlxbtPdSW8u6REOT5bQldvyuMHJOVb5SMEA4HxLqMWseINQ1KC3e3S7nacxPIJCrMcsNwVcjJOOOBgc9Tm132reFbLR/B+na5aPc3Fw0FtdfaW8h7RpHdw1vsbksmwZA8zOG3Ko6dn4p8CeHLrX/E95cXL6db2k8UIgsLcston2RZPOeONGJUt/uD5XO7PFAHh1FFABY4HJoAACThetZfiPWU0iI21syPqDfeYEMIP/AK/8qd4k1saKht7RlOonqwOfIH/xX8q4BmaR2dyWZuSSc59/rQA5WEsrPO7ktklupJ981P5VubN2Mh88MNiBeMd8+9VwOgxT+56dKAN/SNQlNuLUPHKd4cFkzIu3srYJA9gcVa/4SF3uszxqd4B3lTv44AJJ6Dt1FcsDjkZHvmrdjcvFewyMQyp2JI6e45FAHR3YfUIpzC0s0kajYrsN4OeeB26Dv3qWMJp+mSPbIjLFlpFZ9pz3HIyx6dun0rFg1BUkneNirOTwXI25PZuta41iZ4zAMi7bag3JuV48dOOc8e+fasqtGNZJT2PQy/M6+XSlPD2UmrXtdpeV9NfQ5a/vZby4E0+A20ABRwB/nNJY391p7yPY3M0DyKUfy3KiRe6sB1B9DXV+KdKhksIdTsgRbyuqSB1G+NscrgcBfbJNc0mnS3N81tpUct++MgwxMc/QYzitIxUVZbHHWrTrzdSo7ye7Ou0XVY9RhyvyzKP3kfce49q064KzfU9LaWazlltvl2zBZCm9c8qwB5GeCK6/TL77bbiVo/LYnDKOgPse4pmZeooooAK9C8LfEqTw/o+l6VFpUMunw/aP7QhJTGoeZkLvJQldowO+4AA8cV54TjgDJrT8MWEWqeJNJ0+4Z1hu7uKB2QgMFdwpIyCM4PvSvd2NHTcYqT6/f/X9LqdnafE+W30zTrY6UjTW62MM0nnkLJFaStJGFXb8rEkAsSw44UZ4xrLxrdWvxGbxZ5HnStcyTeRNKWxG4K+WG9kbaDjAwOMcVsx+FfD17401fRtP/tbZpcF03lyTxma/liAAiiAj+U5DHo5KjoOcbVt8MNCk1LW7b+2ZpYrS9a186N49tlGLZpfNn4OVDjyzygyrcg8BmZzXhX4gf8IzZWttYaZ5kdvqz6ihmnyTG0JhMRwo+baxO/pn+HtXN+JNVj1a6tmt4Jre2traO1ijmunuHCqO7NwOSeFCqOw6k9J4otdMPww8I3mnWO258y4hu7lGVsSBgdkpCA7iPmQE5Vcj5vvVwtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFABJwBk0AJtJYBd2Sccc1Xv7t7aVrWzEk12EJkKY/djHToTu71U1/WF06Jra2Cm+PLlwCI1x2HrXOWl/eRyxmUueN28ffIPfPeo5EdCxVTrZ+qT/ABaZnzG1Zm8yO4DE8sZQxz6kbRn6ZFbumaRZXOloSZGLEkSfdYc46c8ce9Z+qvBO6yqqoWGCFXBJz1I/z9azXdiFTzGZEyFBOQM9eKyrUZTSUJWPQy7MqOGnKeJoqomrWsl1XZW/C/mW9QsPsjNtuIJlU4wrDcD0wVz6/WqXYdc9zQB1FHf29a2gpJWk7nnYipSqVHKjDlXa97fN6gTnPTBoPVfQHmj25o/iHp2qjAsXN0JY1VYIY1A2/IuCfrTrW+ntW/dSYVsbl7NiqvOSe1L6HNAG/FryzKYb2MpAQVAiGN3pnGM4P1r1qKXQtC8OafZaWj3dzqVr5t1eFw32ZcEtGiYUByehPP514LznHOW7CvWfg74mt9L1yytdaFrPbyNtWWd8JACRlyMcsP8AazQByus6JqGqzHUUtLq00yRjH51wrBNwycfXHOBTPCHiSTw/qtvLeKl5p0RUTaeXxFdKrA7XHQ9O4PvmvpP4wzG48FONEWKTToVBF/LEJCXOR8spwqKAc5XkHAAAr5Du7Zo5nzKj4PLb8k+470AegHW4Nd1TUNStbVLCOaYkWcefLiB5wv8A9bA9AKsK27px61xOn6tBp9kI7WDzLhgTJI3AJ7euQPw/Wur0K5bUtOku4IZdkAAuW2HbGx6EnoAfeuSPtp1XfSH9f16H0FVZbQwEVF82I30V0r9HfR2Xa/veRdAA6UtFFdSSWiPBlJzfNJ3YUUUUyQooooAKKKKACiiigAooooA6z4V6RY67490vTtVg8+ym83zI97LnETsOVIPUDvWs3h/QPEEkS6Ncw20lhptxf6rJZRzSQbY2+QQrOQ5cgjO4hemD1B4SxvLnT7pLmwuZra5TOyWGQo65GDgjkcEj8aLG8udPukubC5mtrlM7JYZCjrkYOCORwSPxoA7t/hylvrWsaXcat519YSKI7WzgWS4uIzEZfMWOSRM4XGVQu2c8YwTbtfBGm61ongOHSpnt9T1hroXE8sZKssRJY43kAqAQoAG/OSV6Vkvo3je2g1KAXVyIZbRtUuo49URlngcENMQsmJAQpyRk9M9Rnk7fUr63gjgt725ihinFykaSsqpKBgSAA4DAfxdaAO3/AOEB0xLXWb6bxPC2n6dbW9wZLWBbhyZSy+UwSQqrhlxwzD5gcgU/wz4FtvEug2DaZdoslzrD2RnuLZkkRFhaXPyyspGxQdu0Hccb8DJ5uNPEeq6VqmpveXMlhIyJeT3N6EW4dFLIh3sPNZQuQo3EcYHIqPTbbXm8OXOoafPMuladcpPKI7sL5ExIVJPL3bg3IAcDseeDgA6hvhzZ2+nX+p32uvBpkFhaahE62W+WRLjeFQpvwrbkx94jkEkc489uBEs8gt3d4QxCO6BGZc8EqCQDjtk/U1rWU+v+INRksLa61C+u9TZEljMzMbgp93fk4IUDOW4UDPAFR3/h7UrLTH1CaOFrFLkWhnguYpk80oH2goxz8p6jjt14oHFXdm7GVRSY9STTreIT3lrbB9j3EqwqzbiAWOATjJxUXl0R0ezorSU2/RXX4tP8BACSABkngAVBeXrW8F5DaLm/RM56mPPoO7Yz1r0b4d/D2XU/F2pwa5Ght9KDBrdGP+lOOwbjC4OfWuW8feBLvw7eSaxpbXF/oQuCJIlcma1JOQDjI29AHHBxR7/kFsOtbt+Vkvxu/wAjzxdDm84maQSA5AcHnvyQf8e9PsoJwtpBPlI43Jd5FwgXuT32+uePata2l+2RtEjhJVw27cMSLjlc8bG9+RVKCxmMk91bfIyqY5o5Pnzn1P8AXp71lQ9vb97Y9DNnlfMv7PUvnt8tL/iVPEOirp99KbJvNtnX5C7hg+e6MvDD6dO4rBMhEZQhQOARjrWzPAt3pSmzkYiN9ssBbJXA4Ze4HNYso2yAZUrjjDZ4roPGGZ7460voD25pufXjml7jrigAXuc85qVYA6giWMeoOcj9Kh69Rz0zW14ZSwuXlttSdIWkK7JsEso7he2T7igA0Tw3qOtSmPTkhlbIA/egZz+v41ut8ONYi1M2VwhLR8yGAeaMexUkGupkuLDw18Prz+zFsTcmYCK7eT/SHBA+UhQAR6ZPrXndv4o1KG5M4upnLHkOxOP15HtQBe1bwpcadrEVi6t+/H7tyjHB6bTheT7YrvPgZ8N7fXPGclt4otruJ7HE32SaMxbwCPvAjPp9a4jT/GGo6fr41O1kBuQoxJydo/2Vzx9K9F8AfFp9K8QanfX0aXd9esG892KoTxwFA9Owx0oA7L4z+P75W1HwbZWcGnRRDyjKkrM7x9iAAuAR1HP19fnXUPD8qm3jsd88s0ixLEqEszHPvXUfEHxq/iTWru7ZZoHDMY4vOLCI7snjuCcnb0GeprF0XxQLMiS9tormRgFGYgdoyM9e59vSuVwrqompXj/Xke9TxOVSwcoVKLjW2TTbXrZy38tvTo/XPAl/4a0yC41qORbu5O2G2VTuBxnJ+n0rm7CK7e7H2FJGnT5vlHQDrn2r2Y2tnq+jXura9qskMYtitraiUyyOxB2Fi7EKuccdfTmsnS9Lk07T1BiijEiBmyNzyZIwOcZ6eo6VvzNbo8r2EZfw5p+uj/HT7mzO0uS4vtKkv2tZUhilEEsm07FkI6bun4damBB6VNNMsZu0uFeKSEswhkyTnHB2gd89Bz+FZ1hdrc2STlkR9/ltDvXzc46lPvbcd8Y96pSUtmZVKNSlbni1cuUUgOelLTMworpPh94Un8ZeI00uGb7PGI3mmn2h/LQcZ2kjOWKrwf4s9jTLTwZ4gvHvkttOeR7Kd7aVRImTKgZmjTn94wCMdqbjjnuKAOeorobvwdrVlp1jf3kFtb2t8qPbPNewIZVbbghS+cfOpJx8oOTgVs638PLjTNe13Tku/tcel2X2wyw+SHI2hvmjaUMqjnJG4j5TtO9cgHC0Vs614X1nRLSG51Sxe3hlYR5LKxRygcI4BJRtrA7WwcduDWNQAUUUUAeqeEfiNo+meFYoNa0dNQ1/T1ZNNu5LZJdij5ogzs28BXJ4XGFAxzWb4d8Y6RZ+Dta0/VItTutS1GO58xpHM0UkzhTHLhnAVlZck7GfOCGH3a4C3ETTxi4d0hLAO6IHZVzyQpIBOO2R9RXo1x8LvK1/RtITX7K4udVkeSBoE3oLRV3CZjuzuYA7VAKnB+figA/4TvTP+eF7/wAin/YX3F/1/wDe+99z36+1Zvwy8WWPhea+N9Fcq9w1u6XNqqtKixyh3iwWX5ZAMH5uwyG7aWnfDWzvbi7EXiSGW2h+xBZLWJJ233MhjCOFl2qysOcM3BBHpUlv4H01vCsdvcTOmunxKNGe5SMvGv8ACVALgFcfPu2hs/LgD5qAMnV/GcV94HvdEt47m0M+sPfJbow8iK2YEiEYI4DndjaBkZ61X8F+KLHQtC1uzvrN7x72eylSEhfKdYZt7o5PQMOOh961tF8HaNJ8SI/DcWqvfyI00UjT2DJCZEUkr8s6uQMPyCPmUfeByM3UfBw0bQbPVp7n7VOba21CS0NrKYfJmdgqmZDw3yjIOzqdrEigDqH+KNmfiFpmsCO6/sy1W4WTZDsuJEl3EROTMwdVbaw5UDnCjAFcm3jCW6+Ht54fvrnUHunvxepKZDIsyn78b5YEDd+8z82W6gHmuw8UfDHT/wC3NbltdTstE0u3uY7O2S5k+TzTbLKd7yOCFJIA272+Y/Lhc15AAWOByaAGsdoJAJ9hTDeJaXlk5bZJvDxSZxtcdBns1UfEGqR6cjwwvuusbWZT/qWzx9T7VT0EC+Rre7KFGO4xngbv7wI/nQB9EfA0Pfa1e3QaTz8b/MYsdzkgsHycnOff69q9X8XeGV1mAXFlILPV4RmG5RRzjJCPx8yEnkV89fDzxBPpLkwYVohsR2+U44+V+eV969r0jxte6lExhtbfzIGzcJhi2zj5lHfr1GfwzQB8y/EHwFrGi3b3IsTa35fzJIYyFSQk/egx99STyvUelcjpeoGC/Md4Ta3akjeVJXdzkEcMp9R09RX21eXnhvxaf7Ku1tb+CWPcMkHnvg5yPqPzryf4mfBstPZ3uiPC9nbwmBkbas+4/dJc4DAcDkgjg880AeG3PhqXUpBcadGgLHLrE2Rz1O09M/5FYF94bvre/FtIqBz0ZzsVu/BbGTXoGr+EtS0qF47wxw3athEdsCRckYDYH4EAg+tdVPDDrvh61tbvRlW9iRQ01lOkTcYznqrHtjbnn8wDxU+ENe+x3N0ml3MttAoaSSJN4Vf73GePesgQOYt2F+U4Kg/MPw617ncxXGj2MaWFzOsJ+aRL2LMkQxwA23KjB43DB7VhN4Q0vxPFNdWs0GlXaDzWjUEBwOuF6HtyDzQB5/ofhu71WWRVaG3VELt50iq3sApIJqDXfD+o6I4F9aTRRt9yVk+Rvoeleqw+FfFPhzRTd2U+l6yl1Bs8iRWeeNPRQRhe3Qg1Q/t06ros3h7W7Gb7XGx8mMsrxxHjcScFlP4jHrSbsrlQjzyUb2v3PMNRtJbSK2MucypuOT0OemOvAI/HNU88D611njCAJaBJwVmSTC/LnJHVcjgdQfwrkQeQP51hhqkqlO81Znq55g6GExbp4aSlCyaaafTy89fRocCcmrUEMTWLztKfOz8sQXP45/8ArVT3c5zn3FP3FVKqxCtyQO/1roPIHGVj95snsvUH3pjnecsSWPcmjnnH0pDkYyc+lAFyDUbqBSI5GwowBnpj/PSujsPEkyG3w5a4I+aWTnHoFHbH4/hXMW8LM6q429jnjA9c1rWscNoyyN88WCN+PvL3weg+uKAN6cy3E3nGVDuy0jOQxJ/D271lXmpFZA1k5MgyFH3/AJf9o+/oMfWpLBvOtTLuWOzjJSMFck59M8E+5q9B4cdo90aPGu3czyDp/n3pOKlujSnWqUvgk1cs6ZcPcWEFw/lB5cgxrMrMCO5QHco9yBVsNxyCK5W4aCGcS2ruyQHakoxl278/3Pbj8K7A2d3Bomn6pcxFLS+YrCxIBYjH8PXHIwcY561PK1szT28ZfxIJ+mj/AA0+9M2fD/irUtB0rVbLSZfI/tDyvMuI2ZZY/LYkbGUjGckHrxXQt8VdfN/eXgh08TTzi5jIibFvN5HkeYnzckp2fcuRnFcfoNxY2+sWc2q2v2vT1kH2iEFgWTo2NrKdwHI5AyBnjIru9S0jwjH43ttI0m6sn020tnkmvLycyLeylSwQMkkacAqB80YyG3E8A0vMxlZv3dv69DjPEGu3Wu/2b9rSFPsFlFYReUCMxx5wWyT83JzjA9q1pvHepz6pqeoywWTXmpaadNupNjDzFKqpkxuwHwq9AF4+7XX6jcaHomkfELSdJv7a60vz9PnsbV7vek2XVpVTawLAYCkqd2FGTkZqC70/4eDxN4btLV3XTL9je3k8tzuNurqfLtiVYhAGGH3DcAR845IZJxnijxXeeJArahaael0WV57qKDE1wwRUBZiTgYX7q7VyScZxjnq6HxzFo8OuCPQInhhWCMTJ5qSJ5uPmMbLJINpGDguxBJGeK56gAooooAKtvqV9JPazve3LTWiolvIZWLQqhyoQ5yoB6AdO1VKKANI6/rBnnnOrah507RvNJ9pfdI0ZBjLHOSVIGCemOKZDrGpwyXEkOo3sclxIs0zJOwMsituV2OeWDfMCeQeaoUUAW4dSvoNROoQXtzHflmc3KSsJSzZ3HcDnJycnPOTRJqV9Lp0Wny3ty9hE2+O2aVjEjc8hM4B+Zucdz61UpQpbhRk0AaX9u6zJJeMdV1BnvVCXJNw5M6gbQH5+YYJGDnjiub8QazHpCtBbSA6iV5OAViH/AMVSa1rY0q3eO1xJetxvwNsP1/2q4eSGV5QWDZc5JJ5PrQAih5GZsltxG/J5atrSvvLEz/Z5lf8AdySkgbv7pPp7VkNDJBhj6dR3FaunWs+oKBG/CgGQY5HPU+o96APU/AEktzd+VehYbhWLAupYOw42sB95Tx7+/SvSPE2rrpFisdiFtdRQczQnKFT0aNwdoxg/Kw3fSvKPDl7LpukT5m3rbKX2S5LKB2U9cfpz+NYmteKxrl/G8wkt1jj8rKHcpI6HAOOc8kZ/GgDphfXd5eXl8sZF0JA3nrxkZ4Y8jBJPHI5r2Hwl48/sOw06DU4ppoLhv3t0W3quQCAc859eMcda+dNP1hEljN5IZPs5BMe9juXPK8YIFdhpF7ArNcO8w066O3dL+88pW6hgMbgPUbT7UAfQni3wRoXiyxMtnHZfa5418uR2YqFHdQpAVufvYPuDXid/8P8AXvDtzd/ZZLvfE/lI0p+adOxQr98cjjr6gVqaFrk1jd2v2eSZ7YNsR4SzoB1yAfmTp6ce9e2aF4h/tJI4Lm2WRjHlm6A9v4uvH/6qAPmm91WZbV4JShnZ9kg2/Ojjv9Oe3pitbwpJDquqxWd5HZK0IBjnuwArn+6G6q2ccHj6V654q8F+GNTtjqKQNp7W7CeaMKkaGNTuIbP3FPOShUn3rzTVE8NnVFjhIhtJos7jMZULdhHuGWPPQ4+vNAFi28Ta/og1KzI+zQB2CLcxhCEbPzJ5ZxjOcOMdPasyPUddW4tp9IvJZb6BWu2keMAOmCW3P/GMDvz3zXR/8JebHTItKntdOudKSJFjW6tD57OQMfuiSV553Ed6n0vU9N8T6kltYyXOj3YVl2pGZBN2wVGPlyTx19/QA8x8VTX/AIn0DVLyJZZJnk8yS4MR2NiNFJXYFVSdrHJ4wPUZrxKSGSJwHVlOAcEEHFfWS67feHvCN/p0ltIqyT3UNtPKpVGPnOCNmc/eyCMnHNfPmtaI0lxLiaI3Uzf6uPIA56DP6Dmop/CmdGL0rSj20+7T9DkVHA6AHjFSeU5wQrY9cda3ZrC0jtrUJBMJVPzO+VZz6gEYx/nFKjKbt2EHl26g/NIuW+megPvirOcIdKg1HTIZoMQz7drc5DEcc+nTP496pvYtbThS0fmxjB+TKjI689TV6O9lt0NtbBd7Aurfe4P49fzp0oWaNJ1UNISGdVGefXvXLSjUpzak/d6HvY+tgsXhqcqELVkvf6J2Vm0u/V2tpdvyz4pEh2+UDIo+XeGxk/lUh2s2ydG+UfJGOw68fX1pUbBmmYAHqm1Q2B/Q+9AuRJKm0b93UE9T/Wuo8E3/AA7axXEqXl1iG2iyEjJAViPb19v0rZ8Ua8LjTRYWGILZgBLIBhm7lfXHTjpxXOW1jqF5AJvmtrKLg3LHy4VA5wp/iPsBVixtLSKRZXR2RGDBpFChz16d6AOn+H/gldbC3MisbRHVVBU/vG9AOmOMH616hrD6LaaDd6BmKa2lz9sm3/KuBn9zj+IccHj+VeZ6l4wntvDH9m2EhhIIz5bYBz2OO3+yMZFYJS4to1utTlLymMAKXwqA9FwOhPp15GaANHULJrKQSxSLJYzkm2JcGUoOnmKOVbHsB2qAEH1/Gs2yM97KwtkM1yGyX2/Ki9k9B9eprXu7WW08lZtxnZN0kYicGI+jEjb/AN8lvrQBHRSA5FLQAUUUUAFFFFABRRRQAUUUUAKAScAc1meIdbi0q3e2tHWS/cFWYHIh/Tk+3arOtS3tjo8l9Y2zyxhvKe5AykDEcf8AAuDivOJJGkkaSRiXYkkk5JPqfegC3bzho5FmPDEnd1IPv6irMbxmKNVUCQH5hu6/Q9qzo2AJDdG9O1SL8qkEcjpjv7GgDqLJba/h8i9h8l1XiRfl3f8A1/pVrQDZwzLFeMYNrfurpMcHPAIPT6EVgaTdXEdxE8EgzF0Rxkbe4PtVzX7m1uYFlg328+dzxN8wbPUBh29jn60AXfFerO05tpCkkkJwsi9HQ9yO3vzXOhXUDd+8jYcgHj8DVZppNwIJ5XGM54pyFiqlG6HjBwRQBq6fLHM7NNt3RjKkg5wPz/TNdLpRtbmIi3uJLS5dQFkDc/TAOCM9hz/KuHeN2dWU4J7Fdrf4H86v6c8+1jDINynlcfMcck9c/jQB6v4EuX0nVfOuX812/dzHzCVKn7x2nn0+XGT0yK+hNGufC1/Y223yN8nyKQBuU4+8V5C9f4sfSvmHRNdsWts3emmWQjAmglKkZOQCuCp9OVJr3/4eeGbHU9ItrmD7baTFVcR3aeYRgDlSeApJ6AA+mBQBqa74J1GHTp003Uori3Yl9tyhEh4J+8rKp55A2ge9fNvjGfVrDX/s+rW16REuYywy+zrgkAbfyx7mvoT4seGPE1x4YX+y9bcw2m6acBhDI6hTwGAxtA5xx+NfMWo6hqxv7h7hZ5peBFKJVdCR3JGQwwOgINAEd1rNxBCiwzTIXPmK4by2HXILcn8AcVN4U8R6haanA1lei2SN1LMj7XIyP4vX26Vz9/emSJ7d4C8hcyMWAXax64HUD2zVnw25h1mwmXIkEigMrbQhzxkf4UAfSvhPxJZz6Tp6jSIdY1Ce6uCGkVZ5VV5pHJAOdvBz7k9DXAfF/R786ub6HQr+KzJx5sluqlWJJ+TIGxR6DOea9d+EulBNLhvo7e7Nze/v3vJFwVDndsXfnIBOcjGeuKZ4zuL6Sa7tb+O5utJjnCmW3k+0BieqvCpBGPQ/KPxqKfwI6MZ/vFT1f5nyPfPL9oufOW5e4VsKGP3B2JAzxWbMlwwQucBjnLcD6c96+i9f+Ct/qdzLd6IkEFvPiZXmkVAARkgxgHH13H6V5b4m8E6npU13HeyWchhi3BbYmRWGM5V8AE45xnPoKs5zjLZ4/NZYXZCBg43ZY+2DirFsZpriOGCPewB3jBJyeCCR1qxYCO2AfaxBTKt82CM9ARgk+xq3Z3ESRK1nAxmV8MXyVjHc+XwAR6nP0pNX0ZUZODUo7oiTw/d3FyIm3QxDDSnhnVeM5H0PXp/KuoOhaRptnbXJTYN21POO+WfvuK4xs/QY71DYnUNTujHp9tcS+Tl2kC4RV7nI4H446VLPDLeOs1zOsdkP3ZbG5WOew53fmR1pRdtGa1IqS9pDbr5P/g7r7uhW1fUxfOHjXfaQr8qfwmTsR2Cj2FVrVIb24Se4kx5WQHCjaDjogPBIx1P5U7Wbm0gna1tfMkhC43tHtC/7ox19yK5m6uN02yHdGgwu7fliB1/P05qjA7F3t4Ejht4mWSH94IVxnzP75Jxhvf8AIVr+HfCN74hkWe4Y+XuLvOwLJHnrs4yX9/5UfDnwvbXLjVfFsv2fTIWHk2JbbJeScFcg9iOcdTXrI1W3jugLSKIBMFLeLiJAB0YdCP8AYHHrk0AaHgzw1pmiaP5raaYoYifKikC+ZcNjJkY54Hqc4GK5rxTa/wBq/bI9Ns1lWV3kacIBvYZyI2OdsQ4zITyQQDjNLNqE2u+KJYb64llt4EEksKOY7eKIdFbH8I7r196o+KPEP9t3T21ozx6Yvy7BwXGODjsnHCe/NAHmV3Elm8arcJcOybnEYb5D9SMHJBxtLds4pqNuUEVNrwEkpWxGEgOTKMYx/d7Z/HgU67s3tEtJGZWS5iEyEKwyM4/iAz9Rke9AENFFFABRRRQAUUUUAFFFFAF611W9ttNfTobq4SwkBV7ZJGWNgeoKg4IrhvEHh5LaGS4t1Cwq3BYcnPaurp6yMCO/Y55BHoaAPLdqru4AYfpVm2dSgR+D2cfyrptf8Orcb7jTFVGJy1v0GfVST/47XLBTG5WRSjqdrKw7/wCNAEkmI5RLDuRgeh5IP9ajmkMzksAM8nHHPrTZXL8FsqvTP8qZnA6UAKT1I5A7UqkjGSQeuaTHBFH8Qx1oAkQuRnfgg5AqyWVjGod8D73yqdh9j6fXFUsc85xTlbY6ttzjk0Ab+kn/AElZY5RFIh3Lv5Xj+LPfntzXvvwc8R6vby42edabi7Ou7c54yCBnqOhIA9TXzpprNJcosKbucknAGO+W4/XNehaFcyWLRyeZNBk5XClME+4Xj6jn3oA+j4viBpGs3d/o2pCN4ZlMYRULgMQBhnBIGM9hxXkfxa+GKWd7pn9h3k6jUZCYormQmNARkhXJJx14KgY71gW1202stc3IvZ50AcTW27bnOe/OR+Ne9fDrXbbVtNCa7OkrEbBHesp44AyGfGev8OefwoA+YZ/h14ijuVto7QzMp/1cYD5OSONmf8ea9N8B/BPUp7VNR1mP7CVbeYWJRuO4UKfTvX0NHZ6dHem2hFmGKeb5YhTeEzj5SO2fbPvXlnjnXYvDmrOLe91MApujhe4mXJ54bc4IBwO3vQB1ngC/tR4Q0GC5eaVo7OGRWeZVCkRqNvVcgc8HP410L22hWoaa7tbGGW6k2sTGgLMecnGefevm2P4j3Sabp2m2Fq9qLWBIpZVj80SAKF3fNjHrwcfSq9h44lkv333t8YkYBlWV4xKTnJ49fTJ61FP4F6HRjP8AeKnq/wAz6b/sC1utOe1juryG3YkN5REbOv8AdJ25I+mK4vxF8Nlub7bYXFrbRiHZbxSKJPnz95lZGyAPTH1FZWl+PrtYFksIpDGAF8lwgXJ/iY8MTjAzmu30XXZ7+yjkmk0q3nJw378CRAcZO05z+fOKs5zjD8FIriH/AImetZlc/M0EAjHI5C88c9MURfALQlnikkv72YIeUc8MPQkHPNdtql9caPO99Nds9iyqflZQhbPUdTyPoK1dF1pNRjZi0DR7CxaOTdtxjhuBg8/oaAOPl8LeHPDml3LSs5jjD+XbygrEGHTbGgDP+ufWvnHxXqUrXs10IZYElnYoEXyo9v8AD/ExXjgZyffAr2P4t3FzbaxF5MMcGlyY/fSROd8rZICE/KTjONpI9hXleq6et+jXB8y8NuC4t4UUrEwyQ0rgbR9B054pNXNKdRwd+j3/AK/rXU89vXgiaV5AJbt2LY525PX3Y/lWZ5jW0kcoIL9AxGNn0Hr/AJzWvq2j3If7VfbGuH5WO3bcCO3XoO3Gfp65yWcE1ws13OI4s4ZI2zgDqM9APpmlF33HVpqDvHZ7f137/wCVmdt4NgvPEcnmLclLe3GySY5+UcZVRnAzznGB7mvTIUsdGtFVpWmkVS21TwvruOAT0HAxXlUfiG3s4YLe2QRW6PlLaPOG9256EY64zitZfENtLALm4VmKnEdugyWIPygDP+fWqMjR1LU5pRJa2jC3sDJ5krHO+4fOQWAwOOygduvplXF6UtzCj7WLfO5HIz/Dn16cDOKoTXtyJ3e+QQTM6mOzT5WRSMhj/d7epqExvPIstyclfuKOi/4n3oAtSNG1usSAmPGSGHX8KsXmo317ZwWl5eXM9rAQYoZZWdI8DA2gnA4A6elVBwKWgAooooAKKKKACiiigAooooAKKKKAAcHNVNV0y21Rcz5S44CzIOR/vf3h+tW6DQB59q+k3WmMDOoaFmISVDlW/wAD7GqIPPHfpXqGchlbBVl2lSMhh6Ed6wNU8MQXJ8ywZYJMcxt9wn2PUfTp9KAOOyRgZ+tOzljjGMVPqFhdadL5d5EyEjcp4Ib6EcVVBHHPNADuMe/epItn/LRSynjI/pTAeTUluXEqsAxIHIXg4oA6Dw9GGf5SjEnhX+Vsds+o9s16TaeHtTn01I7WxhvIpPm3RPg9OuxuD/3zk9s153oN1bvcxDeVlZtoVuDn16EfnXtPg7xHfadZW8drr0EEm/DLM2Mr6bc9OnPHSgDi7eDV1meG2tr6GcSBdm3aSeOCoXH54r0vwDaanJqqW+ume3VAqsPMRHxkfwlvl/LvWP4r1iSSWbUZNSt7m8U+WBZ3L7z1OdvAUev8zWPb/EGG9ksv7Z06K4uoHxCXl8vp3bIyx69SevrzQB9CxXvh+0DxpNeySRZT7QQ5I5xw3QgZzxn8a8u+L+s6RptokelahcXepzHbJ5k26SJTnBJPI5/lxWFFr0u+eaCO2tYwP3aOylkPXdlsf+g/nXO65rWqeIp7g6j/AGYxgiY/aIZlBkA5AwBkt25x04qKnws6MIk68E+6/MsW/jq4udJ8r7JpylFwoW0ClcA4wB0PPr2FcXe6gzS/aLh5VkJ5kwIj19gBXQz/AA+1GW6xbappEoxuMcNyAevfcQBiqeu+C9R0mFLq8fTywwse67gOM9CeScfhVmDberMu01q4QbN8UasCFdP3rsPfnHp1/Ku48N+LJWISOKWV8BZJJB5hI4BwARj8q8nmuZgkitLFITksqk88+gAFOg1Z0MW9pdsY4VW8tcAdOOv0oEe3+IfEKzwfY5I7p227l85mVogQBhVHz7TkcYI5656anw58UypIYA8S2cZP/HvGgfPb73Izzz/9evJ7bxJFcaTJZpFEgdflmRWchsY53DH5+lL4XuTFqcNvaS3DzQqBvTaqoQemeAM8+v40AexePdRun06PUdQtbBY1kzEt3M0plznhBjnt0BJ9QKopYW9/o8N5qWoIlvGu+K2OF2nHRY19u3B6cU66lXUYVlvRFMsCEeaV+SBgejl9vOT2rz6K+sZr50vdRdQjZaKMbVAz94scE8e3NAEXjjWrAm4ttKsGSGAhhIzjfLx1Pfb3xx1715texPI3mI3ljGChHKH09APTOO/WvQ/Ed9bSxzWuixxJARzMUH6dPfjA+prh1tZpm2wATR8h2zhOeuPXnBzg9OhqZLqjalNNezns/wAH3/z7+qRhJM0Ltk5I64PFdBoqXsxM0eYARhZWHzY/2fT/AHqu6bodvBlpVWZ+xZeB9B/U17r4s8Dw3Xxj+wyWb6P4evJ4oo7mK3EULN5AbZGcBN7MrKOvJ6HpTTvqjOcHB8sjx22to4IlRRnHOSckn1zU9et6B4f8OaX4m15Ps9zfmw0KS/EN3GUNtMFG5CssIEhwwZXaMKAeUJwRheL4tOuPhv4V1KxsES7knuo7y4hEYUSbs7JAiAAkfMi8bU4AYchknA0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFHeiigBJAsibJUSSPOdjqGUn3B4rF1Lw3Z3GXtSbaU/wgFkY/QnI/P8K26KAOFufD+pQNhITcAnA8jLHgZPHX8cYrLw5JULyo79q9NA5J55HSoZ7S3nYtNBG7EAFio3Y9M9QKAOQ02CU5eQMeNoJ4P5+ntXWaXPltixMU27TlDy3qMHaOv92oP7JhWQyQMYzvyF42qPQD/Hmrtq0kNwzPDbldu1SmVb8TQBfGorIrW00TjA2YZNw9O2BRqGjTnTftb2lxLaINxcWbEj33A4A/Mc1DJNKVLQxxYLbdqybPxLdTWna6nLZWP2Nb6UKfnKLLnGeOC279MUAcqZNP+VlvJTP02uQOB6AioGvrcTgefcGQAjDcKAOTnGO2aNQnlSdnYzzxSNuQzfLyf4cnGTUKQvcysqRSxbkIKbjhiQRxzjvUVPgfodGD/wB4p+q/Mn/t6MqTG/mSqMAbmxgfj61T1PV5ri3VYrS0Rj1ZIzn8SxPqaItL1axfIgnRZGCR7mX5mPTGTyTV1NB8S3V2rX+k6mUU7dq2bsGB7jAK/lVnOctMztl5NoJ4IOBj36UsMSRhMNvZueCRn9OlbWrW5aApALwbG2hPJ6Y7Hn69vwqrZ6ddGI+Xb5Zj9/AUgewbkfhQBd0+EyoQbZPmG0Hk7eeo/wDr10Vj9pgMZEeMHDHbncPYdBWbpttdWYlG6L5uFLfOQf8AgQJx9MVLcadHcXJmuHkkJGCC5I65zjt9BxQB0A1WG5tD9pmLKrbEhyTuIHb+Ejk8Bs+1ZGoyTXUhW2SK2hJz8owwOT3HOPbNEcMceBGiqB0wMVJQA2cGZI4mwsKf8s04Un1I7/yoVQM+9OooAvR6NqclrbXMenXjW11IIYJVgYpLISQEQ4wzZBGBzwa2tb8B+ItL1u50tdNub6a3VHaSygkljKuMgg7QcZDDOOqsO1Wx40tk8BXXh230SG3luo4Y5ruKQDeY5TJvYbNzMc4OXIH8IUZFW9X+I0uoQeJSli9td69Bax3EsdyQqNEMNtXbna68bSxxk8kHFAHPL4T1lrGO4XT70yyXLWqWws5jIzKGLYOzacbHBG7cCp4wCagtvDWu3W37Loupzbo0mHl2sjZjfO1+B907Tg9Dg10Pg3x9L4Y0uxtINPSd7bVDqJd5SA6tAYWjwBwcMSGycHHBrWT4oxQxQw2+iuIYYNOgQPeBm22kxkBJEYBLA46DGM89KAPPdT02+0udYNTsrmzmZd4juImjYrkjOGAOMg8+1VK6zxt4w/4SezsIPsP2X7Lc3lxu87fu+0TeZj7oxt6Z79eOlcnQAUUUUAFFFFABRRRQAUUUUAFFFKoz7UAJRSEckUpyAB780AFFKcZpB2J9cUAFFHTPp0pM5IHU0ALRRg89OPWm8npz9KAHV6D4a8P+Grz4byajr1zNp10+rG0j1CONpljAhD7XjB5U4bkDOSvOM156V6/41fsp5pbH7E9zMbITCU2/mER78Y3bem7HGeuKAPTdZ8HeH3nlOixvDCvhUavGt2ryM5y2XZllULJjZxhk5b5eBmPUPAOg31/pcVjqM2mWy+HE1i6nktjLuAIBfb5hIYgklV4G0Yznjz281TUUkYJqN6F+z/Y/9e3+o/549fuf7PSoIdY1OK0S2h1K9S1WJ4ViWdggRzl0ABxtYgEjocc0AdT4R8Df8JXdXY0y8uktg3lWt1dWyRpLN5bOUYeaSD8v8AkIB3EAVX8VaXp9v4F8H6naWaW95frdC5ZHciQxSKithmOD1JxgZJ4AwBz+l6xqmleadK1C9sRJjzPs07R78ZxnaRnGT19arTXtzPa29rLcTyW9vuEMTyEpFuOW2joMnk460DTtqjrh4Ntx4JHiga9H9jEXli32Dz/te7Hk7d+MY+fdndt52Vr2PgN9Pm8N32q7p4L3UoNPvbC6HlSRNKisP9XISPlYn5tjAhcrg4rzo3lz9hNitzP9j8zzvIMh8vzMY37em7HGcdKtPr2svBaQPq1+0No6PBGblysLIMKUGcKQOhGMUCO4u/AGnXUviPUbfV4LLTtIvbqG6t5E3SwojHyRGC/7zfwo3FPmBA3Vla14HTSfCVrq0+s2QvJ7aG8WwLKrvFKSBs+bczL8pb5AvJwx2muWbVL1lvYzeXRW9YPdAynE7A5Bfn5jkk855ok1K/l0yHT5L25fT4n3R2zSsYkbnkLnAPzNyB3NAFXvRTed3GCKOccEdaAHUU08nnrQeMUAOopoI3EMBx3o69AcZoAdRSN9MEd+9J/D1yPc0AOopPypCM8YoAdRSAY4paACiiigAooooAKKKKACiiigApCTt+UAmloBwaALaJZeWN1xcK5HzBYAQD3Gd4z+VHl2HA+13X/gOv8A8XVQ96B060AX7d9MtpRNIJ7xQQhgeMRLyRliwYngdgPxou7S2trpxJfRvExDRiBC7YPIz0UY6cMT7Vnkep9xSjOevagC4Y7Ef8vN2B/17L/8XSNHp+M/abr2/wBGXP8A6MqofcnrQeenFAFmSK1UKTdu4ZuPLhJKr/tgkAN7KWHvTwlhji5uv/Adf/i6pAcUvpQBeit7CaeOI389urEBpXtgQg7nAckmr8ZsyPNsE8oI5jVXfLSFTxIR23egyBWCQM5PPpipreY2+7aFbdzyM0AXXtrO4umF1eyWjPl5G8nevX7oIOcntxj3qW/2alBbXcYt7G2jb7GquTnA5ViFBJOOpwfqay5pjKxYgZ+lMGcDJ4z+VAFlUtUZknu3LLxvgh3ofoWZSfxAokawZtkYukVSMTNtbeO/7vjb/wB9H8etVs9Qc/lSDr0oAu+XYf8AP1cjj/n3X/4ujy9P2/8AH1c/+A6//F1SI64FJz70AXRHYcj7Tdfjbr/8XVy2XTHSS0h3vPJCzrdXRWJI3H8IAJ7dyfoPTHySuP50c4HftQBaRbAjm7ucjglbcY/Vxx+FPH9nRFCWu7pSfmXasG33B+fP5CqTAcgfypB245FAFwJYsAWnuVP90QKcfjvGfyFHl2H/AD9XX0+zr/8AF1U5OfzpMcZPNAF3Zp+f+Pi66Zz9mX/4upIf7LgJuJJLu4aH95Hb+QqLKw6Bm3nC+owaz/w9qTGGBGc0AamrwQtdtd/aII47hVma3hJkZWbOVQDCgA9mYEZ6VAYrDH/H1dgHjP2Zf/i6pknnvntRzx/KgC46aexASa6iCggu0YfzD2OARsHqPn+p6VBPD5VssguIJWYgeXHuOB3JLAfkM/hUWP8AGlJ6f4UANXOeR9KdSZyfbFLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-axis view of 2-D echocardiogram showing echo dense calcified aortic valve and left ventricular hypertrophy as evidenced by increased thickness of the posterior wall and septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24660=[""].join("\n");
var outline_f24_5_24660=null;
var title_f24_5_24661="Flupentixol: Patient drug information";
var content_f24_5_24661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flupentixol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/62/34790?source=see_link\">",
"     see \"Flupentixol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fluanxol&reg;;",
"     </li>",
"     <li>",
"      Fluanxol&reg; Depot",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3528243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called Neuroleptic malignant syndrome (NMS) may happen. Call your doctor right away if you have any fever, muscle cramps or stiffness, dizziness, very bad headache, confusion, change in thinking, fast heartbeat, heartbeat that does not feel normal, or are sweating a lot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702145",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flupentixol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Brain problem, drink too much alcohol, kidney disease, liver disease, or very bad heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11946 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-77.94.48.4-8E67DEBC9C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24661=[""].join("\n");
var outline_f24_5_24661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172882\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031343\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031345\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031344\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031349\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031350\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031352\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031347\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031348\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031353\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031354\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/62/34790?source=related_link\">",
"      Flupentixol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_5_24662="Granuloma giant cell Crohns";
var content_f24_5_24662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric granuloma in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph showing a granuloma (arrow) in a patient with Crohn's disease with gastric involvement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beverly Dickson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24662=[""].join("\n");
var outline_f24_5_24662=null;
var title_f24_5_24663="Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)";
var content_f24_5_24663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24663/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24663/contributors\">",
"     Clifford E Kashtan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24663/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24663/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24663/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24663/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/5/24663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary nephritis (or Alport syndrome) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The prevalence of the disease is estimated at approximately 1 in 50,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/5\">",
"     5",
"    </a>",
"    ]. Alport syndrome reportedly accounts for 0.3 to 2.3 percent of new cases of end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, genetics, and renal pathology of Alport syndrome will be reviewed here. The clinical manifestations and course, diagnosis, and treatment of Alport syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elucidation of the pathogenesis of Alport syndrome was facilitated by the chance observation that the glomerular basement membrane (GBM) of most affected patients did not bind antibodies from patients with anti-GBM antibody disease (including Goodpasture's syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/3,8-10\">",
"     3,8-10",
"    </a>",
"    ]. This finding suggested an abnormality in type IV collagen, the protein target of anti-GBM antibodies. Subsequent research efforts confirmed that the primary abnormality resides in type IV collagen as discussed in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alport syndrome is a primary basement membrane disorder arising from mutations in genes encoding several members of the type IV collagen protein family.",
"   </p>",
"   <p>",
"    Type IV collagen molecules are composed of three alpha chains that form triple-helical structures through specific interactions of C-terminal noncollagenous domains [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/9\">",
"     9",
"    </a>",
"    ]. Six distinct IV collagen chains are encoded by six different genes that are distributed in head-to-head pairs on three chromosomes.",
"   </p>",
"   <p>",
"    The genes include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      COL4A1 and COL4A2 at 13q34",
"     </li>",
"     <li>",
"      COL4A3 and COL4A4 at 2q35-37",
"     </li>",
"     <li>",
"      COL4A5 and COL4A6 on chromosome X.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The six alpha chains of type IV collagen form three triple helical protomers: alpha-1-1-2, alpha-3-4-5, and alpha-5-5-6. These protomers are further organized into collagen networks by end-to-end connections via C-terminal and N-terminal interactions.",
"   </p>",
"   <p>",
"    Genetic analyses of affected families have identified the affected genes for the three different modes of transmission seen in patients with Alport syndrome as discussed in the following sections. These mutations disrupt the synthesis of type IV collagen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the formation of type IV collagen protomers and networks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     X-linked inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;X-linked Alport syndrome accounts for approximately 80 percent of Alport syndrome cases. It arises from mutations in the COL4A5 gene on the X chromosome, which codes for the alpha-5(IV) chain of type IV collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/2,11-17\">",
"     2,11-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmation of the direct pathogenetic role of these mutations was provided by an animal model in which a specific known human nonsense mutation was introduced into the mouse COL4A5 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/18\">",
"     18",
"    </a>",
"    ]. The primary clinical and pathologic findings of human X-linked disease were recapitulated in this animal model.",
"   </p>",
"   <p>",
"    This mode of inheritance leads to important clinical characteristics in affected families:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Father to son transmission does not occur, since the father passes only the unaffected Y chromosome to his son.",
"     </li>",
"     <li>",
"      Women with X-linked Alport syndrome are heterozygous carriers of the disease mutation. Almost all carriers have some degree of hematuria, and a significant minority develop renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/19\">",
"       19",
"      </a>",
"      ]. The variable course in women is probably due to lyonization, by which only one X chromosome is active per cell. As a result, in most women with X-linked Alport syndrome, roughly one-half of the cells will express the mutant X gene and the remaining cells the normal COL4A5 gene, leading to a varied phenotype that is generally less severe than in affected males. The influence of X-inactivation on renal outcomes in heterozygotes was recently confirmed in the X-linked Alport syndrome mouse model [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\", section on 'Carriers'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Autosomal recessive inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive inheritance accounts for about 15 percent of patients with Alport syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/15\">",
"     15",
"    </a>",
"    ]. It arises from genetic defects in either the COL4A3 or COL4A4 genes. The COL4A3 and COL4A4 genes encode the alpha-3(IV) chain (which contains the Goodpasture antigen) and the alpha-4(IV) chain, respectively.",
"   </p>",
"   <p>",
"    Females are as severely affected as males [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/12,21,22\">",
"     12,21,22",
"    </a>",
"    ], and the clinical manifestations in both sexes are virtually identical to those of classic X-linked hereditary nephritis in males [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\", section on 'Clinical manifestations and course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Autosomal dominant inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 5 percent of patients with Alport syndrome have autosomal dominant disease, which arises from heterozygous mutations in the COL4A3 or COL4A4 genes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The clinical and pathologic features of this form are similar to those of X-linked disease, although deterioration of renal function tends to occur more slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear why some heterozygous mutations in the COL4A3 or COL4A4 genes cause autosomal dominant Alport syndrome, a progressive renal disease, while others are associated with thin basement membrane nephropathy, which typically has a benign outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/25,26,28\">",
"     25,26,28",
"    </a>",
"    ]. Some evidence suggests that genetic factors other than mutations in these genes may affect underlying clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mechanism of glomerular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alpha-3, alpha-4, and alpha-5(IV) chains are highly expressed and co-distributed within the normal GBM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/29\">",
"     29",
"    </a>",
"    ]. They form a type IV collagen network within the GBM that is distinct from that formed by alpha-1(IV) and alpha-2(IV) chains [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/2,30\">",
"     2,30",
"    </a>",
"    ]. Mutations affecting the alpha-3, alpha-4, and alpha-5(IV) chains impair their deposition into this collagen network, leading to secondary changes in GBM composition that predispose to the development of glomerulosclerosis.",
"   </p>",
"   <p>",
"    Several observations support this explanation of the pathophysiologic processes involved in Alport syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most patients with alpha-5(IV) mutations, the alpha-3, alpha-4 chains, and alpha-5(IV) chains are all absent from the GBM [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/17\">",
"       17",
"      </a>",
"      ]. However, transcription of the alpha-3(IV) and alpha-4(IV) genes is not turned off in the renal cortex, suggesting that failure of incorporation of these chains is responsible for the lack of glomerular expression and not failure of synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/31\">",
"       31",
"      </a>",
"      ]. The GBM is characterized by the absence of the alpha-3, -4, and -5(IV) chains and by persistence of the fetal distribution of alpha-1 and alpha-2(IV) chains [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with autosomal recessive Alport syndrome, primary mutations in the alpha-3(IV) chain prevent the expression of the alpha-3, alpha-4, and alpha-5(IV) chains in GBM.",
"     </li>",
"     <li>",
"      This hypothesis is supported by observations in murine and dog models of hereditary nephritis due to deletion of the alpha-3(IV) chain or a nonsense mutation of the alpha-5(IV) chain [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/32-36\">",
"       32-36",
"      </a>",
"      ]. As an example, in a murine model due to deletion of the alpha-3(IV) chain, abnormalities in the GBM included absence of alpha-4(IV) and alpha-5(IV) collagen chains, the overexpression of alpha-1(IV) and alpha-2(IV) chains and laminin alpha-5, and markedly elevated levels of fibronectin and perlecan (a heparan sulfate proteoglycan) in the basal laminae [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/33,35\">",
"       33,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Alpha-3, alpha-4, and alpha-5(IV) chain tissue distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibody probes have been used to determine the tissue distribution of the alpha-3, alpha-4, and alpha-5(IV) chains in normal tissues and tissues of Alport patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      These chains are normally located in Bowman's capsule and the basement membranes of the glomerulus, distal and collecting tubules, and several basement membranes of the cochlea and eye [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Thus, an abnormality in any of these chains can impair the integrity of basement membranes in these sites leading to the various clinical findings of Alport syndrome.",
"     </li>",
"     <li>",
"      In normal individuals the alpha-5(IV) chain is present in the basement membrane underlying the epidermis, as a component of alpha-5-5-6 networks. The alpha-3 and alpha-4(IV) chains are normally absent from the basement membrane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemical studies with a monoclonal antibody directed against the alpha-5(IV) chain demonstrated complete absence of alpha-5(IV) chain within epidermal basement membranes in most males with X-linked Alport syndrome, while female carriers had discontinuous staining (",
"    <a class=\"graphic graphic_picture graphicRef72404 \" href=\"UTD.htm?3/37/3668\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/37\">",
"     37",
"    </a>",
"    ]. The latter observation is compatible with lyonization in female carriers, in whom it would be expected that one-half of their cells would express a normal alpha-5(IV) chain.",
"   </p>",
"   <p>",
"    However, conventional fluorescence microscopy will detect alpha-5(IV) chain of the skin in about 20 percent of males with X-linked Alport syndrome and 30 to 40 percent of heterozygous females. Confocal laser scanning microscopy (CLSM) has demonstrated either a decrease in expression or an abnormal interrupted distribution of alpha-5(IV) compared to alpha-2(IV) chain staining in some but not all of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Although this technique is currently primarily a research tool, these findings suggest that CLSM may play a future role in the diagnosis of Alport syndrome, as it appears to be a more sensitive diagnostic modality than conventional fluorescence microscopy.",
"   </p>",
"   <p>",
"    All patients with autosomal recessive and autosomal dominant Alport syndrome have normal skin reactivity for alpha-5(IV) (",
"    <a class=\"graphic graphic_picture graphicRef72404 \" href=\"UTD.htm?3/37/3668\">",
"     picture 1",
"    </a>",
"    ). Thus, the presence of epidermal basement membrane staining for the alpha-5(IV) does not exclude a diagnosis of X-linked or autosomal Alport syndrome. However, the absence of alpha-5(IV) chain in a skin biopsy is diagnostic of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunostaining of renal biopsy specimens for type IV collagen is useful in the evaluation of patients with suspected Alport syndrome (",
"    <a class=\"graphic graphic_figure graphicRef81373 \" href=\"UTD.htm?38/17/39192\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked disease &mdash; As noted previously, males with X-linked Alport syndrome typically show complete absence of immunostaining for the alpha-3, alpha-4, and alpha-5(IV) chains in their kidneys, while heterozygous females exhibit patchy loss of staining in GBM and tubular basement membranes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mechanism of glomerular injury'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      As with skin staining for the alpha-5(IV) chain, approximately 20 percent of males with X-linked Alport syndrome have normal staining of renal basement membranes for the alpha-3, alpha-4, and alpha-5(IV) chains. Further quantitative analysis reveals lower amounts of the alpha-3, alpha-4,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alpha-5(IV) chains in these cases compared to normals [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/41\">",
"       41",
"      </a>",
"      ]. Some of these patients have missense mutations of COL4A5, which may explain the detection of alpha IV chains with immunostaining, albeit a decrease in intensity [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Autosomal recessive disease &mdash; Patients with autosomal recessive Alport syndrome have abnormalities of renal type IV collagen expression that differ from those of patients with X-linked disease. These patients typically exhibit complete absence of staining for the alpha-3 and alpha-4(IV) chains. However, while their GBM show no staining for the alpha-5(IV) chain, there is staining of Bowman's capsules and tubular basement membranes for the alpha-5(IV) chain. This observation can be interpreted as failure of the alpha-5(IV) chain to be deposited in the GBM due to the absence of the alpha-3 and alpha-4(IV) chains, but the alpha-5(IV) chain, in conjunction with the alpha-6(IV) chain, is deposited in the basement membranes of the tubule, Bowman's capsules, and epidermis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Lens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anterior lenticonus, which is associated with thinning of the lens capsule, the basement membrane that surrounds the lens, occurs in 20 to 30 percent of males with X-linked Alport syndrome. If present, anterior lenticonus is pathognomonic for Alport syndrome. The lens capsule normally contains alpha-3, alpha-4, and alpha-5(IV) chains. In some patients with anterior lenticonus, these chains are absent from the lens capsule [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cochlea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss in Alport syndrome may reflect impaired adhesion of the Organ of Corti, which contains the auditory sensory cells, to the basilar membrane of the inner ear. This impaired adhesion is thought to be due to the absence of the alpha-3-4-5 type IV collagen network from the Organ of Corti basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other pathologic findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Leiomyomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas are benign tumors characterized by visceral smooth muscle overgrowth within the respiratory, gastrointestinal, and female reproductive tracts. Rarely, X-linked Alport syndrome is associated with leiomyomas. Affected patients carry deletions that involve COL4A5 and extend into the second intron of the adjacent COL4A6 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/45\">",
"     45",
"    </a>",
"    ]. Of note, defects in the alpha-6 chain gene alone do not appear to cause Alport syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenetic relationship between deletions of the 5' end of the COL4A6 gene and the formation of leiomyomas is not understood. One hypothesis suggests that deletions that encompass both the COL4A5 and COL4A6 genes cause misregulation of neighboring genes, which contribute to smooth muscle overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RENAL PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic changes in Alport kidneys increase in severity with age. The changes on light microscopy are nonspecific and include focal increases in glomerular cellularity progressing to glomerulosclerosis over time, and an interstitial infiltrate containing lipid-laden foam cells of uncertain origin.",
"   </p>",
"   <p>",
"    The earliest ultrastructural lesion is thinning of the GBM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/2,46\">",
"     2,46",
"    </a>",
"    ]. This finding is not pathognomonic since it also occurs in thin basement membrane nephropathy. However, with time, there is development of longitudinal splitting of the lamina densa of the GBM producing a laminated appearance that is diagnostic of Alport syndrome (",
"    <a class=\"graphic graphic_picture graphicRef68942 graphicRef79434 \" href=\"UTD.htm?36/44/37577\">",
"     picture 2A-B",
"    </a>",
"    ). In males with X-linked Alport syndrome, the proportion of GBM showing splitting increases from about 30 percent by age 10 to more than 90 percent by age 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24663/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"     \"Thin basement membrane nephropathy (benign familial hematuria)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal biopsy of affected individuals at a young age may manifest only non-specific light microscopic changes and no definitive electron microscopic findings. However, results of immunostaining for type IV collagen alpha chains is frequently diagnostic even in the absence of specific ultrastructural changes. In prepubertal children, less invasive skin biopsy with appropriate immunohistochemical analysis may be the preferred diagnostic study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Skin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary nephritis (or Alport syndrome) is a progressive inherited form of glomerular disease that is often associated with neural hearing loss and ocular abnormalities. Alport syndrome is a primary basement membrane disorder arising from mutations in genes encoding several members of the type IV collagen protein family.",
"   </p>",
"   <p>",
"    Alport syndrome is a genetically heterogeneous disease with X-linked, autosomal recessive, and autosomal dominant variants. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked variant accounts for approximately 80 percent of affected patients. It arises from mutations in the COL4A5 gene on the X chromosome, which encodes alpha-5(IV) chains. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'X-linked inheritance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autosomal recessive variant accounts for about 15 percent of patients with Alport syndrome. It arises from genetic defects in either the COL4A3 and COL4A4 genes, which encodes the alpha-3 and alpha-4(IV) chains, respectively. The clinical manifestations of affected patients regardless of gender are the same as male patients with X-linked Alport syndrome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Autosomal recessive inheritance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link\">",
"       \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autosomal dominant disease accounts for 5 percent of patients with Alport syndrome. It arises from heterozygous mutations in the COL4A3 or COL4A4 genes. The clinical and pathologic features of this variant of Alport syndrome are similar to those of X-linked disease, although deterioration of renal function tends to occur more slowly. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Autosomal dominant inheritance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The alpha-3, alpha-4, and alpha-5(IV) chains are normally located in Bowman's capsule, and the basement membranes of the glomerulus, distal and collecting tubules, cochlea, and eye. Thus, an abnormality in any of these chains can impair the integrity of basement membranes in these sites, leading to the various clinical findings of Alport syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\", section on 'Clinical manifestations and course'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Mechanism of glomerular injury'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Alpha-3, alpha-4, and alpha-5(IV) chain tissue distribution'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with Alport syndrome, renal histologic changes progress with age. The earliest finding is thinning of the GBM. This finding is not pathognomonic since it also occurs in thin basement membrane nephropathy. With increasing age, longitudinal splitting of the lamina densa of the GBM produces a laminated appearance that is diagnostic of Alport syndrome and is present in 90 percent of male patients by 30 years of age (",
"    <a class=\"graphic graphic_picture graphicRef68942 graphicRef79434 \" href=\"UTD.htm?36/44/37577\">",
"     picture 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Renal pathology'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/1\">",
"      Gr&uuml;nfeld JP. The clinical spectrum of hereditary nephritis. Kidney Int 1985; 27:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/2\">",
"      Kashtan CE, Michael AF. Alport syndrome. Kidney Int 1996; 50:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/3\">",
"      Kashtan CE. Familial hematuria due to type IV collagen mutations: Alport syndrome and thin basement membrane nephropathy. Curr Opin Pediatr 2004; 16:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/4\">",
"      Massella L, Onetti Muda A, Faraggiana T, et al. Epidermal basement membrane alpha 5(IV) expression in females with Alport syndrome and severity of renal disease. Kidney Int 2003; 64:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/5\">",
"      Levy M, Feingold J. Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000; 58:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/6\">",
"      Persson U, Hertz JM, Wieslander J, Segelmark M. Alport syndrome in southern Sweden. Clin Nephrol 2005; 64:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/7\">",
"      Heidet L, Gubler MC. The renal lesions of Alport syndrome. J Am Soc Nephrol 2009; 20:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/8\">",
"      McCoy RC, Johnson HK, Stone WJ, Wilson CB. Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis. Kidney Int 1982; 21:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/9\">",
"      Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004; 15:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/10\">",
"      Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992; 42:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/11\">",
"      Heiskari N, Zhang X, Zhou J, et al. Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol 1996; 7:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/12\">",
"      Tryggvason K, Zhou J, Hostikka SL, Shows TB. Molecular genetics of Alport syndrome. Kidney Int 1993; 43:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/13\">",
"      Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/14\">",
"      Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/15\">",
"      Torra R, Taz&oacute;n-Vega B, Ars E, Ballar&iacute;n J. Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure. Nephrol Dial Transplant 2004; 19:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/16\">",
"      Barker DF, Hostikka SL, Zhou J, et al. Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 1990; 248:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/17\">",
"      Antignac C, Knebelmann B, Drouot L, et al. Deletions in the COL4A5 collagen gene in X-linked Alport syndrome. Characterization of the pathological transcripts in nonrenal cells and correlation with disease expression. J Clin Invest 1994; 93:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/18\">",
"      Rheault MN, Kren SM, Thielen BK, et al. Mouse model of X-linked Alport syndrome. J Am Soc Nephrol 2004; 15:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/19\">",
"      Jais JP, Knebelmann B, Giatras I, et al. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \"European Community Alport Syndrome Concerted Action\" study. J Am Soc Nephrol 2003; 14:2603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/20\">",
"      Rheault MN, Kren SM, Hartich LA, et al. X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant 2010; 25:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/21\">",
"      Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994; 8:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/22\">",
"      Longo I, Scala E, Mari F, et al. Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. Nephrol Dial Transplant 2006; 21:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/23\">",
"      Dagher H, Buzza M, Colville D, et al. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome. Am J Kidney Dis 2001; 38:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/24\">",
"      van der Loop FT, Heidet L, Timmer ED, et al. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int 2000; 58:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/25\">",
"      Longo I, Porcedda P, Mari F, et al. COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 2002; 61:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/26\">",
"      Pescucci C, Mari F, Longo I, et al. Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 2004; 65:1598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/27\">",
"      Pochet JM, Bobrie G, Landais P, et al. Renal prognosis in Alport's and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant 1989; 4:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/28\">",
"      Gross O, Netzer KO, Lambrecht R, et al. Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome. Nephrol Dial Transplant 2003; 18:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/29\">",
"      Kim Y, Kleppel MM, Butkowski R, et al. Differential expression of basement membrane collagen chains in diabetic nephropathy. Am J Pathol 1991; 138:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/30\">",
"      Kobayashi T, Uchiyama M. Characterization of assembly of recombinant type IV collagen alpha3, alpha4, and alpha5 chains in transfected cell strains. Kidney Int 2003; 64:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/31\">",
"      Nakanishi K, Yoskikawa N, Iijima K, Nakamura H. Expression of type IV collagen alpha 3 and alpha 4 chain mRNA in X-linked Alport syndrome. J Am Soc Nephrol 1996; 7:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/32\">",
"      Kalluri R, Shield CF, Todd P, et al. Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J Clin Invest 1997; 99:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/33\">",
"      Miner JH, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol 1996; 135:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/34\">",
"      Harvey SJ, Zheng K, Sado Y, et al. Role of distinct type IV collagen networks in glomerular development and function. Kidney Int 1998; 54:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/35\">",
"      Abrahamson DR, Isom K, Roach E, et al. Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects. J Am Soc Nephrol 2007; 18:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/36\">",
"      Kashtan CE. Animal models of Alport syndrome. Nephrol Dial Transplant 2002; 17:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/37\">",
"      Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/38\">",
"      Zehnder AF, Adams JC, Santi PA, et al. Distribution of type IV collagen in the cochlea in Alport syndrome. Arch Otolaryngol Head Neck Surg 2005; 131:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/39\">",
"      Muda AO, Massella L, Giannakakis K, et al. Confocal microscopy of the skin in the diagnosis of X-linked Alport syndrome. J Invest Dermatol 2003; 121:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/40\">",
"      Patey-Mariaud de Serre N, Garfa M, Bessi&eacute;res B, et al. Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients. Kidney Int 2007; 72:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/41\">",
"      Su J, Liu ZH, Zeng CH, et al. Quantitative analysis of type IV collagen subchains in the glomerular basement membrane of patients with Alport syndrome with confocal microscopy. Nephrol Dial Transplant 2006; 21:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/42\">",
"      Naito I, Kawai S, Nomura S, et al. Relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome. Japanese Alport Network. Kidney Int 1996; 50:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/43\">",
"      Cheong HI, Kashtan CE, Kim Y, et al. Immunohistologic studies of type IV collagen in anterior lens capsules of patients with Alport syndrome. Lab Invest 1994; 70:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/44\">",
"      Merchant SN, Burgess BJ, Adams JC, et al. Temporal bone histopathology in alport syndrome. Laryngoscope 2004; 114:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/45\">",
"      Dahan K, Heidet L, Zhou J, et al. Smooth muscle tumors associated with X-linked Alport syndrome: carrier detection in females. Kidney Int 1995; 48:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24663/abstract/46\">",
"      Rumpelt HJ. Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 1980; 13:203.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6086 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24663=[""].join("\n");
var outline_f24_5_24663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - X-linked inheritance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Autosomal recessive inheritance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Autosomal dominant inheritance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mechanism of glomerular injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Alpha-3, alpha-4, and alpha-5(IV) chain tissue distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Lens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cochlea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other pathologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Leiomyomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RENAL PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6086\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6086|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/17/39192\" title=\"figure 1\">",
"      Immunohistol kidney Alport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6086|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/37/3668\" title=\"picture 1\">",
"      Immunohistology skin Alport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/46/34536\" title=\"picture 2A\">",
"      Hereditary nephritis EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/46/24303\" title=\"picture 2B\">",
"      Hereditary nephritis IF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=related_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_5_24664="Ultrasound images of in situ intrauterine device";
var content_f24_5_24664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Ultrasound images of in situ intrauterine devices: Normal position (A-D) and abnormal position (E-F)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 647px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Transabdominal ultrasound shows the normal appearance of the shaft of an intrauterine contraceptive device (IUD) in good position in the endometrial cavity.",
"    <br>",
"     (B) Transvaginal scan shows the shaft of the IUD in good position. Note the echogenic string of the IUD in the cervix.",
"     <br>",
"      (C) View of the fundus shows the cross bars of the IUD in good position.",
"      <br>",
"       (D) Three-dimensional (3D) reconstructed image shows IUD in good position.",
"       <br>",
"        (E) In a different patient, transvaginal ultrasound shows low position of IUD, which is located in the cervix.",
"        <br>",
"         (F) When an IUD is known to be present, but has not been seen on an ultrasound examination, a KUB is helpful. In this case, the IUD is in the right pelvis (arrow).",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Courtesy of Deborah Levine, MD.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24664=[""].join("\n");
var outline_f24_5_24664=null;
var title_f24_5_24665="Leukoreduction to prevent complications of blood transfusion";
var content_f24_5_24665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Leukoreduction to prevent complications of blood transfusion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24665/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24665/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24665/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24665/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/5/24665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytes, a substantial contaminant of cellular blood components, have increasingly been recognized as a contributor to, if not the cause of, a number of adverse consequences of blood transfusion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immunologically-mediated effects",
"     </li>",
"     <li>",
"      Infectious disease transmission",
"     </li>",
"     <li>",
"      Reperfusion injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunologically mediated effects are by far the most common, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consequences of allosensitization to human leukocyte antigens, such as febrile nonhemolytic transfusion reactions (FNHTRs), platelet refractoriness, and transplant rejection",
"     </li>",
"     <li>",
"      Graft-versus-host disease (GVHD)",
"     </li>",
"     <li>",
"      Immunosuppression, which may contribute to tumor recurrence and postoperative infections",
"     </li>",
"     <li>",
"      Reactivation of viral diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the infectious diseases that can be transmitted are viruses, such as cytomegalovirus (CMV), human T-lymphotropic virus",
"    <span class=\"nowrap\">",
"     (HTLV)-I/II,",
"    </span>",
"    and Epstein-Barr virus (EBV), and bacteria (particularly Yersinia enterocolitica).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POTENTIAL ADVERSE EFFECTS OF TRANSFUSED LEUKOCYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will review the various adverse consequences of leukocytes in transfused components and discuss indications, methods, and cost-effectiveness of their removal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Febrile nonhemolytic transfusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 percent of all transfusions are associated with an otherwise unexplained rise in temperature of at least 1&deg;C, with or without chills and rigors. FNHTRs are not serious, as the fever responds to antipyretics and the rigors to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    . However, these reactions are discomforting for the patient and ultimately quite expensive, since they require that an infectious etiology be excluded and, in many cases, that an additional unit of blood be crossmatched and transfused.",
"   </p>",
"   <p>",
"    FNHTRs appear to be mediated both by donor leukocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/2\">",
"     2",
"    </a>",
"    ] and by cytokine generation and accumulation during the storage of blood components and after transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. It has been proposed that an interaction between donor leukocytes and recipient antibody leads to interleukin-1 (IL-1) release from donor leukocytes or recipient monocytes. IL-1 produces fever by stimulating prostaglandin E2 (PGE2) production in the hypothalamus.",
"   </p>",
"   <p>",
"    Regardless of the exact etiology, FNHTRs can be minimized by reducing the number of leukocytes transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/5\">",
"     5",
"    </a>",
"    ]. Each unit of whole blood or unmodified red cells contains roughly 2 to 5 x 10",
"    <sup>",
"     9",
"    </sup>",
"    contaminating leukocytes. FNHTRs can be largely eliminated if the total leukocyte count is reduced by one to two logs (90 to 99 percent) to below 5 x 10",
"    <sup>",
"     8",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/6\">",
"     6",
"    </a>",
"    ]. This degree of leukocyte reduction is achievable utilizing a variety of methods: saline washing, freezing and deglycerolizing, buffy coat removal, and microaggregate (\"second generation\") filters. The most effective current leukocyte reduction filters (\"third generation\") can achieve a three to four log (99.9 to 99.99 percent) reduction, leaving residual leukocyte counts below 5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    , and generally below 1 x 10",
"    <sup>",
"     6",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The magnitude of benefit from leukoreduction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunologic blood transfusion reactions\", section on 'Febrile nonhemolytic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A small fraction of FNHTRs are not eliminated by third generation filtration (post-storage). Cytokine accumulation during storage may play a primary role in this setting, since it has been demonstrated that the risk of a transfusion reaction increases with the age of the unit transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/3\">",
"     3",
"    </a>",
"    ], and that removal of plasma is more effective than post-storage leukoreduction in preventing reactions, especially severe reactions to platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, patients were randomly assigned to receive transfusion of plasma-depleted versus poststorage leukoreduced platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/9\">",
"     9",
"    </a>",
"    ]. Plasma depletion was associated with significant reductions in the frequency of reactions (17 versus 26 percent) and the percent of reactions judged as severe (18 versus 33 percent). Regression analysis identified plasma interleukin-6 levels as the most significant risk factor associated with these reactions.",
"   </p>",
"   <p>",
"    For patients who experience repeated reactions even when transfused with post-storage filtered components, pre-storage filtration may alleviate the problem (see below). However, in some high risk cases, even pre-storage filtration may not alleviate the problems of fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension. As an example, a randomized double-blind study compared the incidence of transfusion reactions in previously untransfused",
"    <span class=\"nowrap\">",
"     HIV+/CMV+",
"    </span>",
"    subjects who were randomly assigned to receive either pre-storage WBC-reduced or unmodified red cell transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/11\">",
"     11",
"    </a>",
"    ]. The incidence of 1&ordm; temperature increase (16 versus 18 percent), 2&ordm; temperature increase (3 versus 4 percent), and hypotension (5 percent for both) was not different between the two treatment groups. The only factor significantly associated with a reduction in the incidence of transfusion- associated fever in this highly specific group of patients was the lack of fever in the seven days prior to transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HLA alloimmunization and platelet refractoriness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain HLA antigens expressed on the surface of donor leukocytes can induce the production of HLA antibodies in multiply transfused patients. Clinical problems that result from such allosensitization include an increased risk of graft rejection in patients awaiting organ or bone marrow transplantation and platelet refractoriness in those requiring subsequent platelet transfusion support.",
"   </p>",
"   <p>",
"    Patients who are alloimmunized and refractory to platelets are often difficult to manage, even with HLA-matched or cross-matched platelets, high-dose intravenous immune globulin, or Rh immune globulin. As a result, it is prudent to try to prevent alloimmunization in patients expected to require prolonged transfusion support. Numerous studies, although varied in statistical and experimental design, provide strong evidence that leukoreduction to below 1 to 5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    cells can decrease the development of primary platelet alloimmunization and refractoriness in patients with hematologic malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link\">",
"     \"Refractoriness to platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best evidence in support of this approach has come from the Trial to Reduce Alloimmunization to Platelets (TRAP) conducted under the sponsorship of the National Heart, Lung, and Blood Institute [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/13\">",
"     13",
"    </a>",
"    ]. This study randomly assigned 530 patients with untreated acute myeloid leukemia who had no alloantibodies at baseline to receive one of four regimens, two of which were pooled platelet concentrates from random donors that were either unmodified (control) or filtered for leukoreduction. Compared with unmodified concentrates, the patients treated with leukoreduced concentrates had a lower incidence of both lymphocytotoxic antibodies (18 versus 45 percent, p&lt;0.001) and refractoriness to platelet transfusions (7 versus 16 percent, p = 0.03). A similar benefit was seen with exposure of the transfused platelets to ultraviolet B irradiation to inactivate antigen-presenting (white blood) cells in those concentrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     RBC alloimmunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukoreduction may reduce the incidence of alloimmunization to red cell antigens. A retrospective cohort study in 410 patients with acute myeloid leukemia indicated a prevalence of alloimmunization to red cell antigens of 2.8 versus 8.2 percent in those receiving or not receiving leukoreduced red cell and platelet transfusions (p = 0.016) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/15\">",
"     15",
"    </a>",
"    ]. Alloimmunization rates progressively decreased over time as leukoreduction became more universal within the reporting medical center. These rates were 3.5, 3.0, and 2.4 per 1000 antibody screens when the overall use of leukoreduced blood products was zero, 40 percent, and 100 percent, respectively. These findings require confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunosuppressive activity of allogeneic blood has been known since the studies on renal allograft survival were published in the 1970s. Increasing attention has been directed towards the impact of the immunosuppressive effect of allogeneic blood (particularly the leukocyte component) on postoperative infection, tumor recurrence, and nosocomial infection in critically ill patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. This phenomenon has been termed \"transfusion-related immunomodulation\" (TRIM). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Postoperative infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence that postoperative infection is increased in patients receiving allogeneic blood during surgery is compelling, though not absolute [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/19-26\">",
"     19-26",
"    </a>",
"    ], as are the data implicating the leukocyte as the \"culprit\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/25,27,28\">",
"     25,27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of the records of 416 consecutive patients undergoing coronary artery bypass at one medical center, the 64 patients developing postoperative pneumonia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wound infection received a significantly higher volume of allogeneic plasma than those not developing infection (mean &plusmn; SE: 957 &plusmn; 181 versus 321 &plusmn; 40 mL, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/29\">",
"       29",
"      </a>",
"      ]. However, on multivariate analysis, which included 25 confounding variables (eg, repeated surgery, endotracheal intubation, time on bypass pump), the association between infection and volume of infused allogeneic plasma was no longer statistically significant.",
"     </li>",
"     <li>",
"      One study compared the incidence of postoperative infection in 50 patients receiving two or three allogeneic transfusions to that in 34 patients treated with autologous transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/20\">",
"       20",
"      </a>",
"      ]. Infection was much less frequent with autologous transfusions (three versus 32 percent).",
"     </li>",
"     <li>",
"      Another report found that the incidence of postoperative infection was much lower in patients treated with leukocyte-depleted blood (two versus 23 percent with whole blood) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients receiving whole blood had decreased natural killer cell function that may have contributed to the development of infection.",
"     </li>",
"     <li>",
"      A multicenter double-blind trial randomly assigned 1089 patients scheduled for total hip arthroplasty to receive autologous whole blood either leukoreduced or unmodified when transfusion was indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/30\">",
"       30",
"      </a>",
"      ]. The primary (overall infection rate, 17 versus 18 percent) and secondary (length of hospital stay, 14 days for each) study outcomes did not differ between treatment arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several meta-analyses have been performed using slightly different approaches and have yielded conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Therefore, it is premature at this time to recommend routine use of leukocyte-depleted blood in order to diminish the risk of postoperative infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Infection and indwelling venous access devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single-institution study retrospectively evaluated the rate of infection in patients with indwelling venous access devices for an 18 month period both before and after implementation of universal leukoreduction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For untransfused patients, the rates of line-related infections were identical during the two time periods (1.5",
"      <span class=\"nowrap\">",
"       infections/10,000",
"      </span>",
"      patient-days).",
"     </li>",
"     <li>",
"      The rates of line-related infection were higher for transfused patients than untransfused patients during both time periods, but decreased significantly from 5.3 to 3.3",
"      <span class=\"nowrap\">",
"       infections/10,000",
"      </span>",
"      patient-days following the use of universal leukoreduction.",
"     </li>",
"     <li>",
"      The change in absolute number of line-related infections after universal leukoreduction was proportional to the amount of blood transfused, being reduced by 15, 32, and 89 percent for those receiving zero, 1 to 30, and &gt;30 transfusions, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations need to be confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Tumor incidence and recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data implicating allogeneic blood transfusion as an independent promoter of tumor incidence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurrence are inconsistent, and may be dependent on other factors, such as the presence of an intact spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/22,35\">",
"     22,35",
"    </a>",
"    ], transfusion of tumor-associated viruses (eg, hepatitis B and C viruses, HIV), as well as life-style choices (eg, tobacco smoking, alcohol use) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/36\">",
"     36",
"    </a>",
"    ]. Some clinical studies and meta-analyses have shown an increase in tumor recurrence risk in patients with colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/37-40\">",
"     37-40",
"    </a>",
"    ], but a statistically significant association between transfusion and recurrence has not been universal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/41\">",
"     41",
"    </a>",
"    ], and the follow-up of one randomized study has shown no effect of leukoreduction on tumor recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strongest evidence for an adverse impact on tumor growth and metastasis (and the singular role of leukocytes in mediating this effect) has been gathered from studies in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. One report, for example, showed increased tumor growth with allogeneic transfusions, an effect that was not seen with leukocyte-depleted blood or with syngeneic transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, it seems clear that allogeneic transfusion is immunosuppressive. However, the role of leukoreduction in preventing adverse immunomodulatory effects in humans is still uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post-transfusion GVHD is a rare complication of transfusion that is mediated by the presence of viable donor lymphocytes. It occurs in two clinical settings: when the recipient is immunodeficient; and when there is a specific type of partial HLA matching between the donor and recipient. Leukofiltration by current methods",
"    <strong>",
"     cannot",
"    </strong>",
"    be relied upon to prevent this almost invariably fatal transfusion complication; the treatment of choice to prevent GVHD is irradiation of blood products. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H10#H10\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Viral diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytes are involved in the transmission, reactivation, and dissemination of viral infections. Of those viruses known to be transmitted almost exclusively by leukocytes",
"    <span class=\"nowrap\">",
"     (HTLV-I/II,",
"    </span>",
"    EBV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/44\">",
"     44",
"    </a>",
"    ], and CMV), only CMV is of major clinical significance in certain transfused patients. Included in this group are immunocompromised oncology patients, individuals undergoing hematopoietic or solid organ transplantation, and low birth weight CMV-seronegative neonates. It is important to appreciate the potential magnitude of this problem:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is high prevalence of CMV seropositivity among blood donors (40 to 60 percent).",
"     </li>",
"     <li>",
"      Current screening tests cannot detect infected seronegative donors (\"window-period\" donors).",
"     </li>",
"     <li>",
"      Blood providers must maintain two inventories &mdash; CMV seronegative and CMV seropositive (or untested).",
"     </li>",
"     <li>",
"      Many patients who require CMV seronegative blood are already receiving leukoreduced components for other reasons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It would therefore be highly advantageous if it could be demonstrated that leukoreduction with current third generation filters was effective in preventing transmission of CMV. Numerous studies, virtually all either retrospective in design or lacking a control group, have suggested that filtration prevents CMV transmission, even in high-risk settings such as hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Similar findings were noted in a prospective randomized study from Seattle in bone marrow transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/47\">",
"     47",
"    </a>",
"    ]. In this study, 502 patients were randomly assigned to receive either CMV seronegative blood or filtered blood (which was often CMV positive pre-filtration). The probability of CMV infection was low and not significantly different in the two groups: 1.3 versus 2.4 percent, respectively (p = 1.0), although the study may have been underpowered to detect a real difference.",
"   </p>",
"   <p>",
"    However, a subsequent retrospective study from the Seattle group suggested that filtered red cell units from CMV positive donors were the primary predictors for transfusion-transmitted CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/48\">",
"     48",
"    </a>",
"    ]. They concluded that there was still a need for CMV-negative blood inventories for populations at high risk for CMV disease.",
"   </p>",
"   <p>",
"    These findings have led some physicians, and at least one consensus panel, to consider whether (or not) leukocyte-reduced blood is equivalent to CMV-seronegative blood. As an example, the Canadian consensus panel concluded: \"We cannot definitely say whether one is better than the other, nor can we say that they are equivalent\" [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/49\">",
"     49",
"    </a>",
"    ]. However, if equivalence is confirmed by additional scrutiny and peer review, this will provide a strong stimulus to more widespread use of leukoreduction to prevent the transmission of CMV [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to direct viral transmission, blood transfusion has also been implicated in reactivation and dissemination of latent CMV and HIV infections. Studies in animals have shown that allogeneic, but not syngeneic transfusions activate latent CMV infection. In humans, viral reactivation correlates with the number of transfusions received and, in the heart transplant setting, use of leukoreduced blood components prevents CMV reactivation in seropositive recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With HIV, allogeneic leukocytes can stimulate expression of HIV in infected cells in culture in a dose-dependent fashion; this phenomenon was not observed when the infected cells were cultured with leukoreduced blood components [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/52\">",
"     52",
"    </a>",
"    ]. However, results of a VATS (Viral Activation Transfusion Study) trial in HIV-infected subjects showed no significant induction of HBV, HCV, HHV-8, HTLV-I, or HTLV-II viral replication following allogeneic transfusion of non-WBC-reduced blood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=see_link&amp;anchor=H25#H25\">",
"     \"Hematologic manifestations of HIV infection: Anemia\", section on 'Transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, despite a 1000- to 10,000-fold (ie, 3- to 4-log) viral reduction after leukocyte depletion, HTLV-I DNA could still be detected after whole blood filtration in asymptomatic carriers with viral loads above 10",
"    <sup>",
"     8",
"    </sup>",
"    <span class=\"nowrap\">",
"     copies/L,",
"    </span>",
"    suggesting that leukocyte depletion alone may not provide complete protection from HTLV-I transmission via transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Contamination with bacteria and other organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;One rare but significant complication of transfusion is bacterial contamination of red cells. This is an important issue because such septic transfusion reactions carry a high fatality rate. Most bacterial contamination occurs either at the time of venipuncture or during component preparation. Less frequently, bacteria are introduced because the donor has a silent bacteremia at the time of donation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=see_link\">",
"     \"Transfusion transmitted bacterial infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common organisms of clinical relevance are Gram negative, endotoxin-secreting bacteria that can survive cold storage. These include Yersinia enterocolitica and some Pseudomonas and Enterobacter species. Studies have shown that leukoreduction performed two to 12 hours after collection (\"pre-storage\" leukoreduction) can significantly reduce bacterial proliferation of Y. enterocolitica [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The decreased proliferation may be mediated by removal of bacteria ingested by leukocytes, filtration of bacteria, and",
"    <span class=\"nowrap\">",
"     /or",
"    </span>",
"    prevention of release and subsequent proliferation of viable bacteria from disintegrating leukocytes. Regardless of the mechanism, it appears that an additional benefit of pre-storage leukoreduction is a decline in the risk of a septic complication of red cell transfusion.",
"   </p>",
"   <p>",
"    In one study, leukodepletion resulted in a substantial reduction in free and intracellular organisms in blood artificially inoculated with Leishmania organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/57\">",
"     57",
"    </a>",
"    ]. In a second study involving infected donors, red cell samples which had tested positive for Leishmania infantum by polymerase chain reaction (PCR) became PCR-negative following leukodepletion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reperfusion injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that reperfusion of ischemic myocardium often leads to further ultrastructural damage, including necrosis. It is postulated that the tissue damage in this setting results from an inflammatory response in which leukocytes play a central role. Leukoreduction can prevent ultrastructural damage and reduce biochemical markers of myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/59\">",
"     59",
"    </a>",
"    ]. Leukoreduction may be an effective method to reduce reperfusion injury after cardiopulmonary bypass [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/60\">",
"     60",
"    </a>",
"    ]. These results and that of subsequent studies suggest that patients undergoing cardiac surgery may have lesser morbidity and mortality if transfused with red cells that have been leukoreduced [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=see_link\">",
"     \"Ischemic reperfusion injury of the heart\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=see_link&amp;anchor=H5#H5\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\", section on 'Improvements in surgical technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TECHNICAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prestorage versus poststorage leukoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukoreduction with third generation filters can be performed shortly after component preparation (representing pre-storage leukoreduction) or at the time of release from the transfusion service or at the bedside (both of which represent poststorage leukoreduction). The only significant advantage of poststorage leukoreduction is that only units requiring leukoreduction will be treated, thereby limiting the extra expense of filtration ($20 to $40 per unit) to those patients for whom it is medically indicated.",
"   </p>",
"   <p>",
"    The benefits of prestorage leukoreduction include immediate availability, more consistent quality, decreased cytokine and histamine production (and fewer transfusion reactions), and, potentially, a diminished risk of alloimmunization, immunosuppression,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    septic transfusion reactions. For these reasons, pre-storage leukoreduction has supplanted post-storage leukoreduction as the method of choice. Furthermore, preliminary studies suggest that the cost of filtration is often less than the cost of treating the complications of transfusing unfiltered components [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hypotension with bedside leukoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are over 80 reports of patients developing significant hypotensive events while receiving blood products (especially platelets) transfused through a bedside leukocyte reduction filter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/64\">",
"     64",
"    </a>",
"    ]. As a result, the Food and Drug Administration in the United States issued the following recommendations, dated May 4, 1999, for patients receiving blood products through a bedside leukocyte reduction filter:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Watch for a precipitous drop in blood pressure, which may be associated with respiratory distress, facial flushing, abdominal pain and nausea, and loss of consciousness.",
"     </li>",
"     <li>",
"      Immediately stop the transfusion if the above reaction occurs. A rapid resolution is usually seen once the transfusion is discontinued. Follow your institution's protocol for treatment of transfusion reactions.",
"     </li>",
"     <li>",
"      Use blood products that are leukoreduced at the time of collection or during laboratory storage whenever feasible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information concerning FDA action on this issue can be obtained from their web site at:",
"    <a class=\"external\" href=\"file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062284.htm\">",
"     www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062284.htm",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Quality assurance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Food and Drug Administration's regulations for the quality of WBC-reduced blood products require that components contain &lt;5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    WBCs per unit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/66\">",
"     66",
"    </a>",
"    ]. A proposed FDA guideline is designed to provide that &gt;95 percent of units intended to be labeled as WBC-reduced meet new component specifications of &le;1 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     WBC/unit",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/67\">",
"     67",
"    </a>",
"    ]. The current European Community standard has been set at &lt;1 x 10",
"    <sup>",
"     6",
"    </sup>",
"    <span class=\"nowrap\">",
"     WBC/unit",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter study of the effectiveness of WBC reduction techniques, over 99 and 91 percent of WBC-reduced units met the current United States and European Community thresholds, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Donors with sickle cell trait",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be difficult to successfully leukoreduce blood from donors with sickle cell trait, due to blockage of the filters used in this process [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. This is likely due to the low oxygen level of venous blood as well as the low pH and hypertonicity of anticoagulant-preservative solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/70\">",
"     70",
"    </a>",
"    ]. Such blockage cannot be predicted by donor or filter characteristics, but its incidence can be reduced by storing units at 4&ordm;C before filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/71\">",
"     71",
"    </a>",
"    ], storage in large-capacity oxygen-permeable bags [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/70\">",
"     70",
"    </a>",
"    ], or use of a metered citrate anticoagulant system [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/72\">",
"     72",
"    </a>",
"    ]. Those blood centers that are 100 percent leukoreduced will generally contact and defer African-American donors whose blood is difficult to filter after the second failed attempt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link\">",
"     \"Sickle cell trait\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Red eye syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1997 there were 159 reactions in 117 patients characterized by conjunctival erythema or hemorrhage, eye pain, photophobia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased visual acuity occurring one to 24 hours after initiation of transfusion, resolving within a median of five days (range: 2 to 21 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/73\">",
"     73",
"    </a>",
"    ]. A subset of patients also reported headache, periorbital edema, arthralgias, nausea, dyspnea, and skin rash.",
"   </p>",
"   <p>",
"    Reactions were association with transfusion of red cells filtered with the LeukoNet filter which employed cellulose acetate membranes. A similar ocular syndrome was elicited in rabbits injected with cellulose acetate derivatives extracted from unused filters or filter precursors, as well as in some patients who developed red eye syndrome after hemodialysis with cellulose acetate-containing hemodialyzers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. No reactions of this type have occurred after LeukoNet filters were withdrawn from the market. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link&amp;anchor=H9#H9\">",
"     \"Reactions to the hemodialysis membrane\", section on 'Other reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4759206\">",
"    <span class=\"h1\">",
"     CONCLUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is the author's opinion that, if cost were not a factor, prestorage leukoreduction would be performed on all cellular components intended for transfusion. Evidence continues to accumulate concerning the adverse consequences of transfusing components containing leukocytes, leukocyte debris, or leukocyte-generated cytokines. Whether this evidence is as yet sufficiently compelling is still a subject for debate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/31,77-84\">",
"     31,77-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, it is clear that chronically transfused patients, potential transplant recipients, patients with previous transfusion reactions (FNHTRs), CMV seronegative at-risk patients for whom seronegative components are not available, and patients undergoing cardiac surgery should receive leukoreduced blood components (",
"    <a class=\"graphic graphic_table graphicRef52206 \" href=\"UTD.htm?11/29/11741\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/81,85,86\">",
"     81,85,86",
"    </a>",
"    ]. It is probable, although less absolute, that surgical oncology patients and surgical patients in general should also receive leukoreduced blood components. There is mounting evidence that prestorage leukoreduction is the leukoreduction method of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24665/abstract/81,87\">",
"     81,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the heat of the debate in the United States on the merits of universal prestorage leukoreduction (ULR), the American Red Cross, which supplies 45 percent of the blood supply, and United Blood Services, which supplies 10 percent, are committed to ULR, as are at least one-half of the remaining independent blood centers. Thus, approximately 75 percent of United States blood is already leukoreduced. At some point in the very near future, maintaining two inventories will be logistically difficult, and it will no longer be feasible for non-leukoreduced blood to be made available. The United States will then join the growing list of countries committed to ULR, despite the view of some that this is without benefit of scientific justification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4758995\">",
"    <span class=\"h2\">",
"     Leukoreduction defined",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each unit of whole blood or unmodified red cells contains roughly 2 to 5 x 10",
"    <sup>",
"     9",
"    </sup>",
"    contaminating leukocytes. The most effective current leukocyte reduction filters (\"third generation\") can achieve a three to four log (99.9 to 99.99 percent) reduction, leaving residual leukocyte counts below 5 x 10",
"    <sup>",
"     6",
"    </sup>",
"    , and generally below 1 x 10",
"    <sup>",
"     6",
"    </sup>",
"    . (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Quality assurance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4759198\">",
"    <span class=\"h2\">",
"     Current practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Red Cross, which supplies 45 percent of the blood supply, and United Blood Services, which supplies 10 percent, are committed to universal prestorage leukoreduction, as are at least one-half of the remaining independent blood centers. Thus, approximately 75 percent of United States blood is already leukoreduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4759079\">",
"    <span class=\"h2\">",
"     Settings in which leukoreduction may be beneficial",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Febrile nonhemolytic transfusion reactions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Febrile nonhemolytic transfusion reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HLA alloimmunization. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'HLA alloimmunization and platelet refractoriness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative infection, bacterial contamination. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunosuppression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac reperfusion injury. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Reperfusion injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4759529\">",
"    <span class=\"h2\">",
"     Settings in which leukoreduction is not helpful",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion-associated graft versus host disease (TA-GVHD). Leukofiltration by current methods",
"      <strong>",
"       cannot",
"      </strong>",
"      be relied upon to prevent this almost invariably fatal transfusion complication; the treatment of choice to prevent TA-GVHD is irradiation of blood products. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=see_link&amp;anchor=H10#H10\">",
"       \"Transfusion-associated graft-versus-host disease\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/1\">",
"      Williamson LM. Leucocyte depletion of the blood supply - how will patients benefit? Br J Haematol 2000; 110:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/2\">",
"      BRITTINGHAM TE, CHAPLIN H Jr. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. J Am Med Assoc 1957; 165:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/3\">",
"      Heddle NM, Klama LN, Griffith L, et al. A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993; 33:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/4\">",
"      Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/5\">",
"      Sirchia G, Rebulla P, Parravicini A, et al. Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. Transfusion 1987; 27:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/6\">",
"      Mintz PD. Febrile reactions to platelet transfusions. Am J Clin Pathol 1991; 95:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/7\">",
"      Cardigan R, Sutherland J, Garwood M, et al. The effect of leucocyte depletion on the quality of fresh-frozen plasma. Br J Haematol 2001; 114:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/8\">",
"      Yomtovian R, Gernsheimer T, Assmann SF, et al. WBC reduction in RBC concentrates by prestorage filtration: multicenter experience. Transfusion 2001; 41:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/9\">",
"      Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999; 39:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/10\">",
"      Azuma H, Hirayama J, Akino M, et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009; 49:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/11\">",
"      Lane TA, Gernsheimer T, Mohandas K, Assmann SF. Signs and symptoms associated with the transfusion of WBC-reduced RBCs and non-WBC-reduced RBCs in patients with anemia and HIV infection: results from the Viral Activation Transfusion Study. Transfusion 2002; 42:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/12\">",
"      Heddle NM. The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies. Transfus Med Rev 1994; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/13\">",
"      Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/14\">",
"      Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/15\">",
"      Blumberg N, Heal JM, Gettings KF. WBC reduction of RBC transfusions is associated with a decreased incidence of RBC alloimmunization. Transfusion 2003; 43:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/16\">",
"      Taylor RW, O'Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006; 34:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/17\">",
"      Michalopoulos A, Geroulanos S, Rosmarakis ES, Falagas ME. Frequency, characteristics, and predictors of microbiologically documented nosocomial infections after cardiac surgery. Eur J Cardiothorac Surg 2006; 29:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/18\">",
"      Shorr AF, Jackson WL. Transfusion practice and nosocomial infection: assessing the evidence. Curr Opin Crit Care 2005; 11:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/19\">",
"      Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994; 34:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/20\">",
"      Murphy P, Heal JM, Blumberg N. Infection or suspected infection after hip replacement surgery with autologous or homologous blood transfusions. Transfusion 1991; 31:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/21\">",
"      Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993; 342:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/22\">",
"      Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/23\">",
"      Llewelyn CA, Taylor RS, Todd AA, et al. The effect of universal leukoreduction on postoperative infections and length of hospital stay in elective orthopedic and cardiac surgery. Transfusion 2004; 44:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/24\">",
"      Innerhofer P, Klingler A, Klimmer C, et al. Risk for postoperative infection after transfusion of white blood cell-filtered allogeneic or autologous blood components in orthopedic patients undergoing primary arthroplasty. Transfusion 2005; 45:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/25\">",
"      Jensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/26\">",
"      Weber WP, Zwahlen M, Reck S, et al. The association of preoperative anemia and perioperative allogeneic blood transfusion with the risk of surgical site infection. Transfusion 2009; 49:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/27\">",
"      Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/28\">",
"      Ottonello L, Ghio M, Contini P, et al. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion 2007; 47:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/29\">",
"      Vamvakas EC, Carven JH. Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. Transfusion 2002; 42:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/30\">",
"      Frietsch T, Karger R, Sch&ouml;ler M, et al. Leukodepletion of autologous whole blood has no impact on perioperative infection rate and length of hospital stay. Transfusion 2008; 48:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/31\">",
"      Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 2003; 43:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/32\">",
"      Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion 2005; 45:33S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/33\">",
"      Blumberg N, Zhao H, Wang H, et al. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007; 47:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/34\">",
"      Blumberg N, Fine L, Gettings KF, Heal JM. Decreased sepsis related to indwelling venous access devices coincident with implementation of universal leukoreduction of blood transfusions. Transfusion 2005; 45:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/35\">",
"      Weitz J, D'Angelica M, Gonen M, et al. Interaction of splenectomy and perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer. J Clin Oncol 2003; 21:4597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/36\">",
"      Hjalgrim H, Edgren G, Rostgaard K, et al. Cancer incidence in blood transfusion recipients. J Natl Cancer Inst 2007; 99:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/37\">",
"      Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/38\">",
"      Amato AC, Pescatori M. Effect of perioperative blood transfusions on recurrence of colorectal cancer: meta-analysis stratified on risk factors. Dis Colon Rectum 1998; 41:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/39\">",
"      Jensen LS, Puho E, Pedersen L, et al. Long-term survival after colorectal surgery associated with buffy-coat-poor and leucocyte-depleted blood transfusion: a follow-up study. Lancet 2005; 365:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/40\">",
"      Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006; :CD005033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/41\">",
"      Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/42\">",
"      Blajchman MA, Bardossy L, Carmen R, et al. Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood 1993; 81:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/43\">",
"      Bordin JO, Bardossy L, Blajchman MA. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion. Blood 1994; 84:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/44\">",
"      Qu L, Xu S, Rowe D, Triulzi D. Efficacy of Epstein-Barr virus removal by leukoreduction of red blood cells. Transfusion 2005; 45:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/45\">",
"      Ronghe MD, Foot AB, Cornish JM, et al. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. Br J Haematol 2002; 118:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/46\">",
"      Thiele T, Kr&uuml;ger W, Zimmermann K, et al. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 2011; 51:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/47\">",
"      Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86:3598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/48\">",
"      Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003; 101:4195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/49\">",
"      Laupacis A, Brown J, Costello B, et al. Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement. Transfusion 2001; 41:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/50\">",
"      Ljungman P. Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction. Br J Haematol 2004; 125:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/51\">",
"      Bracey A, Radovancevic R, Radovancevic B, et al. Effect of leukocyte-depleted blood on CMV disease after heart transplant (abstract). XIII Cong ISBT Abstracts 1994; 13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/52\">",
"      Busch MP, Lee TH, Heitman J. Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type 1 infection: implications for transfusion support of infected patients. Blood 1992; 80:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/53\">",
"      Asmuth DM, Kalish LA, Laycock ME, et al. Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection. Transfusion 2003; 43:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/54\">",
"      Pennington J, Taylor GP, Sutherland J, et al. Persistence of HTLV-I in blood components after leukocyte depletion. Blood 2002; 100:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/55\">",
"      Gong J, H&ouml;gman CF, Hambraeus A, et al. Transfusion-transmitted Yersinia enterocolitica infection. Protection through buffy coat removal and failure of the bacteria to grow in platelet-rich or platelet-poor plasma. Vox Sang 1993; 65:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/56\">",
"      Pietersz RN, Reesink HW, Pauw W, et al. Prevention of Yersinia enterocolitica growth in red-blood-cell concentrates. Lancet 1992; 340:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/57\">",
"      Cardo LJ, Salata J, Harman R, et al. Leukodepletion filters reduce Leishmania in blood products when used at collection or at the bedside. Transfusion 2006; 46:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/58\">",
"      Riera C, Fisa R, L&oacute;pez-Chejade P, et al. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 2008; 48:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/59\">",
"      Pearl JM, Drinkwater DC Jr, Laks H, et al. Leukocyte-depleted reperfusion of transplanted human hearts prevents ultrastructural evidence of reperfusion injury. J Surg Res 1992; 52:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/60\">",
"      van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/61\">",
"      Wallis JP, Chapman CE, Orr KE, et al. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002; 42:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/62\">",
"      Bilgin YM, van de Watering LM, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004; 109:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/63\">",
"      Jensen LS, Grunnet N, Hanberg-S&oslash;rensen F, J&oslash;rgensen J. Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery. Transfusion 1995; 35:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/64\">",
"      Belloni M, Alghisi A, Bettini C, et al. Hypotensive reactions associated with white cell-reduced apheresis platelet concentrates in patients not receiving ACE Inhibitors. Transfusion 1998; 38:412.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079813.htm (Accessed on June 23, 2011).",
"    </li>",
"    <li>",
"     Recommendations and licensure requirements for leukocyte-reduced blood products; May 29, 1996. Division of Blood Applications, Food and Drug Administration, Center for Biologics Evaluation and Research. Available at: www.fda.gov/cber/bldmem/mem52996.txt (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     Guidance for industry, pre-storage leukocyte reduction of whole blood and blood components intended for transfusion (draft), January, 2001. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Available at: www.fda.gov/cber/gdlns/preleuk.htm (Accessed on January 31, 2001).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/68\">",
"      Krailadsiri P, Gilcher R, Seghatchian J. Leukoreduction of sickle cell trait blood: an unresolved issue. Transfus Apher Sci 2001; 24:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/69\">",
"      Jacob EK, Emery RL, Orrock JM, et al. Filter failures with sickling hemoglobin. Transfusion 2009; 49:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/70\">",
"      Stroncek DF, Byrne KM, Noguchi CT, et al. Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective white blood cell reduction by filtration. Transfusion 2004; 44:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/71\">",
"      Beard MJ, Cardigan R, Seghatchian J, et al. Variables determining blockage of WBC-depleting filters by Hb sickle cell trait donations. Transfusion 2004; 44:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/72\">",
"      Bryant BJ, Bianchi M, Wesley RA, et al. Leukoreduction filtration of whole-blood units from sickle trait donors: effects of a metered citrate anticoagulant system. Transfusion 2007; 47:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/73\">",
"      Alonso-Echanove J, Sippy BD, Chin AE, et al. Nationwide outbreak of red eye syndrome associated with transfusion of leukocyte-reduced red blood cell units. Infect Control Hosp Epidemiol 2006; 27:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/74\">",
"      Oba T, Tsuji K, Nakamura A, et al. Migration of acetylated hemicellulose from capillary hemodialyzer to blood, causing scleritis and/or iritis. Artif Organs 1984; 8:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/75\">",
"      Hutter JC, Kuehnert MJ, Wallis RR, et al. Acute onset of decreased vision and hearing traced to hemodialysis treatment with aged dialyzers. JAMA 2000; 283:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/76\">",
"      Averbukh Z, Modai D, Sandbank J, et al. Red eye syndrome: clinical and experimental experience in a new aspect of diffuse eosinophilic infiltration? Artif Organs 2001; 25:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/77\">",
"      Goodnough LT. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 2000; 40:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/78\">",
"      Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001; 41:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/79\">",
"      Uhlmann EJ, Isgriggs E, Wallhermfechtel M, Goodnough LT. Prestorage universal WBC reduction of RBC units does not affect the incidence of transfusion reactions. Transfusion 2001; 41:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/80\">",
"      Dzik WH, Anderson JK, O'Neill EM, et al. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002; 42:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/81\">",
"      Ratko TA, Cummings JP, Oberman HA, et al. Evidence-based recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001; 41:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/82\">",
"      Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center. Transfusion 2002; 42:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/83\">",
"      Vamvakas EC. Platelet transfusion and adverse outcomes. Lancet 2004; 364:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/84\">",
"      Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010; 50:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/85\">",
"      Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/86\">",
"      Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010; 24:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24665/abstract/87\">",
"      Blajchman MA. Transfusion-associated immunomodulation and universal white cell reduction: are we putting the cart before the horse? Transfusion 1999; 39:665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7935 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-FFAD13B8AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24665=[""].join("\n");
var outline_f24_5_24665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POTENTIAL ADVERSE EFFECTS OF TRANSFUSED LEUKOCYTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Febrile nonhemolytic transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HLA alloimmunization and platelet refractoriness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RBC alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Postoperative infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Infection and indwelling venous access devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Tumor incidence and recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Viral diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Contamination with bacteria and other organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reperfusion injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TECHNICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prestorage versus poststorage leukoreduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hypotension with bedside leukoreduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Quality assurance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Donors with sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Red eye syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4759206\">",
"      CONCLUSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4758995\">",
"      Leukoreduction defined",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4759198\">",
"      Current practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4759079\">",
"      Settings in which leukoreduction may be beneficial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4759529\">",
"      Settings in which leukoreduction is not helpful",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7935\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7935|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/29/11741\" title=\"table 1\">",
"      Platelet transfusion guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=related_link\">",
"      Hematologic manifestations of HIV infection: Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6394?source=related_link\">",
"      Ischemic reperfusion injury of the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10471?source=related_link\">",
"      Transfusion transmitted bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_5_24666="Physical urticarias";
var content_f24_5_24666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physical urticarias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24666/contributors\">",
"     John P Dice, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24666/contributors\">",
"     Erika Gonzalez-Reyes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24666/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24666/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24666/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/5/24666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/5/24666/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/5/24666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical urticarias are disorders in which urticaria (ie, hives or wheals) are induced by environmental stimuli, such as heat, cold, pressure applied to the skin, exercise, water, vibration, and sunlight. These conditions probably result from heightened sensitivity by the mast cell to environmental conditions, although the exact pathogenesis is unknown.",
"   </p>",
"   <p>",
"    An urticarial lesion is an intensely pruritic, circumscribed, raised, erythematous plaque, which can range in diameter from a few millimeters to many centimeters (",
"    <a class=\"graphic graphic_picture graphicRef72519 \" href=\"UTD.htm?29/2/29728\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63644 \" href=\"UTD.htm?23/55/24433\">",
"     picture 2",
"    </a>",
"    ). Urticaria may enlarge, sometimes developing central pallor, and coalesce with other adjacent lesions. They usually appear in crops and are typically short-lived, expanding and then resolving over a few hours without leaving residual marks on the skin (unless there is trauma from scratching).",
"   </p>",
"   <p>",
"    Physical urticarias will be discussed in this topic review. Other disorders of acute and chronic urticaria are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"     \"New onset urticaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL POINTS ABOUT PHYSICAL URTICARIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing individual syndromes, it is helpful to review some observations about the physical urticaria disorders as a group.",
"   </p>",
"   <p>",
"    Physical urticarias are considered subtypes of chronic urticaria (CU). In some patients, a specific physical stimulus is the only trigger for hives, whereas in others, a physical stimulus is an identifiable factor in a case of otherwise idiopathic urticaria. A minority of patients have hives triggered by multiple physical stimuli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considered together, the physical urticarias are present in approximately 20 to 30 percent of adults with chronic urticaria, a disorder that afflicts approximately 1 percent of adults. Physical urticarias may be more common in children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/1\">",
"     1",
"    </a>",
"    ]. The prevalence of these disorders in the general population is not well defined, and many cases may be mild and easily managed in the primary care setting. In contrast, most published reports are based upon patient populations referred to specialty centers, and so may overestimate the severity and persistence of these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are differences among experts concerning the best manner of classifying the physical urticarias. Guidelines for classification and diagnosis have been published by a European expert panel [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/2\">",
"     2",
"    </a>",
"    ]; the material in this topic review is similar, although not identical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Variations in clinical presentation and severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical urticarias vary widely in severity. The symptoms of each syndrome can range from mild to disabling, with some patients experiencing potentially dangerous systemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific testing procedures are presented in the discussions of each disorder below and summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/3\">",
"     3",
"    </a>",
"    ]. However, there are some general points to consider in performing challenge procedures for physical urticarias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical challenges are not always needed for diagnosis, although they are sometime invaluable in clarifying or confirming the diagnosis. These challenges are usually performed by allergy specialists with training in the management of the systemic allergic reactions that could conceivably result in anaphylaxis. Proper access to the staff and equipment necessary to treat a potentially life-threatening allergic reaction is essential. This is especially true if the patient has experienced systemic symptoms in the past (eg, bronchospasm or hypotension).",
"   </p>",
"   <p>",
"    During these challenges, physical stimuli are applied to the skin for a specified amount of time, usually a few minutes, and then removed. Urticaria typically develops AFTER removal of the stimulus. Leaving the stimulus in contact with the skin until hives actually appear can result in excessive exposure and systemic symptoms. Similarly, exposure time may need to be reduced in patients who describe unusual levels of sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     When to refer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having a syndrome of physical urticaria should be referred to an allergy or dermatology specialist with experience in these disorders in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The diagnosis is not apparent, or",
"     </li>",
"     <li>",
"      The condition does not respond adequately to initial therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned previously, referral is usually appropriate if a challenge procedure is being considered. Patients with past systemic",
"    <span class=\"nowrap\">",
"     reactions/anaphylaxis",
"    </span>",
"    should be referred to allergists specifically, because there is potential risk involved in challenging such patients and because they can educate patients about how to manage possible recurrent anaphylaxis, including use of an epinephrine autoinjector. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=see_link&amp;anchor=H7657169#H7657169\">",
"     \"Long-term management of patients with anaphylaxis\", section on 'Preparing the patient to treat possible recurrences'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of physical urticarias should be approached in a stepwise manner. Avoidance of the physical stimuli that induce symptoms should always be considered initially, although complete avoidance may not be possible or practical.",
"   </p>",
"   <p>",
"    Pharmacologic therapy is often required but variably successful. Certain types of physical urticaria (eg, dermographism) are responsive to antihistamines, while other forms (eg, local heat urticaria) are typically resistant. However, therapy must be individualized in each case, often by trial and error. In addition, most studies of therapy in these disorders were performed with first-generation, sedating H1 antihistamines, and the relative effectiveness of the newer second- and third-generation drugs has not been evaluated.",
"   </p>",
"   <p>",
"    In most patients with a physical urticaria disorder who cannot avoid the stimulus, a trial of antihistamines is warranted. The approach outlined here is opinion-based, since trials comparing different regimens are lacking.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We usually begin with a second or third generation H1 antihistamine at standard doses, but quickly increase to double the standard dose (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      10 mg twice daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      180 mg twice daily, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      10 mg twice daily) if needed.",
"     </li>",
"     <li>",
"      If symptoms are not controlled, we add an H2 antihistamine at standard dose. If there is no detectable improvement, the H2 antihistamine can be discontinued.",
"     </li>",
"     <li>",
"      If the response is still not adequate, we usually change the second generation H1 antihistamine to a first generation agent, and increase the dose as tolerated (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      , beginning with 25 mg at bedtime, and increasing gradually to an upper limit of 100 to 200 mg daily, divided among four doses).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When symptoms of physical urticaria cannot be controlled with combinations of antihistamines, oral glucocorticoids may be used for short-term treatment and are usually very effective. We typically continue antihistamines and begin glucocorticoid therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , 0.5 to 1.0 mg per kg daily. Symptoms usually improve within days. The dose can then be tapered gradually over two to four weeks to discontinuation, or at least to &lt;10 mg per day. If the prednisone cannot be reduced to &lt;10 mg per day after two to four weeks or stopped entirely within two to three months, then an alternate, steroid-sparing agent should be considered, as the long-term side effects of glucocorticoids make chronic therapy undesirable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agents that have been found to be useful for particular physical urticaria syndromes are discussed in the sections below, as are alternate therapies for refractory disease. The treatment of chronic idiopathic urticaria is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"     \"Chronic urticaria: Standard management and patient education\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DERMOGRAPHISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermographism (also called dermatographism) literally means to ''write on the skin.'' Patients with this condition develop the rapid onset of a wheal and flare reaction after firm stroking, scratching, or the application of pressure to the skin. Dermographism is the most common of the physical urticarias and is often an incidental finding in the evaluation of other skin conditions, most commonly atopic dermatitis, chronic idiopathic urticaria, and the other physical urticarias discussed in this article.",
"   </p>",
"   <p>",
"    There are several forms of dermographism. Most individuals have simple dermographism, which is asymptomatic (non-pruritic) other than the raised urticarial welts that form on the skin with scratching, etc. (",
"    <a class=\"graphic graphic_picture graphicRef50823 \" href=\"UTD.htm?30/33/31248\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef61550 \" href=\"UTD.htm?42/57/43920\">",
"     picture 4",
"    </a>",
"    ). The other forms of dermographism are symptomatic and vary in their clinical appearances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple dermographism is the most common form and is thought to occur in approximately 2 to 5 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The symptomatic forms of dermographism are much less common and usually occur sporadically, although there is a single case report of familial dermographism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;In simple dermographism, a wheal is provoked by stroking the skin with a firm object. The wheal typically appears within 6 to 7 minutes and begins to fade 15 to 30 minutes later [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic dermographism is only slightly different, with lesions appearing in less than 5 minutes and lasting 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to classic wheals, variants of symptomatic dermographism have been described in which the reactions are follicular [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/7\">",
"     7",
"    </a>",
"    ] or inflamed and swollen (red dermographism) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a purposeful stroking of the skin is the most common way to elicit symptoms, patients often are unaware of the inciting action. Occasionally, idiopathic pruritus or pruritus caused by dry skin can be the event that elicits scratching and subsequent dermographism. In this setting, the wheals are typically linear. Simple actions such as scratching, leaning against a solid object, or irritation from clothes or bed sheets may provoke whealing. In one case series, dermographism could be exacerbated by hot water, emotion, exercise, or cold exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dermographism is typically idiopathic and begins without a clear inciting event. However, inflammatory perturbations may occasionally precede onset, as cases have been described in which symptomatic dermographism appeared to be triggered by infections with bacteria, fungi, and scabies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] or after receiving penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/12\">",
"     12",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of dermographism is unknown. The release of vasoactive mediators from cutaneous mast cells is assumed to be involved, and elevated levels of serum histamine have been demonstrated after a whealing episode [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/14\">",
"     14",
"    </a>",
"    ]. Experiments in which serum from a dermatographic patient injected intradermally into a monkey transferred dermographism suggest that the reaction may be IgE-mediated, although no allergen has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dermographism can be diagnosed in an office setting by stroking the skin with a firm (clean) object, such as a tongue blade (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). This action provokes a typical wheal-and-flare response within a few minutes, as described earlier. The patient should refrain from taking antihistamines for several days before the test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple dermographism that is non-pruritic requires no therapy, and treatment involves avoidance of inciting triggers. If the skin appears dry, emollients (such as hydrated petrolatum applied daily, immediately after bathing) can be helpful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H1 antihistamines have been shown to be effective for treatment of pruritus and reduction of whealing, and are the initial drug of choice. Both first-generation antihistamines, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      , and second-generation H1 antihistamines, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      , have demonstrated benefit, although studies comparing different antihistamine regimens are lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/8,16-18\">",
"       8,16-18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It is our practice to initiate therapy for symptomatic dermographism with non-sedating second-generation H1 antihistamines, as described above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overview of treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The addition of an H2 antihistamine was beneficial in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/17,19,20\">",
"       17,19,20",
"      </a>",
"      ], although not all concluded that there was an additive effect [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/14\">",
"       14",
"      </a>",
"      ]. A trial of combination therapy with an H1 and H2 antihistamine is warranted if the response to H1 antihistamines alone is inadequate.",
"     </li>",
"     <li>",
"      Some patients report that sun exposure improves the condition, and one uncontrolled study of 43 patients reported that 39 improved or cleared with ultraviolet B (UVB) light treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/21\">",
"       21",
"      </a>",
"      ]. Such aggressive therapy could be considered in a patient refractory to standard medications and with a severe decrease in quality of life (eg, poor sleep, poor performance at work or school, negative effect on social life).",
"     </li>",
"     <li>",
"      Case reports describe successful treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       omalizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/22\">",
"       22",
"      </a>",
"      ], although this application is not approved by the US Food and Drug Administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DELAYED PRESSURE URTICARIA/ANGIOEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed-pressure",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    (which is sometimes classified as a delayed form of symptomatic dermographism) presents most commonly as an erythematous swelling of the skin that develops four to six hours after pressure has been applied to the area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The leading presentation is erythematous swelling of the skin four to six hours after the application of pressure. Less often, patients develop urticaria with prominent swelling. The amount of pressure that is needed to induce symptoms varies among different individuals. Patients often describe burning and pain instead of or in addition to pruritus, and the swelling can last several hours to several days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/2\">",
"     2",
"    </a>",
"    ]. There may be accompanying arthralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activities that typically induce symptoms in patients with delayed-pressure angioedema include wearing tight clothing (affecting areas of constriction), sitting for prolonged periods of time on a hard surface (affecting the buttocks), an extended period of walking (affecting the soles and feet), or carrying heavy bags of groceries (affecting the palms and hands). Some patients will wake up with facial swelling on the side of the face that was compressed against the pillow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed pressure",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    can often be accurately diagnosed based upon historical features alone. Devices called dermographometers have been used in research protocols in the past, but are not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Alternatively, a sling attached to a 10 pound weight may be placed over the patient's arm for 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/25\">",
"     25",
"    </a>",
"    ], after which the patient is instructed to observe the compressed skin for symptoms over the next 24 hours (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). The patient should refrain from taking antihistamines for several days before the test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment of delayed-pressure",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    is similar to that of symptomatic dermographism, although antileukotriene agents have also shown utility [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial of 36 patients with delayed pressure urticaria confirmed by challenge with a dermographometer (18 of whom had concomitant chronic idiopathic urticaria), patients were assigned to one of three treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"       desloratadine",
"      </a>",
"      (5 mg once daily) plus oral placebo",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"       desloratadine",
"      </a>",
"      (5 mg once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (10 mg once daily)",
"     </li>",
"     <li>",
"      Oral placebo alone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subjects were rechallenged after two weeks of therapy. Patients in both active treatment groups showed a significant reduction in the mean diameter of the induced wheals compared to placebo, and patients in the group receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    were significantly better than those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12934?source=see_link\">",
"     desloratadine",
"    </a>",
"    alone, with fewer episodes and reduced symptoms. The use of other antihistamines in combination with montelukast has not been studied, although different agents are probably also effective.",
"   </p>",
"   <p>",
"    A few case reports describe successful treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], although this application is not approved by the US Food and Drug Administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CHOLINERGIC URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholinergic urticaria (sometimes called generalized heat urticaria) describes hives that are precipitated by an increase in core body temperature. Common triggers include exercise, strong emotions, and bathing in hot water [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholinergic urticaria is believed to account for approximately 30 percent of all cases of physical urticaria and approximately 5 percent of all cases of chronic urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/32\">",
"     32",
"    </a>",
"    ]. Cholinergic urticaria typically has its onset during the second or third decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Whereas one study noted a predominance in male patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33\">",
"     33",
"    </a>",
"    ], others have found that both sexes are affected equally [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Familial cases are rare but have been reported (in which all affected individuals were male) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic initial appearance of cholinergic urticaria is that of numerous small (1 to 3 mm), punctate wheals surrounded by large flares (",
"    <a class=\"graphic graphic_picture graphicRef53590 \" href=\"UTD.htm?41/58/42912\">",
"     picture 5",
"    </a>",
"    ). Many patients note a tingling, itching, or burning sensation of the skin before the appearance of the hives [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33\">",
"     33",
"    </a>",
"    ]. As the response progresses, the flares may coalesce to form large areas of erythema. The wheals typically begin on the trunk and neck and spread distally to involve the face and extremities, although lesions may begin anywhere on the body. In rare cases, cholinergic urticaria has been reported to progress to include systemic symptoms such as hypotension, angioedema, and bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33,37,38\">",
"     33,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned earlier, any trigger that results in an elevation of core body temperature may provoke the onset of cholinergic urticaria. Exercise is one of the most common triggers, and cholinergic urticaria may be confused with exercise-induced urticaria if other triggers are not considered. However, the two conditions can usually be distinguished, because a variety of triggers precipitate cholinergic urticaria, while exercise or exertion is usually the sole trigger for exercise-induced urticaria. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Exercise-induced urticaria'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other typical inciting factors for cholinergic urticaria include hot baths or showers, strong emotional feelings, and ingestion of spicy or hot foods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one study, a patient with preexisting cholinergic urticaria experienced a flare of his condition while undergoing dialysis treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/39\">",
"     39",
"    </a>",
"    ]. A decrease in the patient's dialysate temperature by 1.5&ordm;C led to resolution of his symptoms, and rechallenge with fluid at a higher temperature reproduced his urticaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with many of the other physical urticarias, a variety of pathogenetic mechanisms have been postulated in cholinergic urticaria, and there may be different mechanisms at work in different patients. Elevated levels of histamine have been detected in the serum during an attack [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One theory of pathogenesis proposed that urticaria in this condition was caused by the cholinergic nervous system [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/37\">",
"       37",
"      </a>",
"      ]. In some patients, the injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      intradermally induces urticaria, which can be reversed by administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33,40,41\">",
"       33,40,41",
"      </a>",
"      ]. Patients with cholinergic urticaria have been shown to have an increased number of muscarinic receptors on cutaneous mast cells in areas that demonstrate hives [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of a more typical antigen-antibody reaction or a transferable serum factor has been investigated in a series of passive transfer experiments using sera from patients with cholinergic urticaria that were injected into the skin of a primate [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/43\">",
"       43",
"      </a>",
"      ]. When the monkey subsequently was injected with acetylcholine, a cutaneous reaction was observed with 7 of 16 patient sera. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Diagnosis and testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Many of the triggers for cholinergic urticaria also lead to increased sweating, and a subgroup of patients with symptoms suggestive of cholinergic urticaria have urticaria only in response to sweating.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have suggested that cholinergic urticaria might be caused by an IgE-mediated allergy to some component of human sweat [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Some patients demonstrate immediate reactions to skin testing with their own diluted sweat [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/44,47,48\">",
"     44,47,48",
"    </a>",
"    ]. An IgE-mediated mechanism was also implicated in a case report of a patient successfully treated with anti-IgE therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/46\">",
"     46",
"    </a>",
"    ]. Another found that a group of 18 patients with cholinergic urticaria appeared to have two separate mechanisms for their condition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/45\">",
"     45",
"    </a>",
"    ]. One subset reacted when skin tested to their own sweat, and had a positive acetylcholine skin test. The rest of the patients had a negative acetylcholine test and were skin test negative to sweat.",
"   </p>",
"   <p>",
"    There have been several reports of patients with cholinergic urticaria that was associated with hypohidrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. An explanation was proposed that occlusion of the pores of the stratum corneum could cause hypohidrosis and subsequent abnormal leakage of inflammatory sweat materials into the upper dermis, resulting in a whealing reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of the lesions of classic cholinergic urticaria in the context of typical inciting triggers is often sufficient to make the diagnosis, and a clinical diagnosis is usually all that is required in routine practice. However, several methods of provocation testing have been proposed, which are largely used in research settings (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intradermal injection of 0.01 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      in 0.1 mL saline that produces a local area of hives is diagnostic. However, only about one-third of patients with cholinergic urticaria demonstrate a positive test, so this procedure cannot be used to exclude the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33,40\">",
"       33,40",
"      </a>",
"      ]. In addition, there are currently no injectable forms of methacholine commercially available in the United States.",
"     </li>",
"     <li>",
"      Another diagnostic strategy used in research protocols involves non-exertional elevation of the patient's core body temperature. Patients may have one or both arms submerged in a 40&ordm;C hot water bath until the core body temperature has increased at least 0.7&ordm;C [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/51\">",
"       51",
"      </a>",
"      ]. The appearance of generalized urticaria confirms the diagnosis of cholinergic urticaria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification and avoidance of known triggers are the first steps in controlling cholinergic urticaria. Bathing in hot water and performing strenuous exercise during hot weather are to be avoided.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical therapy consists predominantly of oral H1 antihistamines. Typically these are taken daily, although as needed administration is possible if triggers are easy to identify in advance.",
"     </li>",
"     <li>",
"      We usually initiate therapy with a second generation antihistamine, as described previously. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overview of treatment approach'",
"      </a>",
"      above.)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       Cetirizine",
"      </a>",
"      , a less sedating metabolite of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      , has shown efficacy at doses twice normal (10 mg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      at twice normal dose is not effective, we typically change to the first generation antihistamine",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       hydroxyzine",
"      </a>",
"      , which has been used successfully for decades [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/5,34\">",
"       5,34",
"      </a>",
"      ]. This agent is highly sedating for some patients. Therapy should be initiated with a low dose which is increased gradually until the urticaria is controlled, which typically occurs at doses of 100 to 200 mg divided over 24 hours. Studies comparing the hydroxyzine to cetirizine have not been performed, but clinical experience suggests that some patients who do not respond to cetirizine do respond to hydroxyzine.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33024?source=see_link\">",
"       Ketotifen",
"      </a>",
"      (not available in the United States) has also shown efficacy in treating cholinergic urticaria at doses of 3 to 8 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]. This agent is highly sedating for some patients.",
"     </li>",
"     <li>",
"      The anabolic steroid",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"       danazol",
"      </a>",
"      can be effective [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. This agent is postulated to correct the low blood levels of protease inhibitors that occur in some patients with cholinergic urticaria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/57\">",
"       57",
"      </a>",
"      ]. Given its potential for adverse effects, however, this medication should be reserved only for severe cases refractory to antihistamines.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      has been used successfully in the treatment of cholinergic urticaria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/46,48\">",
"       46,48",
"      </a>",
"      ], although failures are also reported [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Desensitization may be possible as patients will sometimes experience a period of latency after an episode of cholinergic urticaria. In most cases, these relatively symptom-free periods lasted only a few hours but could last more than 24 hours if the initial episode was severe. One study described two patients who treated themselves on a nightly basis using a dose of antihistamine that was followed three hours later by a hot bath [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral anticholinergic agents have NOT been shown to be effective [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for cholinergic urticaria is generally favorable. One study reported only 31 percent of patients with a persistence of symptoms greater than 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/33\">",
"     33",
"    </a>",
"    ]. Another estimated that the average duration of symptoms is 7.5 years (range, 3 to 16 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     LOCAL HEAT URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local heat urticaria describes a rare disorder in which a warm stimulus must come into direct contact with the skin and results in the formation of a wheal at the heated site within minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/25\">",
"     25",
"    </a>",
"    ]. The pathogenesis involves histamine release, implicating the mast cell in the cause of this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/60\">",
"     60",
"    </a>",
"    ]. Passive transfer experiments, however, have been negative. There is one case report of a familial, delayed-type variant of local heat urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic testing is conducted by the application of a test tube containing water at 44&ordm;C to the arm for four to five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/25\">",
"     25",
"    </a>",
"    ]. Other authors recommend using a cylinder heated to 50&ordm;C to 55&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/51\">",
"     51",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). A localized hive should develop within a few minutes after removal of the heated object. The patient should refrain from taking antihistamines for several days before the test. Occasionally, positive test can only be obtained on specific areas of skin that have displayed symptoms in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy using antihistamines and oral cromolyn has not been effective for local heat urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/25\">",
"     25",
"    </a>",
"    ]. Desensitization using daily hot baths was successful in one patient but carries some risk for a systemic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     EXERCISE-INDUCED URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urticaria with exercise has been shown to occur in two distinct situations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholinergic urticaria &mdash; Patients with cholinergic urticaria develop hives after exercising or after experiencing any other trigger that elevates core body temperature. Systemic symptoms are uncommon, but can occur. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Cholinergic urticaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise-induced anaphylaxis &mdash; Urticaria with exercise may also be an early manifestation of exercise-induced anaphylaxis. Unlike in cholinergic urticaria, exercise is the only trigger in exercise-induced anaphylaxis, and passively raising the core body temperature is not sufficient to induce symptoms. This disorder is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=see_link\">",
"       \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hives of exercise-induced anaphylaxis are typically larger in size than those of cholinergic urticaria, although cases of exercise-induced anaphylaxis presenting with punctate lesions have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     AQUAGENIC URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aquagenic urticaria is a rare condition in which urticaria develop as a result of direct skin contact with water.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are fewer than 50 cases of aquagenic urticaria reported in the medical literature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/2,64-68\">",
"     2,64-68",
"    </a>",
"    ]. Women seem to have a slightly higher incidence than men, and in most cases, the age of onset is during or slightly after puberty. Familial occurrences have been reported on several occasions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]; in one report the condition existed across three generations of a single family [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lesions of aquagenic urticaria are characteristically small, punctuate (1 to 3 mm), perifollicular wheals that may occur on all parts of the body, although generally not on the palms and soles. In appearance, they are indistinguishable from the wheals of cholinergic urticaria. However, in aquagenic urticaria, hives appear rapidly after direct contact with various sources of water (ie, distilled, tap, or saline).",
"   </p>",
"   <p>",
"    In some patients, salinity appears to be important. One patient experienced urticaria after exposure to tap water, snow, and sweat but did not develop symptoms after exposure to sea water [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/69\">",
"     69",
"    </a>",
"    ]. Another developed hives on exposure to sea water, but not fresh water, although over time she also because sensitive to tap water as well [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/70\">",
"     70",
"    </a>",
"    ]. Hive formation is not influenced by the temperature or pH of the water [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/68\">",
"     68",
"    </a>",
"    ]. Alcohol and other liquid organic solvents applied to the skin do not lead to wheal formation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]; however, they can potentiate the reaction to water, likely by enhancing the permeability of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wheals appear rapidly within 20 to 30 minutes following exposure to water; once the water source is removed from the skin, the wheals generally fade within 30 to 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/2\">",
"     2",
"    </a>",
"    ]. Systemic symptoms are rare, but have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/66,72\">",
"     66,72",
"    </a>",
"    ]. A refractory period lasting several hours has been demonstrated after an attack [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/73\">",
"     73",
"    </a>",
"    ]. Repeated, short, purposeful exposures to water can lead to exhaustion of the wheal response [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aquagenic urticaria is occasionally associated with other forms of physical urticaria. Case reports describe patients with aquagenic urticaria and coexisting dermographism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/66,74\">",
"     66,74",
"    </a>",
"    ], cholinergic urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/67,73,74\">",
"     67,73,74",
"    </a>",
"    ], or cold urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of this condition is poorly understood and may not be the same in all patients. Several theories have been proposed based upon studies in small numbers of subjects. Serum histamine levels are variable from patient to patient, as is the response to pretreatment with oral antihistamines.",
"   </p>",
"   <p>",
"    The following mechanisms have been postulated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several researchers have proposed that water is primarily acting as a solvent in aquagenic urticaria, solubilizing an antigen that then permeates the skin and activates dermal mast cells. Water may interact with sebum (the oily substance produced by sebaceous glands in the skin) to form a substance capable of acting as a direct mast cell degranulator, resulting in histamine release [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/64\">",
"       64",
"      </a>",
"      ]. One study demonstrated that patch testing with a patient's sweat produced only erythema, whereas testing with sweat and sebum produced marked urticaria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/68\">",
"       68",
"      </a>",
"      ]. Others have proposed that the causative antigen(s) normally reside at the epidermal layer of the skin and solubilization in water allowing these antigens to diffuse more deeply into the skin [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/67\">",
"       67",
"      </a>",
"      ]. It is possible that different antigens in different skin layers are involved.",
"      <br/>",
"      <br/>",
"      In another study, removal of the stratum corneum layer of the skin enhanced reactivity upon contact with water [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/71\">",
"       71",
"      </a>",
"      ]. Similarly, pretreatment of the skin with organic solvents enhanced wheal formation to water. These investigators concluded that enhancing the ability of water to penetrate the stratum corneum layer of the skin increases the wheal-provoking effects of water in these patients.",
"     </li>",
"     <li>",
"      Another theory suggested that activation of the cholinergic pathway was essential for the formation of aquagenic urticaria, based upon the ability of the acetylcholine antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      to suppress wheal formation when applied to the skin before water exposure in two patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/71\">",
"       71",
"      </a>",
"      ]. However, other studies did not find evidence for a cholinergic mechanism, as pretreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      did not suppress subsequent wheal formation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/67\">",
"       67",
"      </a>",
"      ]. In addition,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      injection testing, often positive in cholinergic urticaria, was negative in a series of patients with aquagenic urticaria [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The studies reviewed above were performed before the publication of those implicating hypersensitivity to sweat allergens in cholinergic urticaria, and comparative mechanistic studies of the two conditions have not been undertaken. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Cholinergic urticaria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard test for aquagenic urticaria is the application of a compress of 35&ordm;C water to the upper body for 30 minutes (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). Although water of any temperature can provoke aquagenic urticaria, using ambient-temperature water avoids confusion with cold-induced or local heat urticaria. The upper body is chosen as the preferred site, because other areas, such as the extremities, are affected less commonly in aquagenic urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/76\">",
"     76",
"    </a>",
"    ]. The patient should refrain from taking antihistamines for several days before the test.",
"   </p>",
"   <p>",
"    In some case reports, rinsing specific areas of the body with water or performing direct bath and shower challenges has been attempted. Use of these approaches may be required when localized testing using a small water compress is negative, although it should be avoided in patients with a history of significant systemic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aquagenic pruritus, cholinergic urticaria, cold-induced urticaria, and local heat urticaria may have inciting factors that can be confused with those of aquagenic urticaria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aquagenic pruritus is itching of the skin upon contact with water, without the development of actual hives or other objective findings.",
"     </li>",
"     <li>",
"      Cholinergic urticaria can be elicited by sweating, exercise, heat, and strong emotions, whereas aquagenic urticaria requires the skin to be in direct contact with water.",
"     </li>",
"     <li>",
"      Cold-induced urticaria can be differentiated from aquagenic urticaria by the history of reactions upon exposure to cold air and tolerance of warm or hot water.",
"     </li>",
"     <li>",
"      Local heat urticaria can be distinguished from aquagenic pruritus by reactions to warm but dry triggers (heating pad or test tube filled with warm water).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A trial of H1 antihistamines is warranted in all patients as an initial intervention, although the success of these agents is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/71,77\">",
"     71,77",
"    </a>",
"    ]. Other reported therapies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       Propranolol",
"      </a>",
"      , at doses of 10 to 40 mg daily, was reported to be effective in 5 of 6 patients in a small series [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/78\">",
"       78",
"      </a>",
"      ]. In another report, two patients were successfully treated [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      UVB light treatments twice a week in a child with coexisting aquagenic urticaria, cholinergic urticaria, and dermographism resulted in improvement by 20 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/74\">",
"       74",
"      </a>",
"      ]. Two reports have documented the benefits of PUVA therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stanozolol was effective in a patient with HIV infection, hepatitis C virus infection, and aquagenic urticaria, who had failed therapy with oral antihistamines [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/72\">",
"       72",
"      </a>",
"      ]. Symptoms recurred when stanozolol was stopped.",
"     </li>",
"     <li>",
"      Barrier creams were reported to be effective in a small number of patients, although this may only be practical in very specific circumstances [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/71,76\">",
"       71,76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SOLAR URTICARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solar urticaria involves the induction of urticaria, most commonly following direct exposure of the skin to sunlight [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/82\">",
"     82",
"    </a>",
"    ]. The number of patients affected by this condition is small, and most data are case reports and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. The largest series included 87 cases confirmed by phototesting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective reviews of patients with urticaria found that only approximately 0.5 percent were classified as solar urticaria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. There is a higher incidence in women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/85,87\">",
"     85,87",
"    </a>",
"    ]. Patient age at onset, atopic history, and the wavelength of light responsible for the reaction varies significantly among patients. Geographic and racial differences have not been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solar urticaria generally presents with classic-appearing urticarial lesions developing within minutes after exposure to direct sunlight, and occurring on skin that was uncovered (",
"    <a class=\"graphic graphic_picture graphicRef57783 \" href=\"UTD.htm?33/13/34003\">",
"     picture 6",
"    </a>",
"    ). However, in the series of 87 cases, 76 and 83 percent developed symptoms through thin clothing and glass, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/87\">",
"     87",
"    </a>",
"    ]. Limited exposures provoke only itching or burning erythema, while more prolonged exposures lead to typical wheals. A more delayed onset of symptoms (several hours after light exposure) has been reported in a few patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The severity of the symptoms generally increases with the intensity of the sun exposure. Areas of skin that frequently are exposed to sunlight are less sensitive than areas that are usually covered [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/90\">",
"     90",
"    </a>",
"    ]. The exact mechanism of this \"hardening\" phenomenon remains unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/91\">",
"     91",
"    </a>",
"    ]. A more severe reaction may be provoked by purposeful sunbathing rather than by normal daily sunlight exposure. Systemic, anaphylactic reactions are possible if the exposed body surface area is large enough [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the patient is removed from the sun exposure, symptoms usually fade rapidly. Most patients note disappearance of the urticaria within 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been hypothesized that solar urticaria is dependent on the presence in the skin of a precursor molecule that is activated by exposure to a particular wavelength of light and becomes a photoallergen. This antigen can be activated in vivo or in vitro by irradiating a sample of the patient's serum [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/85\">",
"     85",
"    </a>",
"    ]. The origin of the precursor molecule has not been determined yet. The fact that passive transfer is not always successful could indicate that there are different photoallergens at work in different patients. One group has suggested that the disorder be divided into two subtypes: type I solar urticaria, due to IgE antibodies directed against an abnormal photoallergen present only in affected patients, and type II solar urticaria, due to circulating IgE antibodies against a normal photoallergen present in most people [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Diagnosis and testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical history may be sufficient to differentiate solar urticaria from other conditions. If there is clinical uncertainty, the diagnosis can be established using phototesting (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). The patient should refrain from taking antihistamines for several days before the test.",
"   </p>",
"   <p>",
"    A simple form of testing may be performed by exposing a small area of the patient's skin to natural sunlight, which induces erythema or urticaria. The reaction generally fades quickly after the test is halted. However, patients with cholinergic or local heat urticaria might react to this type of testing as well.",
"   </p>",
"   <p>",
"    More formal evaluation is performed with a visible light source, or using instruments that generate UVA or UVB. The patient's skin is exposed to varying wavelengths using a monochromatic light source. Most patients demonstrate a threshold wavelength at which symptoms develop, which is referred to as the action spectrum. In some patients, testing with monochromatic light failed to provoke urticaria, although exposure to other light sources, such as natural sunlight, high-intensity ultraviolet light, or slide-projector light, did cause symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients exhibit an inhibition spectrum, which when applied to the skin during or immediately after the action spectrum, inhibits the development of the wheal reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/93\">",
"     93",
"    </a>",
"    ]. However, application of the inhibition spectrum before the action spectrum does not prevent symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/85\">",
"     85",
"    </a>",
"    ], so this phenomenon has no immediate clinical utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of photosensitive disorders have been described. Two that can present with symptoms similar to solar urticaria are polymorphous light eruption and erythropoietic protoporphyria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the patient with macular skin lesions\", section on 'Photodistributed macular eruptions'",
"    </a>",
"    .) The symptoms of solar urticaria could initially be mistaken for common sunburn, however, the lesions of solar urticaria develop within minutes of sun exposure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Polymorphous light eruption",
"      </strong>",
"      &mdash; In this idiopathic condition, which is far more common than solar urticaria, papular and papular-vesicular lesions appear on sun-exposed areas, although there is less of a predilection for the face (",
"      <a class=\"graphic graphic_picture graphicRef55477 \" href=\"UTD.htm?16/26/16801\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef67216 \" href=\"UTD.htm?23/26/23970\">",
"       picture 8",
"      </a>",
"      ). The lesions of polymorphous light eruption tend to last two to six days, which usually allows differentiation from solar urticaria, in which lesions resolve within 24 hours. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=see_link\">",
"       \"Polymorphous light eruption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Erythropoietic protoporphyria",
"      </strong>",
"      &mdash; This condition can demonstrate urticaria on sun-exposed areas, although the lesions are typically painful rather than pruritic. Erythropoietic protoporphyria usually presents in early childhood, and there is a family history of the disorder. The cutaneous lesions of erythropoietic protoporphyria can develop within minutes of sun exposure, and diffuse edema of the skin in sun-exposed areas may resemble angioedema. Petechiae and purpuric lesions may be seen. With time, the skin may become lichenified and leathery, with labial grooving and nail changes (",
"      <a class=\"graphic graphic_picture graphicRef68503 \" href=\"UTD.htm?27/44/28354\">",
"       picture 9",
"      </a>",
"      ). This disorder is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=see_link\">",
"       \"Erythropoietic protoporphyria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Treatment and prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;H1 antihistamines provide symptomatic treatment and can be used orally or topically. These medications are effective in reducing pruritus and wheal formation but may not eliminate the erythema. In most of the initial studies, terfenadine was used, and higher-than-standard doses often were required to achieve symptom relief [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/94\">",
"     94",
"    </a>",
"    ]. Whether this finding is true for all antihistamines, including some of the newer agents, remains to be determined. Topical and systemic steroids can be used if antihistamines are insufficient. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Overview of treatment approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When antihistamines provide inadequate relief, other treatment approaches may be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desensitization may be useful in some cases. It has been demonstrated that skin that is regularly exposed to sunlight becomes less reactive than that which is usually covered [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/90\">",
"       90",
"      </a>",
"      ]. Patients may be repeatedly exposed to ultraviolet light sources, although the desensitized state typically lasts only a few days.",
"     </li>",
"     <li>",
"      The use of psoralen plus ultraviolet A radiation (PUVA) has been shown to induce a longer-lasting effect, although the potential long-term adverse effects are greater [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous immune globulin (IVIg), given to seven patients (at doses ranging from 1.4 to 2.5 grams per kilogram, given over two to five days) resulted in lasting remission in five and no response in two [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/95\">",
"       95",
"      </a>",
"      ]. All patients had failed antihistamine therapy and several had failed multiple therapies. Between one and three courses were administered in those who responded.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38629?source=see_link\">",
"       Omalizumab",
"      </a>",
"      (anti-IgE therapy) has been reported to be of benefit in case reports [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/30,96,97\">",
"       30,96,97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At least one instance of the successful use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (4.5 mg per kg per day) for refractory solar urticaria has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Plasmapheresis has been used alone and in conjunction with PUVA therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/99-101\">",
"       99-101",
"      </a>",
"      ]. This modality has been reported to improve symptoms in the few patients included in these studies. One study failed to demonstrate a lasting benefit with plasmapheresis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/102\">",
"       102",
"      </a>",
"      ]. The effectiveness of this therapy may depend on the characteristics of the specific photoallergen at work (ie, circulating antigen versus cutaneous antigen).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The long-term outlook for patients with solar urticaria has been uncertain because of the small number of cases. A review of 87 patients found that 25 percent of 60 subjects who were available for follow-up reported complete resolution of their conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/87\">",
"     87",
"    </a>",
"    ]. An additional 32 percent reported improvement, whereas 35 percent were unchanged, and 8 percent believed that their conditions had worsened. Most of the original case reports indicated that the condition was persistent, and although many experienced overall improvement in symptoms, few patients experienced complete resolution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     VIBRATORY ANGIOEDEMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibratory angioedema refers to the development of pruritus and swelling after the application of a vibratory stimulus to the skin. Hives are usually not observed in this syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of vibratory angioedema are rare. The condition was initially described in four members of one family, in which there was an autosomal dominant inheritance pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/103\">",
"     103",
"    </a>",
"    ]. This was followed by another familial report [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/104\">",
"     104",
"    </a>",
"    ], and the condition was given the name hereditary vibratory angioedema. Other case reports of patients with vibratory angioedema have been sporadic and generally related to the subject's occupation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common triggers for vibratory angioedema include mowing the lawn, riding a motorcycle, horseback riding, or mountain biking. At risk occupations include jackhammer operator, machinist [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/105\">",
"     105",
"    </a>",
"    ], carpenter [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/105\">",
"     105",
"    </a>",
"    ], and metal grinder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients generally complain of local pruritus, erythema, and swelling arising within a few minutes after exposure to vibration and affecting the area that was most exposed to the stimulus (often the hands). There are rare cases of delayed onset symptoms beginning one to two hours after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/107\">",
"     107",
"    </a>",
"    ]. Symptoms peak in severity at four to six hours and typically resolve by 24 hours. In some episodes, the symptoms may persist for several days. The severity and duration of the symptoms may vary and seem to be proportional to the intensity and duration of the applied vibratory stimulus and to the area of exposed body surface. Patterson's initial report described systemic symptoms of headache and generalized erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/103\">",
"     103",
"    </a>",
"    ]. One patient developed carpal tunnel syndrome, and slowed median nerve conduction was documented only during episodes of edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of vibratory angioedema has not been satisfactorily elucidated yet. Elevated levels of serum histamine and mast cell degranulation have been documented during symptomatic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/105,107,108\">",
"     105,107,108",
"    </a>",
"    ]. Most investigators favor a nonimmunologic reaction (eg, direct mast cell stimulation from the vibration causes degranulation and local release of histamine) and passive transfer experiments have been negative [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/103,108\">",
"     103,108",
"    </a>",
"    ]. In a study of vibration exercise in 37 healthy subjects, approximately one-half developed a pruritic erythematous eruption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several methods for reproducing the vibratory stimulus and classifying the reaction have been used in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/2\">",
"     2",
"    </a>",
"    ]. The patient should refrain from taking antihistamines for several days before the test. The subject's arm is held on a level plane, and a vortex mixer is placed in contact with the skin (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). The vibratory stimulus is applied for five minutes, and the site is observed for five to six hours. The test is considered positive if the area becomes erythematous, pruritic, and edematous around the full circumference of the arm, although one study found that this test also induced a positive response in 7 of 20 normal volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/110\">",
"     110",
"    </a>",
"    ], suggesting that this response may not be entirely abnormal, as mentioned previously. Dermographism and pressure urticaria should be excluded using the appropriate tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient avoidance of specific vibratory stimuli is the first line of therapy, although this may not be possible in occupational cases.",
"   </p>",
"   <p>",
"    H1 antihistamines have been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/111\">",
"     111",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Overview of treatment approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A state of tolerance was achieved in one patient by using twice-daily vibration challenges until symptoms were delayed in onset and reduced in duration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/108\">",
"     108",
"    </a>",
"    ]. The patient eventually attained complete control of her symptoms by using a five-minute desensitization protocol every five to seven days. However, a state of tolerance could not be induced in another case report [",
"    <a class=\"abstract\" href=\"UTD.htm?24/5/24666/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/27/44466?source=see_link\">",
"       \"Patient information: Physical hives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=see_link\">",
"       \"Patient information: Hives (urticaria) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical urticarias are forms of chronic urticaria in which hives (sometimes with angioedema) are induced by environmental stimuli. Physical urticarias vary in severity from mild to disabling. Some forms can escalate to systemic reactions and anaphylaxis. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Prevalence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The more common physical urticaria syndromes include dermographism, cholinergic urticaria, and delayed pressure",
"      <span class=\"nowrap\">",
"       urticaria/angioedema.",
"      </span>",
"     </li>",
"     <li>",
"      Rare disorders include",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      following exposure to heat, exercise, water, vibration, or sunlight. (See sections on specific disorders above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical urticarias can often be diagnosed based upon history and physical examination. In some cases, physical challenge procedures are needed to clarify or confirm the responsible trigger (",
"    <a class=\"graphic graphic_table graphicRef50072 \" href=\"UTD.htm?33/35/34364\">",
"     table 1",
"    </a>",
"    ). These challenges are usually performed by allergy or dermatology specialists with experience with these techniques, as overly aggressive challenges can induce systemic reactions. Patients with past systemic reactions should only be challenged by an allergist in a medical setting equipped to manage anaphylaxis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'When to refer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of physical urticaria begins with accurate identification and avoidance of the triggering stimulus.",
"     </li>",
"     <li>",
"      For initial pharmacotherapy, we suggest a less-sedating, second generation antihistamine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      (10 mg daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7799?source=see_link\">",
"       loratadine",
"      </a>",
"      (10 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"       fexofenadine",
"      </a>",
"      (180 mg daily). Many patients will require a doubling of the standard dose to impact symptoms significantly (eg, cetirizine, 10 mg twice daily). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overview of treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subsequent management proceeds in a stepwise manner and includes H2 antihistamines, first generation H1 antihistamines, and in some cases, limited courses of systemic glucocorticoids. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Overview of treatment approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific physical urticarias are more or less responsive to pharmacotherapy, and others agents have shown utility in certain disorders (eg, antileukotriene agents in delayed pressure angioedema). (See sections on specific disorders above).",
"     </li>",
"     <li>",
"      Steroid-sparing therapies should be considered for patients requiring systemic glucocorticoids beyond two to three months. Depending on the disorder, options include phototherapy, physical desensitization protocols, and immunomodulatory agents. (See sections on specific disorders above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/1\">",
"      Khakoo G, Sofianou-Katsoulis A, Perkin MR, Lack G. Clinical features and natural history of physical urticaria in children. Pediatr Allergy Immunol 2008; 19:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/2\">",
"      Kontou-Fili K, Borici-Mazi R, Kapp A, et al. Physical urticaria: classification and diagnostic guidelines. An EAACI position paper. Allergy 1997; 52:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/3\">",
"      Magerl M, Borzova E, Gim&eacute;nez-Arnau A, et al. The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009; 64:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/4\">",
"      Kirby JD, Matthews CN, James J, et al. The incidence and other aspects of factitious wealing (dermographism). Br J Dermatol 1971; 85:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/5\">",
"      Orfan NA, Kolski GB. Physical urticarias. Ann Allergy 1993; 71:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/6\">",
"      Jedele KB, Michels VV. Familial dermographism. Am J Med Genet 1991; 39:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/7\">",
"      Shelley WB, Shelley ED. Follicular dermographism. Cutis 1983; 32:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/8\">",
"      Warin RP. Factitious urticaria: red dermographism. Br J Dermatol 1981; 104:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/9\">",
"      Matthews CN, Kirby JD, James J, Warin RP. Dermographism: reduction in weal size by chlorpheniramine and hydroxyzine. Br J Dermatol 1973; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/10\">",
"      Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/11\">",
"      Schafer CM. Physical urticarias. Immunol Allergy Clin North Am 1995; 15:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/12\">",
"      Smith JA, Mansfield LE, Fokakis A, Nelson HS. Dermographia caused by IgE mediated penicillin allergy. Ann Allergy 1983; 51:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/13\">",
"      Warner DM, Ramos-Caro FA, Flowers FP. Famotidine (pepcid)-induced symptomatic dermatographism. J Am Acad Dermatol 1994; 31:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/14\">",
"      Garafalo J, Kaplan AP. Histamine release and therapy of severe dermatographism. J Allergy Clin Immunol 1981; 68:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/15\">",
"      Murphy GM, Zollman PE, Greaves MW, Winkelmann RK. Symptomatic dermographism (factitious urticaria)--passive transfer experiments from human to monkey. Br J Dermatol 1987; 116:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/16\">",
"      Breathnach SM, Allen R, Ward AM, Greaves MW. Symptomatic dermographism: natural history, clinical features laboratory investigations and response to therapy. Clin Exp Dermatol 1983; 8:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/17\">",
"      Deutsch PH. Dermatographism treated with hydroxyzine and cimetidine and ranitidine. Ann Intern Med 1984; 101:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/18\">",
"      Juhlin L, de Vos C, Rihoux JP. Inhibiting effect of cetirizine on histamine-induced and 48/80-induced wheals and flares, experimental dermographism, and cold-induced urticaria. J Allergy Clin Immunol 1987; 80:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/19\">",
"      Kaur S, Greaves M, Eftekhari N. Factitious urticaria (dermographism): treatment by cimetidine and chlorpheniramine in a randomized double-blind study. Br J Dermatol 1981; 104:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/20\">",
"      Cook J, Shuster S. The effect of H1 and H2 receptor antagonists on the dermographic response. Acta Derm Venereol 1983; 63:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/21\">",
"      Johnsson M, Falk ES, Volden G. UVB treatment of factitious urticaria. Photodermatol 1987; 4:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/22\">",
"      Krause K, Ardelean E, Kessler B, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy 2010; 65:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/23\">",
"      Barlow RJ, Warburton F, Watson K, et al. Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. J Am Acad Dermatol 1993; 29:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/24\">",
"      Dice JP. Physical urticaria. Immunol Allergy Clin North Am 2004; 24:225.",
"     </a>",
"    </li>",
"    <li>",
"     Kaplan AP. Urticara and angioedema. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1063.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/26\">",
"      Berkun Y, Shalit M. Successful treatment of delayed pressure urticaria with montelukast. Allergy 2000; 55:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/27\">",
"      Nettis E, Pannofino A, Cavallo E, et al. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol 2003; 112:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/28\">",
"      Nettis E, Colanardi MC, Soccio AL, et al. Desloratadine in combination with montelukast suppresses the dermographometer challenge test papule, and is effective in the treatment of delayed pressure urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006; 155:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/29\">",
"      Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010; 65:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/30\">",
"      Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011; 154:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/31\">",
"      Duke WW. Urticaria caused specifically by the action of physical agents. JAMA 1924; 83:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/32\">",
"      Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 1999; 140:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/33\">",
"      Hirschmann JV, Lawlor F, English JS, et al. Cholinergic urticaria. A clinical and histologic study. Arch Dermatol 1987; 123:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/34\">",
"      Moore-Robinson M, Warin RP. Some clinical aspects of cholinergic urticaria. Br J Dermatol 1968; 80:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/35\">",
"      Zuberbier T, Althaus C, Chantraine-Hess S, Czarnetzki BM. Prevalence of cholinergic urticaria in young adults. J Am Acad Dermatol 1994; 31:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/36\">",
"      Onn A, Levo Y, Kivity S. Familial cholinergic urticaria. J Allergy Clin Immunol 1996; 98:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/37\">",
"      Grant RT, Pearson RSB, Comeau WJ. Observations on urticaria provoked by emotion, by exercise, and by warming the body. Clin Sci 1936; 2:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/38\">",
"      Soter NA, Wasserman SI, Austen KF, McFadden ER Jr. Release of mast-cell mediators and alterations in lung function in patients with cholinergic urticaria. N Engl J Med 1980; 302:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/39\">",
"      Confino-Cohen R, Goldberg A, Magen E, Mekori YA. Hemodialysis-induced rash: a unique case of cholinergic urticaria. J Allergy Clin Immunol 1995; 96:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/40\">",
"      Commens CA, Greaves MW. Tests to establish the diagnosis in cholinergic urticaria. Br J Dermatol 1978; 98:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/41\">",
"      Sigler RW, Levinson AI, Evans R 3rd, et al. Evaluation of a patient with cold and cholinergic urticaria. J Allergy Clin Immunol 1979; 63:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/42\">",
"      Shelley WB, Shelley ED, Ho AK. Cholinergic urticaria: acetylcholine-receptor-dependent immediate-type hypersensitivity reaction to copper. Lancet 1983; 1:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/43\">",
"      Murphy GM, Greaves MW, Zollman PE, Winkelmann RK. Cholinergic urticaria, passive transfer experiments from human to monkey. Dermatologica 1988; 177:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/44\">",
"      Adachi J, Aoki T, Yamatodani A. Demonstration of sweat allergy in cholinergic urticaria. J Dermatol Sci 1994; 7:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/45\">",
"      Fukunaga A, Bito T, Tsuru K, et al. Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol 2005; 116:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/46\">",
"      Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/47\">",
"      Takahagi S, Tanaka T, Ishii K, et al. Sweat antigen induces histamine release from basophils of patients with cholinergic urticaria associated with atopic diathesis. Br J Dermatol 2009; 160:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/48\">",
"      Otto HF, Calabria CW. A case of severe refractory chronic urticaria: a novel method for evaluation and treatment. Allergy Asthma Proc 2009; 30:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/49\">",
"      Itakura E, Urabe K, Yasumoto S, et al. Cholinergic urticaria associated with acquired generalized hypohidrosis: report of a case and review of the literature. Br J Dermatol 2000; 143:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/50\">",
"      Kobayashi H, Aiba S, Yamagishi T, et al. Cholinergic urticaria, a new pathogenic concept: hypohidrosis due to interference with the delivery of sweat to the skin surface. Dermatology 2002; 204:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/51\">",
"      Casale TB, Sampson HA, Hanifin J, et al. Guide to physical urticarias. J Allergy Clin Immunol 1988; 82:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/52\">",
"      Zuberbier T, M&uuml;nzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 1996; 193:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/53\">",
"      McClean SP, Arreaza EE, Lett-Brown MA, Grant JA. Refractory cholinergic urticaria successfully treated with ketotifen. J Allergy Clin Immunol 1989; 83:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/54\">",
"      Czarnetzki BM. Ketotifen in cholinergic urticaria. J Allergy Clin Immunol 1990; 86:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/55\">",
"      Wong E, Eftekhari N, Greaves MW, Ward AM. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol 1987; 116:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/56\">",
"      La Shell MS, England RW. Severe refractory cholinergic urticaria treated with danazol. J Drugs Dermatol 2006; 5:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/57\">",
"      Eftekhari N, Ward AM, Allen R, Greaves MW. Protease inhibitor profiles in urticaria and angio-oedema. Br J Dermatol 1980; 103:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/58\">",
"      Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol 2010; 35:e127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/59\">",
"      Sibbald RG. Physical urticaria. Dermatol Clin 1985; 3:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/60\">",
"      Grant JA, Findlay SR, Thueson DO, et al. Local heat urticaria/angioedema: evidence for histamine release without complement activation. J Allergy Clin Immunol 1981; 67:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/61\">",
"      Micha&euml;lsson G, Ros AM. Familial localized heat urticaria of delayed type. Acta Derm Venereol 1971; 51:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/62\">",
"      Darling M, Lambiase MC, Hodson DS. Localized heat induced urticaria: report of a case. J Drugs Dermatol 2004; 3:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/63\">",
"      Daman L, Lieberman P, Ganier M, Hashimoto K. Localized heat urticaria. J Allergy Clin Immunol 1978; 61:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/64\">",
"      SHELLEY WB, RAWNSLEY HM. AQUAGENIC URTICARIA. CONTACT SENSITIVITY REACTION TO WATER. JAMA 1964; 189:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/65\">",
"      Treudler R, Tebbe B, Steinhoff M, Orfanos CE. Familial aquagenic urticaria associated with familial lactose intolerance. J Am Acad Dermatol 2002; 47:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/66\">",
"      Luong KV, Nguyen LT. Aquagenic urticaria: report of a case and review of the literature. Ann Allergy Asthma Immunol 1998; 80:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/67\">",
"      Czarnetzki BM, Breetholt KH, Traupe H. Evidence that water acts as a carrier for an epidermal antigen in aquagenic urticaria. J Am Acad Dermatol 1986; 15:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/68\">",
"      Chalamidas SL, Charles CR. Aquagenic urticaria. Arch Dermatol 1971; 104:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/69\">",
"      Tkach JR. Aquagenic urticaria. Cutis 1981; 28:454, 463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/70\">",
"      Gallo R, Cacciapuoti M, Cozzani E, Guarrera M. Localized aquagenic urticaria dependent on saline concentration. Contact Dermatitis 2001; 44:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/71\">",
"      Sibbald RG, Black AK, Eady RA, et al. Aquagenic urticaria: evidence of cholinergic and histaminergic basis. Br J Dermatol 1981; 105:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/72\">",
"      Fearfield LA, Gazzard B, Bunker CB. Aquagenic urticaria and human immunodeficiency virus infection: treatment with stanozolol. Br J Dermatol 1997; 137:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/73\">",
"      Davis RS, Remigio LK, Schocket AL, Bock SA. Evaluation of a patient with both aquagenic and cholinergic urticaria. J Allergy Clin Immunol 1981; 68:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/74\">",
"      Parker RK, Crowe MJ, Guin JD. Aquagenic urticaria. Cutis 1992; 50:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/75\">",
"      Mathelier-Fusade P, Aissaoui M, Chabane MH, et al. Association of cold urticaria and aquagenic urticaria. Allergy 1997; 52:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/76\">",
"      Bayle P, Gadroy A, Messer L, Bazex J. Localized aquagenic urticaria: efficacy of a barrier cream. Contact Dermatitis 2003; 49:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/77\">",
"      Wasserman D, Preminger A, Zlotogorski A. Aquagenic urticaria in a child. Pediatr Dermatol 1994; 11:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/78\">",
"      Nosbaum A, Pecquet C, Bayrou O, et al. Treatment with propranolol of 6 patients with idiopathic aquagenic pruritus. J Allergy Clin Immunol 2011; 128:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/79\">",
"      Thomsen K. Aquagenic pruritus responds to propranolol. J Am Acad Dermatol 1990; 22:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/80\">",
"      Mart&iacute;nez-Escribano JA, Quecedo E, De la Cuadra J, et al. Treatment of aquagenic urticaria with PUVA and astemizole. J Am Acad Dermatol 1997; 36:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/81\">",
"      Juhlin L, Malmros-Enander I. Familial polymorphous light eruption with aquagenic urticaria: successful treatment with PUVA. Photodermatol 1986; 3:346.",
"     </a>",
"    </li>",
"    <li>",
"     Merklen P. Urticaria. In: La pratique dermatologique: trait de dermatologie applique'e, Besnier E, Brocq L, Jacquet L (Eds), Masson et Cie, Paris 1904. p.728.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/83\">",
"      Champion RH. Urticaria: then and now. Br J Dermatol 1988; 119:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/84\">",
"      Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/85\">",
"      Uetsu N, Miyauchi-Hashimoto H, Okamoto H, Horio T. The clinical and photobiological characteristics of solar urticaria in 40 patients. Br J Dermatol 2000; 142:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/86\">",
"      Ryckaert S, Roelandts R. Solar urticaria. A report of 25 cases and difficulties in phototesting. Arch Dermatol 1998; 134:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/87\">",
"      Beattie PE, Dawe RS, Ibbotson SH, Ferguson J. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol 2003; 139:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/88\">",
"      Monfrecola G, Nappa P, Pini D. Solar urticaria with delayed onset: a case report. Photodermatol 1988; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/89\">",
"      Ghigliotti G, Brusati C, Guarrera M, Nigro A. Persistent solar urticaria. A case report. Photodermatol Photoimmunol Photomed 1999; 15:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/90\">",
"      Blum HF, West RJ. STUDIES OF AN URTICARIAL RESPONSE TO BLUE AND VIOLET LIGHT IN MAN. J Clin Invest 1937; 16:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/91\">",
"      Leenutaphong V, H&ouml;lzle E, Plewig G. Solar urticaria: studies on mechanisms of tolerance. Br J Dermatol 1990; 122:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/92\">",
"      Botto NC, Warshaw EM. Solar urticaria. J Am Acad Dermatol 2008; 59:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/93\">",
"      Hasei K, Ichihashi M. Solar urticaria. Determinations of action and inhibition spectra. Arch Dermatol 1982; 118:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/94\">",
"      Rajatanavin N, Bernhard JD. Solar urticaria: treatment with terfenadine. J Am Acad Dermatol 1988; 18:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/95\">",
"      Adamski H, Bedane C, Bonnevalle A, et al. Solar urticaria treated with intravenous immunoglobulins. J Am Acad Dermatol 2011; 65:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/96\">",
"      G&uuml;zelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/97\">",
"      Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010; 125:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/98\">",
"      Edstr&ouml;m DW, Ros AM. Cyclosporin A therapy for severe solar urticaria. Photodermatol Photoimmunol Photomed 1997; 13:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/99\">",
"      Duschet P, Leyen P, Schwarz T, et al. Solar urticaria--effective treatment by plasmapheresis. Clin Exp Dermatol 1987; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/100\">",
"      Leenutaphong V, H&ouml;lzle E, Plewig G, et al. Plasmapheresis in solar urticaria. Dermatologica 1991; 182:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/101\">",
"      Hudson-Peacock MJ, Farr PM, Diffey BL, Goodship TH. Combined treatment of solar urticaria with plasmapheresis and PUVA. Br J Dermatol 1993; 128:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/102\">",
"      Collins P, Ahamat R, Green C, Ferguson J. Plasma exchange therapy for solar urticaria. Br J Dermatol 1996; 134:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/103\">",
"      Patterson R, Mellies CJ, Blankenship ML, Pruzansky JJ. Vibratory angioedema: a hereditary type of physical hypersensitivity. J Allergy Clin Immunol 1972; 50:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/104\">",
"      Epstein PA, Kidd KK. Dermo-distortive urticaria: an autosomal dominant dermatologic disorder. Am J Med Genet 1981; 9:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/105\">",
"      Keahey TM, Indrisano J, Lavker RM, Kaliner MA. Delayed vibratory angioedema: insights into pathophysiologic mechanisms. J Allergy Clin Immunol 1987; 80:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/106\">",
"      Wener MH, Metzger WJ, Simon RA. Occupationally acquired vibratory angioedema with secondary carpal tunnel syndrome. Ann Intern Med 1983; 98:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/107\">",
"      Metzger WJ, Kaplan AP, Beaven MA, et al. Hereditary vibratory angioedema: confirmation of histamine release in a type of physical hypersensitivity. J Allergy Clin Immunol 1976; 57:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/108\">",
"      Ting S, Reimann BE, Rauls DO, Mansfield LE. Nonfamilial, vibration-induced angioedema. J Allergy Clin Immunol 1983; 71:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/109\">",
"      Rittweger J, Beller G, Felsenberg D. Acute physiological effects of exhaustive whole-body vibration exercise in man. Clin Physiol 2000; 20:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/110\">",
"      Mathelier-Fusade P, Vermeulen C, Leynadier F. [Vibratory angioedema]. Ann Dermatol Venereol 2001; 128:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/5/24666/abstract/111\">",
"      Lawlor F, Black AK, Breathnach AS, Greaves MW. Vibratory angioedema: lesion induction, clinical features, laboratory and ultrastructural findings and response to therapy. Br J Dermatol 1989; 120:93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8109 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24666=[""].join("\n");
var outline_f24_5_24666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H50\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL POINTS ABOUT PHYSICAL URTICARIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Variations in clinical presentation and severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      When to refer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OVERVIEW OF TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DERMOGRAPHISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DELAYED PRESSURE URTICARIA/ANGIOEDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CHOLINERGIC URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      LOCAL HEAT URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      EXERCISE-INDUCED URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      AQUAGENIC URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SOLAR URTICARIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Diagnosis and testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      VIBRATORY ANGIOEDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8109|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/2/29728\" title=\"picture 1\">",
"      Urticaria 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/55/24433\" title=\"picture 2\">",
"      Urticaria 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/33/31248\" title=\"picture 3\">",
"      Dermatographism 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/57/43920\" title=\"picture 4\">",
"      Dermatographism 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/58/42912\" title=\"picture 5\">",
"      Cholinergic urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/13/34003\" title=\"picture 6\">",
"      Solar urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/26/16801\" title=\"picture 7\">",
"      Polymorphic light eruptionA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/26/23970\" title=\"picture 8\">",
"      Polymorphic light eruptionB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/44/28354\" title=\"picture 9\">",
"      Erythro protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/35/34364\" title=\"table 1\">",
"      Physical urticaria testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=related_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15834?source=related_link\">",
"      Erythropoietic protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26777?source=related_link\">",
"      Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5833?source=related_link\">",
"      Long-term management of patients with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/45/2772?source=related_link\">",
"      Patient information: Hives (urticaria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/27/44466?source=related_link\">",
"      Patient information: Physical hives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/62/20455?source=related_link\">",
"      Polymorphous light eruption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_5_24667="DSM-IV-TR diagnostic criteria for cannabis abuse";
var content_f24_5_24667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F53923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F53923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for cannabis abuse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       The two criteria for cannabis abuse are:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       1. A maladaptive pattern of cannabis use leading to clinically significant impairment or distress, as manifested by one or more of the following, during a 12 month period:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Recurrent cannabis use that interferes with major role obligations at work, school, or home. Examples include frequent absences, poor performance, suspensions, job loss or expulsion from school, neglect of children or household.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Recurrent cannabis use in situations in which it is physically hazardous. Examples include driving or operating machinery when intoxicated.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       c. Recurrent legal problems related to cannabis use.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       d. Persistent cannabis use despite continued social or interpersonal problems caused or exacerbated by the effects of cannabis, such as arguments with a spouse about the consequences of intoxication.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. The symptoms have never met criteria for cannabis dependence.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24667=[""].join("\n");
var outline_f24_5_24667=null;
var title_f24_5_24668="Treatment of Candida UTIs";
var content_f24_5_24668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of Candida infections of the bladder and kidneys in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Condition or treatment group",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Primary",
"       </td>",
"       <td class=\"subtitle2\">",
"        Alternative",
"       </td>",
"       <td class=\"subtitle2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic cystitis",
"       </td>",
"       <td>",
"        Therapy not usually indicated, unless patients are at high risk (eg, neonates and neutropenic adults) or undergoing urologic procedures",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Elimination of predisposing factors recommended. For high-risk patients, treat as for disseminated candidiasis (see related table). For patients undergoing urologic procedures, fluconazole, 200 to 400 mg (3 to 6 mg/kg) orally daily or amphotericin B deoxycholate 0.3 to 0.6 mg/kg IV daily for several days before and after the procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic cystitis",
"       </td>",
"       <td>",
"        Fluconazole 200 mg (3 mg/kg) orally daily for two weeks",
"       </td>",
"       <td>",
"        Amphotericin B deoxycholate IV 0.3 to 0.6 mg/kg daily for 1 to 7 days; or flucytosine 25 mg/kg orally four times daily for 7 to 10 days",
"       </td>",
"       <td>",
"        Alternative therapy as listed is recommended for patients with fluconazole-resistant organisms. Amphotericin B deoxycholate bladder irrigation is recommended only for patients with refractory fluconazole-resistant organisms (eg,",
"        <em>",
"         Candida krusei",
"        </em>",
"        and",
"        <em>",
"         Candida glabrata",
"        </em>",
"        ).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyelonephritis",
"       </td>",
"       <td>",
"        Fluconazole 200 to 400 mg (3 to 6 mg/kg) orally daily for two weeks",
"       </td>",
"       <td>",
"        Amphotericin B deoxycholate 0.5 to 0.7 mg/kg IV daily with or without flucytosine 25 mg/kg orally four times daily; or flucytosine alone for two weeks",
"       </td>",
"       <td>",
"        For patients with pyelonephritis and suspected disseminated candidiasis, treat as for candidemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary fungus balls",
"       </td>",
"       <td>",
"        Surgical removal strongly recommended; fluconazole 200 to 400 mg (3 to 6 mg/kg) orally daily; or amphotericin B deoxycholate 0.5 to 0.7 mg/kg IV daily with or without flucytosine 25 mg/kg orally four times daily",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Local irrigation with amphotericin B deoxycholate may be a useful adjunct to systemic antifungal therapy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infections Diseases Society of America. Clin Infect Dis 2009; 48:503. Copyright &copy; 2009 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24668=[""].join("\n");
var outline_f24_5_24668=null;
var title_f24_5_24669="Syndromic microcephaly";
var content_f24_5_24669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected syndromes with microcephaly as a characteristic feature",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Down syndrome",
"        </p>",
"        <p>",
"         OMIM #190685",
"        </p>",
"       </td>",
"       <td>",
"        Brachycephaly, upslanting palpebral fissures, epicanthal folds, short neck, transverse palmar crease, space between first and second toes, hypotonia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Trisomy 18",
"       </td>",
"       <td>",
"        Prominent occiput, narrow bifrontal diameter, hypoplastic supraorbital ridge, short palpebral fissures, micrognathia, structural cardiac lesions (ventricular septal defect, atrial septal defect, patent ductus arteriosus)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Trisomy 13",
"       </td>",
"       <td>",
"        Holoprosencephaly, wide saggital suture, cleft lip, cleft palate, loose skin, transverse palmar crease, polydactyly, posterior prominence of heel; structural cardiac lesions (ventricular septal defect, patent ductus arteriosus, atrial septal defect, dextrocardia)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fetal alcohol syndrome",
"       </td>",
"       <td>",
"        Pre- and postnatal growth retardation, short palpebral fissures, flat philtrum, thin upper lip",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Seckel syndrome",
"        </p>",
"        <p>",
"         OMIM #210600",
"        </p>",
"       </td>",
"       <td>",
"        Pre- and postnatal growth retardation, average birth weight approximately 1540 g, proportionate short stature; micrognathia, facial asymmetry, downslanting palpebral fissures, prominent beaked nose; limb hypoplasia; gap between first and second toes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Smith-Lemli-Opitz",
"        </p>",
"        <p>",
"         OMIM #270400",
"        </p>",
"       </td>",
"       <td>",
"        Ptosis, broad nasal tip, anteverted nostrils, cleft palate, micrognathia, congenital heart defects, syndactyly of second and third toes, postaxial polydactyly, hypospadias or cryptorchidism (in boys)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Williams (7q11.23 deletion)",
"        </p>",
"        <p>",
"         OMIM #194050",
"        </p>",
"       </td>",
"       <td>",
"        Cardiovascular disease (supravalvular aortic stenosis), idiopathic hypercalcemia, periorbital fullness, short upturned nose, long philtrum, wide mouth, full lips",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Cornelia de Lange",
"        </p>",
"        <p>",
"         OMIM 122470, 300590, 610759",
"        </p>",
"       </td>",
"       <td>",
"        Pre- and postnatal growth retardation, generalized hirsuitism, fusion of eyebrows (synophrys), arched brows, long eyelashes, small upturned nose, thin lips, midline beaking of the upper lip; limb reduction defects, missing fingers, syndactyly of second and third toes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Miller-Dieker (17p13.3 deletion)",
"        </p>",
"        <p>",
"         OMIM #247200",
"        </p>",
"       </td>",
"       <td>",
"        Bitemporal narrowing, upturned nose, small jaw, vertical furrowing of forehead, micrognathia, genitourinary anomalies",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Wolf-Hirschhorn (4p deletion)",
"        </p>",
"        <p>",
"         OMIM #194190",
"        </p>",
"       </td>",
"       <td>",
"        Congenital heart disease, hearing loss, prominent glabella, hypertelorism, wide nasal bridge, beaked nose, short philtrum, down-turned upper lip",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Cri-du-chat (5p15.2 deletion)",
"        </p>",
"        <p>",
"         OMIM #123450",
"        </p>",
"       </td>",
"       <td>",
"        Round face, hypertelorism, micrognathia, epicanthal folds, hypotonia, high-pitched cry",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Monosomy 1p36 deletion",
"        </p>",
"        <p>",
"         OMIM #607872",
"        </p>",
"       </td>",
"       <td>",
"        Brachycephaly, large fontanelle, pointed chin, hearing loss, flat nasal bridge, flat nose, cleft lip, cleft palate, short fifth finger",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Mowat-Wilson",
"        </p>",
"        <p>",
"         OMIM #235730",
"        </p>",
"       </td>",
"       <td>",
"        Pre- or postnatal microcephaly, short stature, hypertelorism, iris coloboma, deep-set eyes, downslanting palpebral fissures, cupped ears, pointed chin, seizures, hypospadias (in boys), Hirschsprung's disease, congenital heart disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Rubinstein-Taybi",
"        </p>",
"        <p>",
"         OMIM #180849",
"        </p>",
"       </td>",
"       <td>",
"        Postnatal short stature, low anterior hairline, hypoplastic maxilla, micrognathia, heavy eyebrows, long eyelashes, broad thumbs and big toes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Pseudo-TORCH (Aicardi-Gouti&egrave;res syndrome)",
"        </p>",
"        <p>",
"         OMIM #225750",
"        </p>",
"       </td>",
"       <td>",
"        Congenital microcephaly, abnormal eye movements, hepatosplenomegaly, cerebral calcification, thrombocytopenia, spasticity, seizures",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Abuelo D. Microcephaly syndromes. Semin Pediatr Neurol 2007; 14:118.",
"       </li>",
"       <li>",
"        Firth HV, Hurst JA, Hall JG. Microcephaly. In: Oxford Desk Reference: Clinical Genetics, 1st ed. Oxford University Press, Oxford 2005. p.172.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24669=[""].join("\n");
var outline_f24_5_24669=null;
var title_f24_5_24670="Brain death criteria by country A";
var content_f24_5_24670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for  brain death by country: 2001 International Survey data",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Continent/country",
"      </td>",
"      <td class=\"subtitle1\">",
"       Apnea test",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of physicians",
"      </td>",
"      <td class=\"subtitle1\">",
"       Observation time, h",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ancillary test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       North America",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       United States",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2*",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Canada",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Caribbean",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cuba",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Jamaica",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Trinidad and Tobago",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Central and South America",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Argentina",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Brazil",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chile",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Columbia",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       2 (N)",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Costa Rica",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       El Salvador",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mexico",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Paraguay",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Uruguay",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Venezuela",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2 (N)",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Europe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Austria",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Belgium",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cyprus",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Czech Republic",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Denmark",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Estonia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Finland",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       France",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Germany",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Greece",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hungary",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       12 (72)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ireland",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Italy",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Luxembourg",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Malta",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Netherlands",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Norway",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Poland",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Portugal",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2-24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Romania",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Russia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCO2: target PCO",
"     <sub>",
"      2",
"     </sub>",
"     defined (50 or 60 mmHg); A: absent criterion or guideline; DVO: disconnection from ventilatory only; N: neurologist.",
"     <br>",
"      * Eight US states only; time within parentheses indicates observation time due to anoxia.",
"      <br>",
"       &bull; Observation time can be shortened or eliminated if one confirmatory test is positive for brain death.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wijdicks, EFM. Brain death worldwide: Accepted fact but no global consensus in diagnostic criteria. Neurology 2002; 58:20. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24670=[""].join("\n");
var outline_f24_5_24670=null;
var title_f24_5_24671="Surv rates appendix CA";
var content_f24_5_24671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64182&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Observed survival rates for 931 cases with carcinoma of the appendix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 455px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the SEER 1973-2005 Public Use File diagnosed in years 1991-2000. Stage I includes 150; Stage II, 369; Stage III, 76; and Stage IV, 346.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_5_24671=[""].join("\n");
var outline_f24_5_24671=null;
